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Abstract 
TNF is a cytokine with important functions in inflammation and immunity. Binding to its 
receptor TNF-Receptor-1 (TNFR1) induces the formation of a signalling platform which leads 
to TNF-target gene transcription and consequently the induction of cellular immune 
responses. To understand and possibly influence the effects observed upon TNF stimulation, 
it is important to define the molecular machinery responsible for signal transduction. In order 
to resolve the composition of the TNF-Receptor signalling complex (TNF-RSC) our group 
developed a highly sensitive modified tandem affinity purification method (moTAP). Using 
this technique, we recently reported on the recruitment of the two In-Between-RING (IBR) 
family members HOIL-1 (heme-oxidized IRP2 Ub ligase-1) and HOIP (HOIL-1 interacting 
protein) to the TNF-Receptor signalling complex (TNF-RSC) (reviewed in Haas et al, 2009). 
Together, HOIL-1 and HOIP form an E3 ligase complex that is capable of generating linear 
ubiquitin chains and therefore referred to as “linear ubiquitin chain assembly complex” 
(LUBAC) (Kirisako et al, 2006). 
In addition to HOIL-1 and HOIP, we also identified Sharpin (SHANK-associated RH domain-
interacting protein) as a further component that is recruited to the TNF-RSC in a stimulation-
dependent manner. In this study I show that Sharpin forms an endogenous, stimulation-
independent complex with HOIL-1 and HOIP. Although the mRNA levels of HOIL-1 and 
HOIP are unchanged in the absence of Sharpin, their respective protein levels are strongly 
diminished. These data indicate that Sharpin, HOIL-1 and HOIP form a tripartite complex. As 
previously shown for HOIL-1 and HOIP, overexpression of Sharpin together with HOIP also 
stabilises the TNF-RSC and leads to activation of NF-κB. Therefore, LUBAC does not only 
consist of HOIL-1 and HOIP, but also includes Sharpin. 
A spontaneous point deletion in the Sharpin gene ablating its expression leads to the 
development of chronic proliferative dermatitis (cpdm) in mice (HogenEsch et al, 1993; 
HogenEsch et al, 1999; Seymour et al, 2007). Cpdm mice develop a multi-organ 
inflammatory disease with prominent skin lesions and display severe abnormalities in 
lymphoid architecture, including absence of Peyer’s patches, marginal zones, germinal 
centres, and follicular dendritic cells. Mouse embryonic fibroblasts (MEFs) and primary 
keratinocytes generated from these mice show impaired TNF-induced NF-κB and MAPK 
signalling. Although activation of these pathways is not completely dependent on LUBAC 
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activity, its presence is required for full activation as demonstrated by proper induction of 
TNF-target genes. In line with these TNF-induced signalling defects, cpdm-derived cells are 
prone to TNF-mediated cell death, which is partially apoptotic and partially necroptotic. Thus, 
loss of Sharpin results in a cell death favouring dysregulation of TNF-induced signalling 
which is responsible for the inflammatory phenotype observed in cpdm mice. 
Following the identification of a role for LUBAC in TNF signalling I determined whether it 
also played a role in signalling by the TNF related ligands TRAIL and CD95 ligand 
(CD95L/FasL). As compared to TNF, absence of a LUBAC component also sensitised cells to 
TRAIL- and CD95L- induced cell death, indicating that LUBAC plays a crucial role in cell 
survival. Accordingly, non-apoptotic TRAIL- and CD95L-induced signalling was also 
affected in the absence of LUBAC as determined by altered NF-κB and MAPK responses, 
respectively. 
Taken together, the results obtained in this thesis determine LUBAC as a novel regulator of 
various death receptor-driven signalling pathways implicated in gene activation, cell death 
induction and, as a consequence, innate immunity and inflammation. 
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1. Introduction 
1.1 The TNF and TNF-Receptor Superfamily 
In 1975, a bacterially-induced factor capable of initiating cell death in various tumours was 
discovered (Carswell et al, 1975). Designated as tumour necrosis factor (TNF), it was found 
to be the prototype of a family of molecules involved in immune regulation and inflammation. 
To date, a superfamily of TNF proteins consisting of 19 members that signal through 29 
receptors has been reported. These families have been designated as the TNF and TNF-
Receptor (TNFR) superfamiles. The receptors of this superfamily are type I transmembrane 
proteins containing one to six characteristic cysteine-rich domains (CRDs) in their 
extracellular amino-terminal domains that are required for ligand binding (Croft, 2003; 
Hymowitz et al, 1999). Their cognate ligands are type II transmembrane proteins with an 
extracellular, C-terminal TNF homology domain (THD). There is 20-30% amino acid identity 
between the THD of the different TNF superfamily members and the THDs are responsible 
for trimerisation and binding to the receptor (Locksley et al, 2001). The extracellular domain 
is frequently released as a soluble cytokine upon proteolytic processing (Bodmer et al, 2002). 
The 26 kDa transmembrane TNF molecule for instance is cleaved by the TNFα converting 
enzyme (TACE) into a 17 kDa soluble molecule (Black et al, 1997). Whereas some of the 
released ligands have agonistic activity, others are rather antagonistic by blocking binding of 
the transmembrane ligand to the receptor as reported for soluble CD95 ligand (CD95L) (Suda 
et al, 1997). However, a pre-dominant transmembrane expression of the TNF-superfamily 
ligands suggests that they are meant to act locally.  
Members of the TNFR superfamily can be subdivided into three groups. The first group is 
characterised by the presence of an intracellular, 80-amino acid death domain (DD) that is 
required for cell death induction and forms six anti-parallel α-helixes with highly conserved 
topology. The DD was initially discovered in the cytoplasmic regions of CD95 and TNF-
Receptor 1 (TNFR1) by two independent groups (Itoh & Nagata, 1993; Tartaglia et al, 1993). 
Subsequently, DDs have also been identified in TNF-related apoptosis inducing ligand 
receptor 1 and 2 (TRAIL-R1/R2), DR3, DR6 and EDAR.  
The second group of TNFR superfamily members does not contain a death domain, but is 
rather distinguished by the presence of an intracellular TRAF-interacting motif (TIM). These 
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receptors are known to induce cell proliferation, survival and differentiation by delivering co-
stimulatory signals required for complete immune cell activation. Members of this second 
family include 4-1BB, BAFF-Receptor, BCMA (B cell maturation antigen), CD27, CD30, 
CD40, fibroblast growth factor 14 (Fn14), Glucocorticoid-induced TNFR family receptor 
(GITR), Herpes virus entry mediator (HVEM), lymphotoxin β Receptor (LTβR), OX40, 
receptor activator of NF-κB (RANK), transmembrane activator and calcium signal 
modulating cyclophilin ligand interactor (TACI),  TNFR2, TROY and X-linked EDA-A2 
receptor (XEDAR).  
The last sub-group neither contains a functional death domain nor a TIM but functions as 
decoy receptors by binding their respective ligand without inducing subsequent signal 
transduction. TRAIL-R3, TRAIL-R4 and osteoprotegerin (OPG) constitute this third class.  
Upon receptor-ligand interaction, receptors of the TNFR superfamily associate in trimers and 
become capable of transmitting distinct signals internally, leading to cell proliferation, 
survival, differentiation or cell death. Since none of the TNFR superfamily members 
possesses any enzymatic activity, intracellular adaptors need to be recruited in order to 
facilitate downstream signalling events. A variety of yeast-two-hybrid approaches revealed 
the interaction of TNFR-associated factors (TRAFs) with most TNFR superfamily members 
following stimulation with the cognate ligand (Arch et al, 1998). So far, seven TRAF proteins 
have been identified, designated as TRAF1-TRAF7 (Xu et al, 2004). Except for TRAF1, all 
TRAF proteins contain five to seven amino-terminal zinc binding motifs, one of which 
constitutes a really interesting new gene (RING) finger and a TRAF domain that can be sub-
divided into a carboxy-terminal (TRAF-C) and amino-terminal (TRAF-N) TRAF domain 
(Bishop et al, 2007; Pineda et al, 2007). The TRAF-C domain is highly conserved in the 
TRAF family and facilitates homo- and hetero-dimerisation of the TRAF proteins as well as 
binding to the intracellular TIM of TNFR superfamily members (reviewed in Ha et al, 2009); 
in contrast, TRAF-N forms a coiled-coiled structure that is less conserved among the TRAF 
family.  As described in chapter 1.2.2, recruitment of TRAF proteins to the receptor signalling 
platforms induces nuclear factor kappa B (NF-κB) and mitogen activated protein kinase 
(MAPK) activation, resulting in survival, proliferation and induction of immune responses.  
1.1.1 Biological function of the TNF/TNFR superfamily 
Although TNF and other TNF superfamily members fulfil important physiological functions 
in immune cell homeostasis and removal of transformed or infected cells, their expression and 
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activities need to be tightly regulated to prevent harmful reactions such as auto-inflammatory 
diseases. Several reports showed the importance of this family of molecules in the regulation 
and development of the immune system and revealed the generation of immune diseases if 
one of the systems is genetically ablated or mutated (Basak & Hoffmann, 2008; Xie et al, 
2008). 
In particular, the immune system relies on signals exerted by TNF/TNFR superfamily 
members to confer innate immunity, lymphoid organ development, co-stimulatory 
lymphocyte activation, cytokine production, immunogloblin switching and removal of virus-
infected cells (Chang et al, 2006; Gallagher et al, 2007; Sakurai et al, 2006). A good example 
of deregulated TNFR superfamily signalling is seen in mice with mutated CD95 (lpr, 
lymphoproliferation) or CD95L (gld, generalised lymphoproliferative disease). Under 
physiological conditions, CD95L is up-regulated on activated T cells to induce activation-
induced cell death (AICD) of CD95-sensitive lymphocytes once an infection has been cleared 
(Dhein et al, 1995). However, mutations in the CD95 ligand or the receptor prevent deletion 
of mature T cells following activation and subsequent accumulation of activated T cells 
results in the development of auto-inflammatory syndromes (Nagata, 1999).  
A variety of TNF superfamily members has important functions in the co-stimulation and 
subsequent activation and maturation of T cells and B cells. Accordingly, mice lacking the 
expression of one of the TNF/TNFR superfamily members show defects in the development 
of particular types of immune cells and/or in the induction of an efficient immune response. In 
particular, BAFF, TNF, LT and CD40L were shown to be essential cytokines for the 
development of B cells, OX40L, 4-1BBL and CD27L for T cells and CD40L and RANKL for 
dendritic cells (reviewed in Aggarwal, 2003).  
A role for TNF superfamily members in anti-tumour responses has been suggested. In 
particular, TNF was initially discovered as a cytokine possessing anti-cancer activity 
(Carswell et al, 1975). The oncologist William Coley was the first to treat cancer with 
bacterial extracts (so-called Coley’s toxins) with some success (Coley, 1891). Ongoing 
studies revealed the presence of TNF, as a result of lipopolysaccharide (LPS) signalling, in 
these extracts and showed that TNF was able to induce necrotic cell death in a variety of 
tumour samples (Carswell et al, 1975; O'Malley et al, 1963). However, the effectiveness of 
TNF as an anti-cancer drug has been proven rather limited due to its systemic toxicity. 
Furthermore, TNF was shown to even enhance tumour growth by promoting NF-κB 
activation, therefore contributing to tumour invasion, proliferation and metastasis formation 
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(Szlosarek et al, 2006). Skin-specific TNF knockout mice were resistant to skin 
carcinogenesis, indicating a pro-tumoural activity of TNF (Moore et al, 1999). In contrast, 
TRAIL was shown to specifically induce cell death in transformed cells without affecting 
normal cells. Although most primary tumour samples were shown to be TRAIL-resistant, a 
variety of reagents were able to sensitise tumour cells to TRAIL-induced apoptosis (reviewed 
in Cordier et al, 2009b).  
 
1.2 The TNF/TNFR1 system 
1.2.1 Biological functions of TNF 
As described in the previous chapter, TNF was the first cytokine of the TNF superfamily 
identified in the late 70s’ (Carswell et al, 1975) and is probably the best described member of 
the superfamily with more than 50.000 publications since its first isolation and 
characterisation in 1985 (Aggarwal et al, 1985). TNF can bind to two transmembrane 
receptors, TNFR1 and TNFR2 to execute its pleiotropic biological functions. Since TNFR2 
lacks a death domain, this receptor has exclusively pro-survival activity, whereas TNFR1 can 
also induce cell death under certain circumstances. While the expression of TNFR2 is 
restricted pre-dominantly to immune cells and the endothelium, TNFR1 is ubiquitously 
expressed with the exception of erythrocytes (Wajant et al, 2003). In contrast to TNFR1, 
TNFR2 has very low affinity for soluble TNF and cannot be efficiently activated by this form 
of TNF; however, membrane-bound TNF induces strong cross-linking and activation of both, 
TNFR1, and TNFR2 (Grell et al, 1995; Grell et al, 1998; Krippner-Heidenreich et al, 2002).  
TNF is the key cytokine involved in the initiation of innate immune responses against 
invading pathogens that is produced by a variety of cells including macrophages, dendritic 
cells (DCs), monocytes, lymphocytes and keratinocytes. Following bacterial infection, LPS or 
other pathogen-associated molecular patterns (PAMPs) derived from invading microbes are 
recognised by their specialised pattern recognition receptors (PPRs) on and in host cells to 
induce the expression and secretion of TNF and other pro-inflammatory cytokines. 
Subsequent binding of TNF to TNFR1 results in the initiation of host defence mechanisms 
including the production of additional pro-inflammatory cytokines associated with increased 
phagocytic activity of surrounding macrophages (Bekker et al, 2001). Furthermore, enhanced 
TNF-induced production of chemokines and cell adhesion molecules on the vascular 
endothelium allows for the infiltration of a variety of immune cells to the place of 
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inflammation to clear pathogens (Roach et al, 2002). Accordingly, it is not surprising that host 
defence mechanisms in mice lacking TNF were severely impaired (Aggarwal, 2003). TNF 
and TNFR1 knockout mice showed increased susceptibility to Listeria monocytogenes and 
Mycobacterium tuberculosis, rapid death from infection and resistance to LPS-induced septic 
shock, further underscoring the great importance of the TNF/TNFR1 system in protection 
against infection (Ehlers, 2003; Pfeffer et al, 1993).  
A variety of auto-immune diseases is associated with deregulated TNFR1 signalling, 
including rheumatoid arthritis, Crohn’s disease and asthma (McInnes & Liew, 2005; O'Shea 
et al, 2002; van der Poll & Lowry, 1995). Application of TNF-neutralising antibodies 
(Infliximab/Remicade® and Adalimumab/Humira®) or TNFR2-Fc fusion proteins 
(Etanercept/Enbrel) has been proven beneficial in the treatment of these auto-immune 
diseases (Feldmann & Maini, 2001; Taylor & Feldmann, 2009; Van Deventer, 1997). Thus, 
even though TNF constitutes one of the major cytokines required for the induction of 
immunity, it can also play an eminent role in thr pathophysiology of a number of diseases. It 
is therefore of great importance to understand the molecular mechanism underlying TNF 
signalling. 
1.2.2 The TNFR1 signalling complex 
Binding of trimeric TNF to TNFR1, which was initially isolated and cloned in 1990 (Gray et 
al, 1990; Loetscher et al, 1990; Schall et al, 1990), results in receptor trimerisation and 
subsequent recruitment of a variety of intracellular adaptor proteins (see Figure 1).  TNF 
Receptor associated death domain (TRADD) is one of the most important adaptors required 
for stable TNF-Receptor Signalling Complex (TNF-RSC) formation and ablation of TRADD 
completely inhibits TNF-induced signal transduction. As indicated by its name, TRADD 
possesses a DD, which can be utilised to bind to the intracellular DD of TNFR1 (Hsu et al, 
1996b; Hsu et al, 1995; Micheau & Tschopp, 2003). TRADD then serves as a recruitment 
platform for TRAF2 (and possibly TRAF5) (Hsu et al, 1996b; Tsao et al, 2000), which in turn 
interacts with cellular inhibitor of apoptosis 1 and 2 (cIAP1/2) (Rothe et al, 1995; Shu et al, 
1996). TRAF2 was shown to directly interact with cIAP1 and cIAP2 via its cIAP-interacting 
motif (CIM) (Vince et al, 2009). On the other hand, the baculovirus IAP repeat 1 (BIR1) of 
cIAP1/2 is essential for binding to TRAF2 (Samuel et al, 2006; Varfolomeev et al, 2006). 
Zheng et al. recently demonstrated by crystallography that one cIAP2 molecule interacts with 
a trimeric TRAF2 structure (Zheng et al, 2010). Although TRADD was originally described 
to recruit the receptor-interacting protein kinase 1 (RIP1) to the TNF-RSC (Hsu et al, 1996a), 
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RIP1 can also directly bind to the DD of TNFR1 via its own DD. Yet, it has now been 
demonstrated that in the absence of TRADD and hence TRAF2/5 and cIAP1/2, RIP1 does not 
get ubiquitinated and is not capable of activating NF-κB and MAPKs (Ermolaeva et al, 2008; 
Haas et al, 2009; Pobezinskaya et al, 2008). Therefore, recruitment of RIP1 alone to the TNF-
RSC is insufficient to activate down-stream signals but requires additional modifications. 
Besides the DD, RIP1 also contains a kinase domain at its N-terminus. However, several 
reports have proven this kinase domain to be dispensable for TNF-induced signalling since 
Figure 1: TNFR1 signal transduction. Binding of TNF to TNFR1 induces receptor trimerisation and 
subsequent binding of TRADD to the receptor via its DD. TRADD then recruits RIP1 and TRAF2/5, which in 
turn interacts with cIAP1/2 via the CIM domain. LUBAC is recruited to cIAP1/2-generated chains and linearly 
ubiquitinates NEMO and RIP1. The TAK1/TAB complex and the IKK complex are recruited to polyubiquitin 
chains and become activated by not completely resolved mechanisms. TAK1 then phosphorylates IKKβ, which 
subsequently phosphorylates IκB proteins that are then K48-uiquitinated by SCFβTrCp and degraded by the 
proteasome. Thereby, the NF-κB heterodimers p65/p50 is released and translocates to the nucleus to drive the 
transcription of a variety of target genes implicated in cell survival and proliferation. TAK1 also activates the 
p38 and JNK MAPKs pathways, leading to ATF and AP-1 activation guiding in transcription of pro-survival 
target genes. Amongst these targets, the DUBs A20 and CYLD are transcribed and subsequently remove 
ubiquitin chains at the TNF-RSC to on the one hand terminate NF-κB and MAPK signalling and on the other 
hand induce internalisation of the signalling complex to form complex II. NF-κB/MAPK-driven up-regulation of 
c-FLIP inhibits caspase-8 activation in complex II, whose activation otherwise leads to cell death. 
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reconstitution of RIP1 null cells with a kinase-dead RIP1 mutant fully restored NF-κB 
signalling (Lee et al, 2004; Ting et al, 1996). Thus, regarding gene activatory signalling, RIP1 
is thought to act as an adaptor protein rather than to exert catalytic activity within the TNF-
RSC.  
Both cIAP and TRAF proteins possess a RING domain with potential E3 ubiquitin ligase 
activity which allows for the recruitment of E2 proteins (UBCs) to the complex and therefore 
the formation of ubiquitin chains (see chapter 1.5). Considering that TRAF2 forms K63-
linked polyubiquitin chains in vitro and that RIP1 remains unubiquitinated in the absence of 
TRAF2 (Lee et al, 2004; Wertz et al, 2004), it has long been assumed that TRAF2 itself 
functions as an E3 ubiquitin ligase for RIP1 in vivo following TNFR1 activation. However, a 
direct in vitro ubiquitination of RIP1 could not be detected for TRAF2, but only for cIAP1/2 
(Bertrand et al, 2008; Park et al, 2004). Furthermore, deletion of the E2 Ubc13, which was 
shown to act in concert with TRAF proteins to generate K63-linked polyubiquitin chains, did 
not alter TNF-induced NF-κB activation (Yamamoto et al, 2006). These results indicate that 
either the E3 activity of TRAF2 is dispensable for TNF signalling or that TRAF2 utilises 
another E2 to enzyme to generate ubiquitin chains. More recent reports suggested that the 
major role of TRAF2 in TNF signalling is to rather serve as a recruitment platform for 
cIAP1/2, which then in turn facilitates RIP1 ubiquitination (Bertrand et al, 2008; Ea et al, 
2006; Varfolomeev et al, 2008). Indeed, only recently Vince et al. showed that TRAF2/5 
knockout mouse embryonic fibroblasts (MEFs) reconstituted with cIAP-binding deficient 
TRAF2 were unable to form a functional TNF-RSC and to activate NF-κB and MAPK 
signalling. In contrast, reconstitution with a RING deficient mutant of TRAF2 allowed proper 
TNF-RSC formation and signal propagation (Vince et al, 2009). Taken together, a revised 
model of TNFR1 signalling proposes TRAF2 to function as an adaptor protein for the 
recruitment of cIAP1/2, thereby bringing them in close proximity to possible targets within 
the TNF-RSC which can then be (poly-)ubiquitinated. In line with this notion, cIAP1/2 were 
described to be capable of forming a variety of different ubiquitin chain types in vitro 
(Bertrand et al, 2008; Blankenship et al, 2009).  
Only recently, Dynek et al. showed the cIAP/UbcH5-dependent generation of K11-linked 
ubiquitin chains on RIP1 under endogenous, physiological conditions within the TNF-RSC 
(Dynek et al, 2010). Furthermore, our group recently expanded the complexity of TNFR1 
signalling by showing the presence of linear ubiquitin chains attached to RIP1 and NEMO in 
the native TNF-RSC (Gerlach et al, 2011; Haas et al, 2009). These reports showed for the first 
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time that TNFR1 signalling is not only restricted to K63- and K48-linked ubiquitin chains but 
indicate that signal transduction is far more complex. We are just beginning to understand the 
complex interplay between ubiquitin-conjugating enzymes, ubiquitin accepting molecules and 
de-ubiquitinating enzymes, which will be discussed later in this chapter. 
1.2.3 TNF-induced IKK and TAK1 activation 
Ubiquitin chains generated within the TNF-RSC following stimulation serve as binding sites 
for the recruitment of the TGF-β activated kinase 1/TAK1-binding protein (TAK1/TAB) 
complex and the IKK complex to the TNF-RSC (Ea et al, 2006; Wu et al, 2006). The 
TAK1/TAB complex consists of the kinase TAK1 and the two adaptor proteins TAB1 and 
TAB2 (or its homologue TAB3). TAB2 and TAB3 were shown to preferentially bind to K63-
linked ubiquitin chains via their Npl4-type zinc-finger (NZF) and are recruited via poly-
ubiquitinated RIP1 to the TNF-RSC (Cheung et al, 2004; Kanayama et al, 2004; Lee et al, 
2003).  
The IKK complex consisting of Inhibitor of κB kinase α (IKKα, also known as IKK1), IKKβ 
(IKK2) and NF-κB essential modulator (NEMO, also known as IKKγ) is recruited to the 
TNF-RSC via NEMO. NEMO does not possess any catalytic activity but rather serves as an 
adaptor protein allowing binding of the IKK complex to ubiquitin chains of different linkages 
(as discussed in chapter 1.5.3) within the complex, preferentially to linear ubiquitin chains 
(Lo et al, 2009).  
Through as yet incompletely resolved mechanisms, TAK1 auto-phosphorylates at Thr-187 
and thereby gets activated once the TAK1/TAB complex is recruited to the TNF-RSC 
(Kanayama et al, 2004).  Only recently, Xia et al. suggested free, unanchored poly-ubiquitin 
chains to directly activate TAK1 in vitro (Xia et al, 2009). However, considering the high 
turnover rate of free ubiquitin chains, it remains controversial whether such a model could 
also hold true in vivo. Alternatively, a conformational change within TAK1 induced by the 
recruitment to the TNF-RSC or a direct modification (e.g. ubiquitination or phosphorylation) 
might be responsible for its activation. Simultaneous binding of the IKK complex to ubiquitin 
chains (possibly on RIP1, but also other TNF-RSC components) within the complex allows 
TAK1 to phosphorylate and activate IKKβ which in turn phosphorylates inhibitor of κB (IκB) 
proteins. IκB proteins are known to sequester NF-κB subunits in the cytoplasm of 
unstimulated cells by masking their nuclear localisation sequence, thereby inhibiting the 
translocation of NF-κB to the nucleus. Once phosphorylated, IκB proteins are modified by 
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K48-linked ubiquitin chains by a ubiquitin ligase complex consisting of Skp1, Cul1, Roc1 and 
the F-box protein β-TrCP (β-transducin repeat-containing protein; SCFβ-TrCP) (Maniatis, 
1999). Subsequently, IκB proteins are degraded by the 26S proteasome (Ben-Neriah, 2002), 
thereby liberating NF-κB subunits which then enter the nucleus to drive transcription (Ghosh 
& Karin, 2002). Besides NF-κB, MAPKs are also stimulated following TNFR1 ligation and 
both their functions will be described in more depths in chapter 1.3. 
Though RIP1 has long been regarded as essential for IKK activation following TNF 
stimulation and for conferring protection against TNF-cytotoxicity (Kelliher et al, 1998; 
Pimentel-Muinos & Seed, 1999), a recent report by Wong et al. challenged this concept by 
showing that NF-κB activation was normal in a variety of cells obtained from RIP1 knockout 
mice (Wong et al, 2010). In line with this, the IKK complex was still recruited to the TNF-
RSC in RIP1 knockout MEFs, suggesting that other ubiquitinated target proteins exist which 
might serve as a recruitment platform for NEMO. Indeed, TRADD (Micheau & Tschopp, 
2003), cIAP1/2 (Haas et al, 2009) as well as TRAF2 (Brown et al, 2002; Habelhah et al, 2004; 
Li et al, 2002) have been reported to be ubiquitinated in the TNF-RSC. Thus, ubiquitin chains 
on these molecules might compensate for the loss of RIP1 to allow IKK recruitment and 
activation. Indeed, already in 2000, Devin et al. proposed that the IKK complex binds to 
TRAF2 in the absence of RIP1 (Devin et al, 2000).  
The termination of NF-κB signalling at a certain stage is critical in preventing chronic 
inflammation and tumour formation (Pikarsky et al, 2004). The action of E3 ligases is 
reverted by deubiquitinating enzymes (DUBs) which remove ubiquitin chains of particular 
linkage from target proteins (described in more detail in chapter 1.5.4). A20 and 
cylindromatosis (CYLD) constitute the major DUBs involved in TNFR1 signalling and were 
both shown to de-ubiquitinate TNF-RSC components, particularly RIP1, thereby terminating 
NF-κB and MAPK activation (Brummelkamp et al, 2003; Kovalenko et al, 2003; Trompouki 
et al, 2003; Wertz et al, 2004).  
Taken together, TNFR1 signalling is regulated at a variety of levels. Besides phosphorylation, 
ubiquitination has proven to be a central mechanism conferring control of signal propagation 
and termination. Conjugation of ubiquitin chains (e.g. by cIAPs), recruitment to ubiquitin 
chains (e.g. NEMO, TAB2/3) and their removal (e.g. A20, CYLD) represent decisive check 
points for TNFR1 signalling. Mutations in TNF-RSC components unbalance this output, 
leading to pathophysiological conditions as observed in various human diseases. Thus, it 
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remains essential to dissect the complex network of TNFR1 signalling in order to understand 
and possibly interfere with the signalling output. 
 
1.3 TNF-induced NF-κB and MAPK signalling 
The activation of NF-κB and MAPKs, albeit to different extents and with different kinetics, is 
shared by all stimulated TNFR superfamily members. While TNF-induced signalling is a fast 
and strong process, peaking 5-15 min following stimulation, TRAIL and CD95L are rather 
weak inducers of relatively late NF-κB and MAPK activation (Varfolomeev et al, 2005). The 
mechanism leading to the activation of these two major signalling pathways will be described 
in the following sections.  
1.3.1 NF-κB activation 
NF-κB is a heterodimeric family of transcription factors that control the expression of genes 
involved in immunity, inflammation and cell survival (Hayden & Ghosh, 2008). The family is 
composed of the five members p65 (RelA), p50 (NF-κB1), c-Rel, RelB and p52 (NF-κB2). 
p50 and p52 are generated from their precursors p105 and p100, respectively, by partial 
proteasomal degradation of their C-terminal, IκB-like domain. NF-κB subunits are 
characterised by a 300 amino-acid N-terminal Rel homology domain (RHD) that is required 
for dimerisation, nuclear translocation and DNA binding (Chen & Greene, 2004).  
Furthermore, the RHD domain is responsible for binding to IκB proteins, an ankyrin-repeat 
containing family of proteins that binds to NF-κB subunits via these repeats. The IκB family 
consists of the typical IκB proteins IκBα, IκBβ and IκBε, and the atypical members IκBδ, 
IκBξ and Bcl-3 (Figure 2). IκBα, IκBβ and IκBε reside in the cytosol and bind to NF-κB 
subunits, thereby masking their nuclear localisation sequence and preventing their entry into 
the nucleus. In contrast, the other IκB proteins reside in the nucleus and function as co-
activators once NF-κB heterodimers are liberated and enter the nucleus (Bours et al, 1993; 
Kitamura et al, 2000).  
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Besides the RHD, p65, c-Rel and RelB additionally contain a transcriptional activator domain 
(TAD) required to induce gene transcription. Since p50 and p52 lack a TAD, they have to 
heterodimerise with p65, c-Rel or RelB to form a functional NF-κB dimer.  Alternatively, 
they can repress transcription when bound to κB sites as homodimers. Fifteen potential 
NF-κB homo- and heterodimers can form of which 12 are capable of binding DNA and nine 
possess transcriptional activator functions, thereby conferring a high degree of complexity 
(Hoffmann & Baltimore, 2006). However, most publications do not distinguish between the 
different dimers and simply monitor IκB degradation and p100 processing, thereby 
simplifying the view of NF-κB activation. However, one clear distinction has been made: 
NF-κB signalling can be subdivided into canonical and non-canonical pathways, which serve 
distinct physiological functions and are also molecularly very different (Sun & Ley, 2008).  
1.3.1.1 Canonical NF-κB signalling 
Canonical NF-κB activation is a fast process mediated by IκB degradation and subsequent 
rapid translocation of NF-κB dimers to the nucleus. It can be induced by all TNFR 
superfamily members as well as a variety of pro-inflammatory cytokines and Toll-like 
receptor (TLR) agonists (Vallabhapurapu & Karin, 2009). Following formation of a signalling 
platform at the membrane (induced by TNFR superfamily ligation) or intracellularly 
(mediated by a variety of PAMPs), the IKK complex consisting of the catalytic subunits 
IKKα, IKKβ and the regulatory subunit NEMO is recruited and activated (Rothwarf et al, 
1998; Yamaoka et al, 1998; Zandi et al, 1997). IKKβ and NEMO fulfil non-redundant 
functions and are both essential for the canonical NF-κB pathway, whereas IKKα is 
dispensable (Hu et al, 1999; Li et al, 1999b; Rudolph et al, 2000). The canonical pathway is 
Figure 2 : Members of the NF-κB and IκB family. NF-κB family members are characterised by the presence 
of a RHD domain. Since p52 and p50 do not contain a TAD, they have to heterodimerise with another NF-κB 
family member to activate transcription. RHD: Rel homology domain; TAD: transactivation domain; LZ: leucine 
zipper; GRR: glycine-rich region; ANK: ankyrin repeat; DD: death domain; PEST: proline-, glutamic acid-, 
serine- and threonine rich. 
GRR 
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involved in a variety of physiological processes including innate and adaptive immunity as 
well as cell survival. Activation of the IKK complex by yet unknown mechanisms leads to 
IKKβ-mediated phosphorylation of IκB proteins at two N-terminal regulatory serine residues. 
IκBα, the prototypic IκB member whose degradation is usually monitored and regarded as the 
definitive sign of NF-κB activation, becomes phosphorylated at serine 32 and serine 36 
(DiDonato et al, 1996). Subsequently, IκB is targeted for ubiquitination by the SCFβ-TrCP E3 
ubiquitin ligase complex, which attaches K48-linked ubiquitin chains to lysine residues K21 
and K22, thereby marking it for proteasomal degradation. Subsequently, NF-κB is liberated, 
enters the nucleus and transcribes stimulus-dependent gene programs (Brown et al, 1995). 
Canonical NF-κB signalling is classically characterised by nuclear translocation of p50/p65 
and c-Rel/p50 heterodimers (Basak & Hoffmann, 2008). Though the mechanisms remain 
elusive, p65 has been reported to become phosphorylated and acetylated following liberation, 
thereby presumably changing its transcriptional activity (Chen & Greene, 2004). 
It is essential to terminate NF-κB responses in order to prevent the generation of chronic 
inflammation and/or tumourigenesis. Thus, NF-κB signalling is tightly regulated and has 
evolved to include negative feedback loops, including the transcription of inhibitory proteins 
able to down-regulate NF-κB activation. In particular, IκB itself becomes up-regulated to 
sequester liberated NF-κB dimers, thereby shutting off gene transcription (Sun et al, 1993). 
Furthermore, the expression of DUBs including A20, CYLD and Cezanne is induced, which 
then serve to dissolve the signalling platform responsible for IKK activation. 
1.3.1.2 Non-canonical NF-κB signalling 
The observation that overexpression of TRAF proteins was sufficient to activate NF-κB was 
in sharp contrast to an observed degradation of TRAF2 and/or TRAF3 following ligation of 
CD30 (Csomos et al, 2009; Duckett & Thompson, 1997), TNFR2 (Li et al, 2002) and CD40 
(Brown et al, 2001; Liao et al, 2004), all of which are also associated with NF-κB activation. 
The missing link explaining these diametrically opposing effects of TRAF protein levels on 
NF-κB signalling was revealed with the discovery of an alternative, non-canonical NF-κB 
activation pathway. 
Non-canonical NF-κB signalling is a rather slow process requiring new protein synthesis of 
NF-κB inducing kinase (NIK) resulting in IKKα-mediated p100 processing to p52 (Hacker & 
Karin, 2006). In contrast to canonical NF-κB activation, it can only be initiated by a distinct 
subset of TNF superfamily ligands, including TNF weak inducer of apoptosis (TWEAK), 
RANKL, CD40L, BAFF and LTβ (Claudio et al, 2002; Coope et al, 2002; Dejardin et al, 
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2002; Kayagaki et al, 2002). The prototypic NF-κB dimer characterising non-canonical 
NF-κB activation consists of p52 and RelB. Entering the nucleus, it induces transcription of a 
variety of genes controlling B cell survival and lymphoid organogenesis (Sun & Ley, 2008).  
NIK is the central kinase regulating non-canonical NF-κB signalling (Xiao et al, 2001). In 
unstimulated cells, NIK levels are maintained low by a ubiquitin-ligase complex consisting of 
TRAF2, TRAF3 and cIAP1/2 (Liao et al, 2004; Vallabhapurapu et al, 2008; Zarnegar et al, 
2008). Overexpression of the TNFR superfamily members RANK, CD30 and CD40 caused 
increased generation of p52 (Hauer et al, 2005), indicative of constitutive non-canonical 
signalling. Since concomitant TRAF3 overexpression inhibited this effect, TRAF3 can be 
regarded as negative regulator of non-canonical NF-κB activation. In line with this finding, 
TRAF3 knockout MEFs showed increased NIK levels in unstimulated cells and therefore a 
higher p100 turnover rate, without further stimulation. Constitutive ablation of TRAF3 
expression caused perinatal death in mice, a phenotype that was completely rescued by 
concomitant depletion of NIK (Vallabhapurapu et al, 2008) or p100 (He et al, 2006). Thus, 
global, constitutive activation of non-canonical NF-κB signalling results in lethality. 
Accordingly, TRAF2 knockout mice also died shortly after birth (Yeh et al, 1997). Traf2-/- 
cells were hypersensitive to TNF-induced death and the lethality of TRAF2 ablation was 
rescued by concomitant TNF or TNFR1 deletion, demonstrating that the death of the mice 
was TNF/TNFR1-dependent (Nguyen et al, 1999). Surprisingly, TRAF2 knockout cells did 
not show major defects on TNF-induced IKK activation, but rather exhibited defects in JNK 
activation and present with elevated levels of non-canonical NF-κB activation in unstimulated 
cells (Lee et al, 1997; Yeh et al, 1997). Concomitant deletion of only one allele of NIK 
sufficed to rescue the lethality of TRAF2 knockout mice (Vallabhapurapu et al, 2008).  
Other major players regulating non-canonical signalling are cIAP1 and cIAP2. Genetic 
ablation of cIAP1/2 or forced degradation by IAP antagonists, also referred to as Smac 
mimetics (SM), were also associated with stabilisation of NIK and enforced p100 processing 
(Vallabhapurapu et al, 2008; Vince et al, 2007; Zarnegar et al, 2008). SM treatment of Traf2-/- 
cells did not further potentiate p100 processing, suggesting that cIAP and TRAF proteins act 
in the same pathway (Vince et al, 2007). Accordingly, in 2008 two independent groups 
provided the missing link explaining the mechanism of TRAF2/TRAF3/cIAP-mediated 
inhibition of alternative NF-κB activation (Vallabhapurapu et al, 2008; Zarnegar et al, 2008). 
They showed that NIK, TRAF2, TRAF3 and cIAP1/2 are part of the same complex, in which 
TRAF3 directly interacts with NIK and TRAF2. Binding of cIAP1/2 to TRAF2 brings them 
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in close proximity to NIK, allowing cIAP1/2 to attach K48-linked ubiquitin to NIK, thereby 
targeting it for proteasomal degradation. However, stimulation of a distinct set of TNFR 
superfamily members leads to recruitment of TRAF and cIAP proteins to the respective 
receptor signalling complexes followed by their own degradation. Depending on the stimulus, 
TRAF3 (CD30), TRAF2 and TRAF3 (TNFR2, CD40) or TRAF2 and cIAP1/2 (Fn14) are 
degraded. Despite utilising different mechanisms, CD40, CD30, TNFR2 and Fn14 induce 
inactivation of the TRAF/cIAP destruction complex accompanied by stabilisation of NIK 
protein levels. Once stabilised, NIK phosphorylates IKKα, which in turn phosphorylates 
p100, thereby inducing its ubiquitination by the SCFβ−TrCP complex. Interestingly, only the C-
terminal, ankyrin repeat-containing part of p100 is degraded, leaving the N-terminus (p52) 
intact. Although the precise mechanism that governs this partial degradation remains to be 
determined, it might be due to the tightly folded conformation formed by a stable dimer 
(Piwko & Jentsch, 2006). Since ablation of one of the components of the 
TRAF2/TRAF3/cIAP complex is sufficient to stabilise NIK levels, these proteins possess 
non-redundant functions and are equally important for the regulation of non-canonical NF-κB 
signalling.  
1.3.2 MAPK signalling 
MAPK signalling converts a variety of extracellular signals into a wide range of cellular 
responses. So far, 14 MAPKs have been described in mammals. These can be divided into 
conventional MAPKs including extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-
Jun amino (N)-terminal kinases 1, 2 and 3 (JNK1/2/3), p38 isoforms (α, β, γ, δ) and ERK5 
(reviewed in Chen et al, 2001) and atypical MAPKs comprising ERK3/4, ERK7 and Nemo-
like kinase (NLK) (Coulombe & Meloche, 2007). MAPKs are characterised by a 
Serine/Threonine (Ser/Thr) kinase domain flanked by N- and C-terminal regions of different 
lengths. Additionally, some MAPKs possess a TAD or nuclear localisation sequences. 
Conventional MAPKs are composed of a set of three evolutionarily conserved, sequentially 
activated kinases: MAP kinase kinase kinases (MAP3Ks) are initially activated at the receptor 
level on the membrane by proximity-induced auto-phosphorylation or co-recruited kinases 
(MAP4Ks). Subsequently, they phosphorylate MAP kinase kinases (MAP2Ks) at Ser and Thr 
residues, which then activate MAPKs through dual phosphorylation on Thr and Tyr residues 
within a conserved Thr-X-Tyr motif located in the activation loop of the kinase domain. 
While some MAP3Ks possess specificity for a single pathway, others are rather promiscuous 
phosphorylating a wide array of down-stream MAP2Ks. MAPKs are proline-directed kinases 
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that phosphorylate target substrates on Ser and Thr residues followed by prolines. Activation 
of atypical MAPKs involves neither a three-tiered kinase cascade nor phosphorylation of the 
conserved Thr-X-Tyr motif and will not be discussed to any further extent in this thesis. 
Reversion of MAPK activation is achieved by MAPK phosphatases (MKPs) which remove 
stimulatory phosphate residues from the kinases, thereby rendering them inactive and 
terminating the signal. 
TNFR superfamily members activate MAPKs via TRAF proteins following receptor 
trimerisation, leading to activation of transcription factors including activator protein-1 
(AP-1) composed of Fos (c-Fos, FosB, Fra-1 and Fra-2), and Jun (c-Jun, JunB and JunD) 
members. Depending on the extracellular stimulus, the seven TRAF proteins are of 
differential importance. CD40-induced p38 and JNK activation for instance primarily rely on 
TRAF2, whereas the contribution of TRAF6 is less, though still significant (Matsuzawa et al, 
2008). By contrast, TRAF2 is the main TRAF protein implicated in TNFR1 signalling, which 
most potently activates p38 and JNK. JNK activation was severely impaired in Traf2-/- 
fibroblasts, whereas NF-κB responses were only mildly affected (Yeh et al, 1997). This might 
be due to partial redundancy with TRAF5 given that Traf2-/- Traf5-/- double knockout cells 
completely lacked IKK activation (Tada et al, 2001). However, these results indicate that JNK 
activation primarily depends on TRAF2, whereas TRAF5 can partially compensate for 
TRAF2 in NF-κB responses.  
1.3.2.1 MAP3Ks in TNFR1 signalling 
As described before, activation of MAPKs requires a tightly controlled three-tiered cascade, 
in which a kinase is activated by phosphorylation by its particular up-stream kinase (Figure 
3). However, the mechanisms leading to activation of the “initiator” kinases, i.e. the MAP3Ks 
remain inconclusive. Genetic approaches ablating expression as well as genome-wide small 
interference RNA-mediated down-regulation approaches both aim at identifying potential 
MAP3Ks involved in p38 and JNK activation.  
Among the diverse pathways, receptor tyrosine kinase (RTK) signalling is probably best 
characterised. Early work revealed that the adaptor protein GRB2 is recruited though its SH2 
domain to phospho-tyrosine residues of activated growth receptors. Subsequently, GRB2 
serves to recruit the nucleotide exchange factor son of sevenless (SOS), which then mediates 
recruitment of the small GTPase Ras and its activation at the cell membrane. In its guanosine-
triphosphate (GTP) bound form, Ras subsequently performs direct protein-protein interaction 
with the MAP3K Raf-1, inducing its phosphorylation and hence activation. 
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For TNFR1 signalling, several MAP3Ks have been described with TAK1 being the best 
characterised. TAK1 was initially identified as MAP3K activated by TGFβ (Yamaguchi et al, 
1995). TAK1-deficient mice die embryonically at day E10.5 and fibroblasts generated from 
these embryos showed defective IL-1- and TNF-induced NF-κB, JNK and p38 responses, 
indicating a crucial function for TAK1 in activation of these pathways (Sato et al, 2005). 
TAK1 is recruited to the TNF-RSC by its adaptor proteins TAB2/3. Tab1-/- fibroblasts 
exhibited normal NF-κB and MAPK responses, indicating that TAB1 is dispensable for 
TAK1 activation. Although no defects were monitored in cells devoid of TAB2, concomitant 
depletion of its homologue TAB3 severely impaired TAK1 and hence IKK and MAPK 
activation (Ishitani et al, 2003), indicating that TAB2 and TAB3 play redundant functions and 
that TAK1 activation depends on the presence of at least one of these proteins. In particular, 
TAB2 or TAB3 are required to recruit the TAK1/TAB complex to the TNF-RSC by binding 
to K63-linked poly-ubiquitin chains via their NZF domains (see chapter 1.5.3) (Kanayama et 
al, 2004). Although TAK1 is clearly required for NF-κB, JNK and p38 activation, the 
mechanism leading to TAK1 activation itself remain poorly defined. Possible mechanisms 
include proximity-induced and conformational change-induced trans-autophosphorylation. 
Figure 3: MAPK signalling. Following receptor recruitment, the MAP3Ks TAK1, MEKK1 and ASK are 
activated and subsequently phosphorylate down-stream MAP2Ks. MKK3/6 then activate the MAPK p38, 
whereas MKK4/7 are associated with JNK1/2 activation. Together with concomitant NF-κB activation, MAPKs 
activate gene transcription of pro-survival genes. Amongst these, SOD scavenges ROS, thereby inhibiting ASK 
activation. Hence, MKPs are no longr inhibited and allow for the termination of MAPK signalling. Active JNK1 
stimulates the E3 ligase Itch, which attaches K48-linked ubiquitin chains to c-FLIP, thereby inducing its 
degradation and consequently allowing cell death to occur via complex II-activated caspase-8. 
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Alternatively, Wang et al. proposed that TAK1 becomes activated by K63-linked 
ubiquitination through an undefined ligase (Wang et al, 2001). 
MEKK1 was the second MAP3K identified and was shown to potently activate p38 and JNK 
upon overexpression (Minden et al, 1994). These results were confirmed in knockout cells, 
which showed impaired JNK and p38 activation upon various stimuli (Xia et al, 2000; Yujiri 
et al, 2000). Co-sedimentation experiments showed that MEKK1 associated with 
oligomerised TRAF2, thereby providing a possible link between MEKK1 function and TNF-
RSC formation (Baud et al, 1999). Together with TRAF2, MEKK1 was shown to recruit 
Germinal Centre Kinases (GCKs) and Germinal Centre Related Kinases (GCRKs) to the 
TNF-RSC, thereby providing another layer of kinases (MAP4Ks) involved in TNFR1 
signalling (reviewed in Kyriakis, 1999). However, the exact mechanism for GCK/GCRK-
mediated MEKK1 activation remains poorly described. Besides its kinase domain, MEKK1 
possesses a RING finger motif exhibiting ligase activity (Lu et al, 2002). However, a target 
for this domain implicated in TNFR1 signalling has not yet been identified. 
MEKK3 was proposed as further MAP3K implicated in TNFR1-mediated p38 and JNK 
activation, given that its overexpression was sufficient to activate both pathways (Blank et al, 
1996). However, knockout experiments revealed a rather modest effect on TNF-induced 
MAPK activation, but a strong influence on NF-κB signalling (Yang et al, 2001). 
Consistently, MEKK3 has been shown to be recruited to RIP1 and to phosphorylate IKKα 
and IKKβ, providing another possible mechanism of IKK activation. Given its minor 
influence on MAPK activation, MEKK3 seems to act up-stream of TAK1 specifically 
stimulating NF-κB signalling.   
Apoptosis signal-regulating kinase-1 (ASK1) was also described as MAP3K to activate the 
JNK and p38 pathway. Prolonged JNK activation was inhibited in ASK1-ablated fibroblasts, 
indicating a function for ASK1 in JNK stimulation (Matsuzawa & Ichijo, 2008). Following 
TNFR1 stimulation, ASK1 associates with TRAF2 and becomes activated (Hoeflich et al, 
1999). ASK1 function is endogenously inhibited by thioredoxin (Trx), which directly binds to 
the N-terminal non-catalytic domain of ASK1, thereby preventing its activation by TNF 
(Saitoh et al, 1998). However, TNFR1 stimulation leads to TRAF2-dependent reactive 
oxygen species (ROS) production (Liu et al, 2000), which was shown to inhibit Trx binding 
to ASK1. Released ASK1 is then activated by TRAF2 by so far uncharacterised mechanisms, 
most likely involving homo-oligomerisation of ASK1. Moreover, ROS was shown to oxidise 
critical cysteine residues in the active centres of MKPs, thereby inhibiting their activity.  
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1.3.2.2 The ERK1/2 module  
ERK1 and ERK2 show 83% amino acid identity and are expressed in all tissues, though to 
various extents. ERK1 was the first MAPK identified and cloned in the early 90’s and found 
to be activated by growth factor RTKs (Boulton et al, 1991; Boulton et al, 1990). Apart from 
growth factors, ERK1/2 is also activated by a variety of other stimuli, including cytokines, 
osmotic shock and insulin (Raman et al, 2007). While the MAP3Ks A-Raf, B-Raf, Raf-1 are 
the major activators of ERK1/2 in RTK signalling, MEKK1 and Tpl2 (tumour progression 
locus 2) function in a more cell-type and stimulus-restricted manner to activate the MAP2Ks 
MEK1 and MEK2. 
Stimulation of the ERK1/2 pathways results in its re-localisation from the cytoplasm into the 
nucleus, in which it activates the transcription factor Elk-1. Elk-1 is known to induce the 
expression of early-intermediate genes including c-Fos, which is furthermore stabilised by 
direct ERK1/2 phosphorylation. Dimerisation of c-Fos with c-Jun induces the formation of 
active AP-1 complexes, which subsequently activate the transcription of a variety of target 
genes including cyclinD1, a protein critically linked to cell cycle progression. Thus, ERK1/2 
regulate cell proliferation and efficient G1 to S-phase transition (Cargnello & Roux, 2011).  
1.3.2.3 The JNK module 
JNK (also known as stress-activated protein kinase (SAPK)) is expressed in three different 
isoforms sharing 85% identity, which were cloned in the mid 90s by two independent groups 
(Derijard et al, 1994; Kyriakis et al, 1994). While JNK1/2 are widely expressed, JNK3 is 
primarily detected in neuronal tissues, testis and cardiac myocytes (Bode & Dong, 2007). The 
three-tiered kinase cascade leading to JNK1/2/3 activation involves the MAP2Ks MKK4 and 
MKK7 and the MAP3Ks MEKK1-4, MLK1-3, Tpl2, DLK, TAK1 and ASK1/2.  
Both Mkk4 (Ganiatsas et al, 1998; Nishina et al, 1999; Yang et al, 1997) and Mkk7 genes 
(Dong et al, 2000) are required for embryonic viability, indicating non-redundant functions of 
these proteins. Indeed, JNK is preferentially phosphorylated on Tyr by MKK4 and on Thr by 
MKK7 (Lawler et al, 1998), suggesting that dual phosphorylation by both kinases is required 
for full JNK activation. Consistently, Tournier et al. demonstrated that MKK7-induced JNK 
phosphorylation on Thr residues activated JNK. However, maximal in vitro JNK activation 
required dual phosphorylation mediated by MKK4 and MKK7. Furthermore, intensive studies 
using MKK4 and MKK7 deficient fibroblasts showed an essential role for MKK7 in JNK 
activation induced by pro-inflammatory cytokines (IL-1, TNF) as well as exposure to 
extracellular stress. In contrast, though MKK4 was required for UV radiation-induced JNK 
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activation, cytokine-induced signalling was only marginally affected, consistently with a lack 
of TNF- and IL-1-induced MKK4 activation (Tournier et al, 2001). Taken together, these data 
indicate that MKK4 is required for full JNK activation and that basal MKK4 activity in the 
presence of MKK7 is sufficient to maximally stimulate JNK activity.  
Once activated, JNK phosphorylates c-Jun on Ser63/73, thereby increasing c-Jun-mediated 
transcription of target genes involved in cell proliferation, including cyclin D1 (Sabapathy et 
al, 2004). In contrast, Jnk1/2-/- double knockout fibroblasts were resistant to DNA damage- 
and UV-irradiation-induced cell death due to impaired cytochrome c release, indicating a 
function of JNK in intrinsic apoptotic responses (Tournier et al, 2000). Liu et al. showed that 
JNK1 had a more prominent function in TNF-induced cell death induction as compared with 
JNK2, indicating that although these proteins share high sequence homology, their functions 
are not completely redundant (Liu et al, 2004).  
JNK signalling involves two phases (Ventura et al, 2006), with the first one being transiently 
activated early after receptor stimulation leading to the induction of pro-survival genes (Lamb 
et al, 2003). In contrast, the second, sustained phase is involved in cell death responses and 
tightly controlled by a crosstalk to NF-κB as well as activation by ROS-mediated ASK1 
activation.  
1.3.2.4 The p38 MAPK module 
The p38 family of MAPKs consists of the four members p38α, p38β, p38γ and p38δ. The 
p38α isoform, which was identified in 1994, is the prototypic member of this family and is 
generally more responsive to stress stimuli as compared to ERK1/2 (Han et al, 1994; Lee et 
al, 1994; Rouse et al, 1994). Like p38β, p38α is ubiquitously expressed (Jiang et al, 1996). 
However, due to its higher expression in most tissues, most literature about p38 is restricted to 
the α isoform. MKK3 and MKK6 are the major MAP2Ks implicated in p38 activation, 
whereas MKK4 has a lower activity and is most prominently implicated in JNK activation. 
However, most stimuli do not exclusively activate one MAPK pathway, but p38 and JNK are 
generally activated at the same time by the same agents. While MKK6 activates all isoforms, 
MKK3 is unable to stimulate p38β. Various MAP3Ks have been implicated in the three-tiered 
p38 kinase cascade, including MEKK1-3, ASK1, Tpl2 and TAK1. The major function of p38 
MAPKs is the production of pro-inflammatory cytokines, either by directly inducing their 
expression or by enhancing their mRNA stability and translation. Furthermore, p38 is 
implicated in cell proliferation and survival as it negatively regulates cell cycle transition at 
the G1-S and G2-M phase levels by down-regulating cyclins. 
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1.4 Cell death induction by death ligands of the TNF-Receptor superfamily 
Most TNFR-superfamily members are involved in inflammation and immunity. However, 
based on the presence of a DD in the cytoplasmic part of the receptor, TNFR1, CD95 and 
TRAIL-R1/R2 are able to induce cell death. Although TNFR1 signalling is primarily involved 
in survival and proliferation, imbalances in NF-κB and MAPK activation lead to cell death. In 
contrast, the main function of CD95 and TRAIL-R1/R2 in immunity is to induce cell death of 
activated lymphocytes to prevent them from responding excessively against healthy tissue, 
thereby conferring tissue homeostasis. While CD95L- and TRAIL-induced cell death 
originates at the plasma membrane immediately following receptor engagement, TNF-
induced death responses are rather slow and mediated via an intracellular complex derived 
from the membrane-associated complex. Initially, death ligand-induced cell death was solely 
attributed to be of apoptotic nature involving a tightly controlled cascade of caspase-cleavages 
resulting in the death of individual cells without affecting neighbouring tissue. However, 
intense research in the past decade revealed that death ligands can also induce a caspase-
independent form of cell death (Laster et al, 1988)  which has been referred to as necroptosis 
(Degterev et al, 2005). Unlike necrosis, in which cells die “accidentally”, necroptosis is, 
similar to apoptosis, a tightly controlled process regulated by the two closely related kinases 
RIP1 and RIP3 (Vandenabeele et al, 2010). 
1.4.1 CD95L- and TRAIL-induced apoptosis 
1.4.1.1 The CD95L/CD95 and TRAIL/TRAIL-R1/2 systems 
Cell death mediated by TNFR superfamily members is primarily associated with the 
CD95L/CD95 as well as TRAIL/TRAIL-R1/R2 systems. The major function of CD95L 
(APO-1L, FasL) is mediated by its binding to CD95 (APO-1, Fas). Although binding to 
Decoy-Receptor3 (DcR3) has been suggested to neutralise its apoptosis-inducing function, the 
physiological relevance of this interaction is less clear (Wroblewski et al, 2003). 
CD95 is ubiquitously expressed, though predominantly in the thymus, liver, heart, kidney and 
in virus-transformed lymphocytes. In contrast, CD95L expression is very restricted and tightly 
regulated. Following activation, T cells up-regulate CD95L and subsequently die by AICD 
(Dhein et al, 1995). Accordingly, deregulation of the CD95 system, as in ALPS (autoimmune 
lymphoproliferative syndrome) patients carrying a heterozygous mutation in the CD95 gene, 
is hallmarked by the inability to shut down immune responses. Activated T cells are not 
eliminated but remain active, thereby creating autoimmune reactions against self-antigens 
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(Rieux-Laucat et al, 1995). Another important function of the CD95L/CD95 system is to kill 
virus-infected and oncogene transformed cells.  
CD95L can be found as membrane-bound ligand or soluble protein generated by the metallo-
protease ADAM10 (Schulte et al, 2007). Aggregation of pre-assembled CD95L trimers is 
required for CD95L-induced cell death. Yet, the contribution of membrane-bound versus 
soluble CD95L remained obscure. To answer this question, O’Reilly et al. recently generated 
mice which either lacked soluble CD95L (lacking the ADAM10-cleavage site; FasL∆s/∆s) or 
membrane bound CD95L (lacking the transmembrane domain; FasL∆m/∆m). This study showed 
that only T cells obtained from FasL∆s/∆s, not FasL∆m/∆m mice were capable of killing target 
cells (O'Reilly et al, 2009). Furthermore, FasL∆m/∆m mice developed lymphadenopathy and 
hyper-gammaglobulinaemia, similar to FasLgld/gld animals, which exhibit mutations in the 
CD95L sequence abolishing its binding to CD95. However, FasL∆m/∆m additionally developed 
systemic lupus erythematosus (SLE)-like auto-immune kidney destruction and histocytic 
sarcomas, alterations only rarely seen in FasLgld/gld mice. Taken together, these results 
implicate that membrane-bound CD95L confers cytotoxicity and prevents autoimmunity and 
cancer development. In contrast, excessive accumulation of soluble CD95L amplifies non-
apoptotic CD95 signalling, thereby promoting tumourigenesis and manifestation of 
autoimmune disorders. 
TRAIL was found to bind to five receptors in the human system, i.e. TRAIL-R1 (DR4), 
TRAIL-R2 (DR5, APO-2, KILLER, TRICK2), TRAIL-R3 (DcR1), TRAIL-R4 (DcR2) and 
OPG. However, only TRAIL-R1 and TRAIL-R2 are capable of inducing apoptosis due to the 
presence of an intracellular DD. It is still a matter of debate why cells express two receptors 
with apparently similar functions, although expression of only one is sufficient to induce cell 
death in a variety of tumour cells (Sprick et al, 2002). However, non-apoptotic functions 
including cell migration and proliferation might differentially require TRAIL-R1 and 
TRAIL-R2, respectively. 
Although the extracellular domains of TRAIL-R3 (Degli-Esposti et al, 1997a; Degli-Esposti 
et al, 1997b) and TRAIL-R4 (Degli-Esposti et al, 1997a) are highly homologous to their 
apoptosis-inducing counterparts, both receptors completely or partially lack intracellular DDs 
and are therefore referred to as decoy receptors. Merino et al. proposed that both decoy 
receptors use diverse mechanisms to inhibit TRAIL-induced apoptosis. On the one hand, 
TRAIL-R3 was shown to retain TRAIL within lipid rafts, thereby competitively inhibiting its 
binding to TRAIL-R1/2. On the other hand, TRAIL-R4 formed hetero-dimers with 
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TRAIL-R2 following TRAIL binding, which prevented the formation of active signalling 
platforms transmitting apoptotic signals (Merino et al, 2006). However, this study was based 
on overexpression experiments and a regulatory function of TRAIL-R3/4 under physiological 
conditions has not been demonstrated yet. Moreover, expression of the decoy receptors does 
not correlate with resistance of a given cell towards TRAIL-induced cell death, challenging a 
decoy function of these receptors.  
OPG was described as the fifth, rather low-affinity receptor for TRAIL (Truneh et al, 2000). 
Initially, OPG was shown to competitively inhibit interactions between RANKL and RANK, 
thereby repressing osteoclast formation. However, given that Trail-/- and Trail-R-/- mice do not 
show any obvious defects in bone architecture, it is rather unlikely that TRAIL-OPG 
interactions are involved in bone remodelling (Cretney et al, 2002; Diehl et al, 2004).  
TRAIL and TRAIL-R1/2 are ubiquitously expressed through human tissues, including spleen, 
thymus, peripheral blood lymphocytes, prostate, testis, ovary, uterus and multiple tissues 
along the gastrointestinal tract (Walczak et al, 1997; Wiley et al, 1995). Thus, in contrast to 
CD95 signalling, which is tightly controlled by regulated CD95L expression, other regulatory 
mechanisms except from mRNA expression have to account for the TRAIL system. 
1.4.1.2 The extrinsic apoptotic pathway 
Cell death initiated by TRAIL or CD95L is a tightly controlled process characterised by a 
caspase-activation cascade, which can be interrupted or promoted at various check-points by 
intracellular pro- and anti-apoptotic proteins. Pre-formed TRAIL or CD95L trimers bind to 
their respective receptors, which can form pre-assembled receptors connected via a pre-ligand 
assembly domain (PLAD). This domain allows for di- or trimerisation of the receptor without 
binding of the respective ligand. Although the PLAD domain differs from the interaction 
surface required for ligand binding and is not capable of transmitting a death signal, it might 
depict a pre-requisite for efficient higher-order oligomerisation of the receptor following 
binding of the respective ligand to ensure efficient signal transduction (Chan et al, 2000). 
Ligand binding to this pre-assembled receptor complex results in juxtaposition of the DDs, 
allowing for the recruitment of Fas-associated death domain (FADD), which binds via its DD 
to the DD of the receptor. Subsequently, pro-caspase-8 and -10, as well as the cellular FLICE-
like inhibitory protein (c-FLIP) are recruited by interaction of their death-effector domains 
(DEDs) with the DEDs of FADD (Figure 4). Together, these proteins form the death-inducing 
signalling complex (DISC). 
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Caspases are cysteinyl-aspartate specific proteases possessing cysteine residues in their active 
centres which are crucial for cleaving their target proteins after aspartic acid residues. They 
are synthesised as pro-enzymes consisting of a large and a small catalytic subunit and an 
amino-terminal pro-domain. Initiator caspases including caspase-2, -8, -9 and -10 activate 
caspase-cascades, while the effector/executioner caspases-3, -6 and -7 translate apoptotic 
signals through cleavage of non-caspase target proteins.  
Recruitment of pro-caspase-8 and -10 to the DISC results in auto-catalytic processing through 
not completely defined mechanism, most likely involving proximity-induced activation. Once 
caspase-8 is processed to its active form, it cleaves down-stream caspases including caspase-3 
by separating the large from the small subunit. However, this step is not sufficient to activate 
Figure 4: The extrinsic and intrinsic apoptotic pathways. Binding of TRAIL or CD95L to TRAIL-R1/R2 or 
CD95, respectively, induces receptor trimerisation associated with the recruitment of FADD, caspase-8/10 and  
c-FLIP to the DISC. Caspases-8/10 are then activated at the DISC by auto-catalytic cleavage and subsequent 
process caspase-3 and Bid. Truncated bid (tBid) then translocates to the mitochondria and activates Bax/Bak, 
thereby inducing a loss of mitochondrial membrane potential associated with the release of Smac/DIABLO and 
cytochrome c. Cytochrome  c together with Apaf-1 and caspase-9 form the apoptosome, leading to caspase-9 
activation followed by cleavage of caspase-3. Active caspase-3 then processes down-stream substrates to induce 
apoptosis. DNA damage is capable of activating other BH3-only proteins except of Bid, which result in 
mitochondrial changes and release of pro-apoptotic factors. Apoptosis can be inhibited by c-FLIP at the DISC 
level by interfering with caspase-8 maturation. Alternatively, XIAP inhibits caspase-3 maturation to prevent 
propagation of the apoptotic signal. However, mitochondrial release of Smac/DIABLO counteracts the function 
of XIAP, thereby removing its inhibitory function and allowing apoptosis to occur. 
1. Introduction 
24 
 
caspase-3 which requires a further auto-catalytic maturation step involving the removal of its 
pro-domain (Figure 5). Once activated, caspase-3 cleaves a variety of cellular proteins, 
including poly(ADP)-Ribose-Polymerase (PARP), lamins and cytokeratins. Furthermore, it 
inactivates ICAD/DFF45, the inhibitor of Caspase Activated DNase (CAD), thereby 
liberating CAD, which subsequently enters the nucleus to fragment DNA, thereby producing 
the “DNA ladder” characteristic for apoptotic cells (Inohara et al, 1999; Liu et al, 1998). 
1.4.1.3 The intrinsic apoptotic pathway 
Apart from death receptor-induced activation of the above described extrinsic pathway, 
apoptosis can also be initiated autonomously by intracellular caspase activation following 
irradiation- or chemotherapeutic agent-induced DNA damage. This so-called intrinsic 
apoptotic pathway primarily depends on mitochondria. Mitochondrial integrity is tightly 
regulated by a functionally diverse class of proteins that belong to the B cell lymphoma 2 
(Bcl-2) family. Due to their domain structure, members of the Bcl-2 family can be subdivided 
Figure 5: Schematic representation of caspse-3 activation. Caspase-3 is activated in a two-step mechanism in 
which the small p12 sub-unit is initially cut off by caspase-8 or -9 to produce a p20 fragment lacking enzymatic 
activity. In a second auto-catalytic cleavage process, which can be inhibited by XIAP, caspase-3 removes its pro-
domain to generate a p17 fragment, which heterodimerises with the p12 fragment to form active caspase-3.  
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into three groups (Borner, 2003). Anti-apoptotic proteins like Bcl-2, Bcl-extra large (Bcl-XL) 
and myeloid leukaemia cell differentiation 1 (Mcl-1) are associated with the outer membrane 
of the mitochondria in order to maintain mitochondrial integrity, to prevent cytochrome c 
release and to promote cell survival. In contrast, members of the pro-apoptotic Bcl-2 family 
including Bcl-2-associated X protein (Bax), Bcl-2-antagonist/killer (Bak) and Bok destabilise 
mitochondrial integrity possibly by generating a transmembrane pore through the outer 
mitochondrial membrane during apoptosis, thereby inducing loss of the mitochondrial 
transmembrane potential and release of pro-apoptotic factors. Pro-apoptotic Bcl-2 family 
members are activated by molecules of the Bcl-2 homology 3 (BH3)-only family of proteins 
including BH3-interacting domain death agonist (Bid), Bcl-2 antagonist of cell death (Bad), 
p53 up-regulated modulator of apoptosis (PUMA), NOXA and Bcl-2-interacting mediator of 
cell death (Bim). It remains controversial whether these proteins directly activate the pro-
apoptotic Bcl-2 proteins Bax and Bak or only indirectly via neutralisation of Bcl-2-like anti-
apoptotic proteins (Strasser, 2005). 
Genotoxic stress-activated BH3-only proteins increase the permeability of the outer 
mitochondrial membrane, resulting in the release of cytochrome c and other pro-apoptotic 
factors from the mitochondrial intermembrane space into the cytosol. Together with apoptotic 
protease-activating factor-1 (Apaf-1), dATP and pro-caspase-9, cytochrome c forms a 
complex referred to as apoptosome (Baliga & Kumar, 2003). Like caspase-8, apoptosome-
activated caspase-9 is also able to activate pro-caspase-3. Activated caspase-3 not only 
cleaves down-stream targets involved in apoptosis execution, but also pro-caspase-9, thereby 
providing a positive feedback loop assuring apoptosis to be inevitably carried out.  
Bid is not only activated by DNA damage and cellular stress but also cleaved by caspase-8. 
Truncated Bid (tBid) translocates to the mitochondria to allow the release of pro-apoptotic 
factors, which then facilitate full caspase-3 activation. Thus, Bid bridges the extrinsic and 
intrinsic apoptotic pathways. 
1.4.1.4 Checkpoints in apoptotic responses 
Depending on the need of the intrinsic apoptotic pathway to undergo death receptor-induced 
apoptosis, cells can be classified as type I and type II cells. Type I cells are characterised by 
strong DISC formation and therefore strong caspase-8 activation, which fully activates 
caspase-3. In contrast, DISC formation in type II cells is rather weak. Thus, these cells 
additionally require the mitochondrial amplification loop to efficiently activate effector 
caspases to undergo apoptosis (Ozoren & El-Deiry, 2002). However, this view was recently 
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challenged by Jost et al. who showed that the dependency on the intrinsic pathway is defined 
by intracellular X-chromosome linked inhibitor of apoptosis (XIAP) levels (Jost et al, 2009). 
CD95L induced caspase-dependent rapid loss of XIAP levels in thymocytes, which represent 
the prototype of type I cells. In contrast, XIAP levels increased in type II-classified 
hepatocytes in response to CD95 stimulation, whereas other anti-apoptotic proteins including 
Bcl-2, Bcl-XL and Mcl-1 or pro-apoptotic Smac/DIABLO (second mitochondria-derived 
activator of caspases/direct IAP binding protein with low PI) did not significantly change 
during CD95 engagement. Injection of CD95L or agonistic anti-CD95 antibodies into mice 
resulted in rapid death due to massive hepatocyte death and hence liver failure (Huang et al, 
1999; Ogasawara et al, 1993). Given that type II cells depend on the mitochondrial 
amplification loop to execute cell death, it is not surprising that Bid-/- mice are resistant 
towards this treatment (Kaufmann et al, 2009). However, Bid-/- Xiap-/- double knockout mice 
succumbed to CD95L-induced death, indicating that XIAP is the crucial factor discriminating 
between type I and type II cells. 
XIAP inhibits cell death by directly interacting via the BIR2, the preceding linker region and 
the BIR3 domain with caspase-3, -7 and -9 (Riedl et al, 2001). XIAP blocks the removal of 
the inhibitory pro-domain of caspase-3, thereby inhibiting the above-mentioned maturation 
step. Moreover, XIAP has been shown to catalyse the ubiquitination of caspase-3, leading to 
its proteasomal degradation (Vaux & Silke, 2005). Consistently, murine cells expressing an 
E3 ligase-deficient version of XIAP exhibited elevated levels of active caspase-3 and 
increased sensitivity towards apoptotic stimuli (Schile et al, 2008).  
The activity of XIAP is in turn controlled by another set of proteins that antagonises their 
function. Once released from the mitochondrial intermembrane space, pro-apoptotic 
Smac/DIABLO interacts with the BIR domains of XIAP, cIAP1 and cIAP2 via its N-terminal 
four amino acid AVPI sequence (Liu et al, 2000; Wu et al, 2000). Binding of Smac/DIABLO 
or its mimetics to XIAP directly relieves its interaction with caspase-3, -7 and -9 (Chai et al, 
2000; Li et al, 2004). Liberation of caspase-3 from XIAP subsequently induces its auto-
catalytic cleavage and hence full activation, thereby allowing apoptosis to proceed. 
Furthermore, Smac/DIABLO functions as an allosteric activator of the E3 ligase activity of 
cIAP1/2, thereby promoting cIAP1/2 auto-ubiquitination and subsequent proteasomal 
degradation (Du et al, 2000; Varfolomeev et al, 2007; Vince et al, 2007). 
The family of c-FLIP constitute another major control point regulating death receptor-induced 
responses. Due to the presence of two DEDs, c-FLIP closely resembles caspase-8 in structure 
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and hence competes with it for binding to FADD (Krueger et al, 2001). However, due to a 
lack of the critical cysteine residue within the active centre, c-FLIP does not possess 
proteolytic activity. Hence, displacement of caspase-8 from the DISC prevents the initiation 
of the caspase cascade responsible for apoptosis transmission. The amount of c-FLIP within a 
cell inversely correlates with the amount of caspases that are activated at the DISC and is 
hence a decisive factor for apoptosis induction.  
c-FLIP exists in three splice variants giving rise to a long poly-peptide of 55 kDa (c-FLIPL), a 
short one of 26 kDa (c-FLIPs) and a third, 23 kDa form which has been initially described in 
the Raji B cell line (c-FLIPR) (Golks et al, 2005). Overexpression of c-FLIPL modulates DISC 
formation in a way that the entire pool of DISC-recruited caspase-8 constitutes of immature 
p41/p43 fragments. However, generation of the active p18 fragment is inhibited. In contrast, 
high levels of c-FLIPS in the DISC reduce overall DISC-recruited caspase-8 levels and 
completely inhibit its processing (Kuvari et al, 2011). Comprising two DEDs and an 
additional C-terminal caspase domain, c-FLIPL closely resembles caspase-8 in its overall 
structure. Recruitment of c-FLIPL to the CD95 and TRAIL-R1/2 DISC induces its caspase-
mediated cleavage to produce a 43 kDa isoform which still contains the DEDs and the 
pseudo-caspase-motif. This fragment remains bound to FADD and inhibits caspase-8 
maturation. Whereas c-FLIPS and c-FLIPR completely inhibit pro-caspase-8 cleavage at the 
DISC, cFLIPL rather interferes with full maturation of DISC-recruited pro-caspase-8.  
Another layer of complexity regulating death receptor signalling is provided by 
ubiquitination. Although the function of the ubiquitin system for cell signalling has been best 
characterised for TNFR1, Jin et al. described that caspase-8 ubiquitination is required for its 
full activity in TRAIL-R signalling (Jin et al, 2009). The RING E3 ligase Cullin3 was 
reported to be recruited to the DISC to induce caspase-8 ubiquitination, followed by p62-
mediated aggregation of caspase-8, leading to its stabilisation and thereby augmenting its 
activation and full processing. Thus, ubiquitination in death receptor signalling has recently 
emerged as a new mechanism positively controlling its outcome. 
Several tumours overexpress anti-apoptotic IAPs, a condition generally associated with poor 
prognosis (Hunter et al, 2007). The function of cIAP1/2 is also crucially linked to the 
regulation of death receptor responses given that cIAP1 ubiquitinates caspase-3 and -7 (Choi 
et al, 2009) as well as Smac (Hu & Yang, 2003), thereby enhancing cell survival. Constitutive 
activation of the NF-κB pathway by translocation-induced generation of a cIAP2-MALT1 
(mucosa-associated lymphoid tissue) fusion protein is associated with the development of 
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non-Hodgkin MALT lymphomas, characterised by enhanced pro-survival and pro-
inflammatory signalling, tumour progression and resistance to anti-cancer drugs (Zhou et al, 
2005). Targeting IAPs in tumours exhibiting enhanced expression or activity of theses E3 
ligases constitutes a promising strategy in cancer therapy. The most promising approach 
developed so far involves small molecule IAP antagonists mimicking the N-terminal AVPI 
sequence of active Smac/DIABLO. IAP antagonists efficiently bind to the BIR domains of 
IAP proteins and have been proven efficient in inhibiting tumour growth in vivo (Ndubaku et 
al, 2009). Unexpectedly, IAP antagonists not only prevent the interaction of XIAP and cIAPs 
with caspases, but induce conformational changes in cIAP1/2, resulting in their activation, 
auto-ubiquitination and subsequent degradation (Sun et al, 2007). As described in chapter 
1.3.1.2, depletion of cIAPs induces NIK stabilisation and activation of non-canonical 
signalling. Translocation of p52/RelB dimers to the nucleus drives transcription of various 
target genes involved in pro-inflammatory responses, including TNF. Secreted TNF 
subsequently binds to TNFR1 and, in the absence of cIAP1/2, induces cell death (see chapter 
1.4.2). However, as shown in vitro using a panel of tumour cell lines, TNF is only produced 
by a subset of cell lines, which are therefore referred to as Smac mimetic (SM) sensitive 
(Vince et al, 2007). With regard to therapeutic use, IAP antagonists might be especially useful 
for the treatment of SM-sensitive tumours.  
Only recently, Geserick et al. provided new mechanistic insights into how cIAP1/2 regulate 
TRAIL- and CD95L-induced cell death responses. SM-induced depletion of cIAP1/2 in 
keratinocyte cell lines strongly sensitised for CD95L- and TRAIL-induced cell death, which 
was accompanied by increased levels of RIP1 at the DISC (Geserick et al, 2009).  RIP1 as 
well as caspase-8 activity was required for cell death in the absence of cIAP1/2, indicating 
that SM-induced cell death possesses apoptotic as well as necroptotic characteristics (see 
chapter 1.4.3). Furthermore, c-FLIPL but not c-FLIPS inhibited RIP1 recruitment to the DISC 
and rescued cell death in the absence of cIAP1/2. Thus, RIP1 has a fundamental role in 
TRAIL- and CD95L-induced signalling and provides an alternative, caspase-independent 
death pathway. 
So far, no differences in DISC composition between the CD95 and TRAIL-R1/R2 have been 
identified. However, biological outcomes of TRAIL versus CD95L-stimulation are extremely 
diverse. While systemic CD95 stimulation kills normal tissues including hepatocytes, TRAIL 
can specifically eliminate malignantly transformed cells without damaging healthy tissue, 
proposing TRAIL as promising strategy in anti-cancer therapy. More studies analysing the 
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DISC compositions in the two systems will be required to identify target proteins explaining 
the diverse cellular responses.  
Taken together, cell death induction by TRAIL and CD95L is a highly controlled process that 
can be modified at different levels, including the DISC (c-FLIP, caspase-8 ubiquitination), 
mitochondria (Bcl-2 family members, Smac/DIABLO release) as well as intracellular E3s 
(XIAP, cIAPs). Imbalances in the signalling cascade are readily linked to the development of 
autoimmune disorders and tumourigenesis.  
1.4.1.5 Non-apoptotic TRAIL- and CD95L-induced signalling 
Apart from their abilities to induce cell death, CD95 and TRAIL-R1/2 can also activate 
NF-κB and MAPKs, albeit to a lesser extent and with delayed kinetics when compared to 
TNFR1 signalling (reviewed in Falschlehner et al, 2007). Death receptor-induced activation 
of JNK and p38 in HaCaT cells appeared rather late, peaking st around two hours (Kavuri et 
al, 2011). Inhibition of caspases or overexpression of any c-FLIP isoform suppressed TRAIL- 
and CD95L-induced MAPK activation. In contrast, NF-κΒ activation, which was also 
inhibited by c-FLIP overexpression, did not depend on caspase-8 activity but on its mere 
presence. Consistent with a missing function of c-FLIP in TNF-RSC formation, its 
overexpression did not interfere with TNF-induced NF-κB and MAPK activation. Thus, anti-
apoptotic TRAIL- and CD95L-induced signalling depends on the presence (NF-κB) or 
activity (MAPKs) of caspase-8 and is negatively regulated by c-FLIP (Kavuri et al, 2011). 
In line with a pro-survival function of TRAIL, Varfolomeev et al. proposed the generation of 
one or several secondary intracellular complexes following TRAIL stimulation which contain 
caspase-8, FADD, NEMO, TRAF2 and RIP1 (Varfolomeev et al, 2005). However, little is 
known about the function of the secondary complexes, whether they merely serve anti-
apoptotic functions or also contribute to cell death induction. Furthermore, it remains to be 
determined whether the proteins mentioned above form part of the same complex or constitute 
various sub-complexes with different functions. However, unlike delayed TNF-induced 
complex II (see next chapter), TRAIL- and CD95L-induced secondary complexes seem to 
form simultaneously with the primary, membrane-bound signalling platforms. Thus, more in-
depths analyses are required to understand the function and relevance of these secondary 
complexes. 
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1.4.2 TNFR1-induced apoptosis 
1.4.2.1 TNF-complex II formation 
In 2003, Micheau and Tschopp described the formation of a secondary, intracellular complex 
following TNFR1 activation, which they referred to as complex II (Micheau & Tschopp, 
2003). In contrast to the transmembrane complex, also known as complex I, complex II was 
shown to be implicated in cell death induction. Complex II forms as a consequence of 
complex I and appears with delayed kinetics once the primary complex disassembles. RIP1, 
TRADD and possibly TRAF2 dissociate from the membrane to form a cytosolic complex 
with FADD and caspase-8. This intracellular platform is capable of activating caspase-8 by 
cleavage, resulting in subsequent caspase-3 and Bid activation and hence apoptosis execution. 
Although the precise mechanism remains elusive, Oshima et al. proposed an anti-apoptotic 
function of ABIN-1 in complex II formation by inhibiting caspase-8-FADD interactions and 
subsequent TNF-mediated death (Oshima et al, 2009). However, TNF does not induce cell 
death in most cell lines under physiological conditions. Currently, this is thought to be due to 
rapid, complex I-induced activation of NF-κB, which results in the transcription of anti-
apoptotic genes including c-FLIP, Bcl-2 family members, TRAF proteins and cIAPs 
(Micheau et al, 2001; Wang et al, 1998). Although several anti-apoptotic factors were shown 
to be up-regulated following TNF-induced NF-κB activation, major attention has been 
attributed to c-FLIP regulation, given that Flip-/- fibroblasts undergo TNF-induced cell death 
even without inhibition of NF-κB-dependent gene expression (Yeh et al, 2000). High c-FLIP 
levels in complex II inhibit activation of caspase-8, thereby limiting the cytotoxic potential of 
TNF. Thus, TNF-induced cell death is negatively regulated by NF-κB-dependent c-FLIP 
induction.  
1.4.2.2 TNF-induced JNK mediated cell death 
In contrast to a well-established role for NF-κB in cell survival under normal physiological 
conditions, prolonged JNK activation has been associated with TNF-induced cell death (De 
Smaele et al, 2001; Papa et al, 2004; Tang et al, 2001). Crosstalk between these two pathways 
decides about the fate of a particular cell, i.e. survival or cell death. In this context, NF-κB 
was shown to induce the expression of antioxidants, including superoxide dismutase 2 
(SOD2) (Pham et al, 2004). These antioxidants subsequently prevent oxidation and hence 
suppression of MKPs by ROS, which is also produced upon TNF-stimulation (Kamata et al, 
2005). Thus, MKP-induced dephosphorylation of JNK terminates its activity and hence 
prevents JNK-mediated cell death under physiological conditions. However, in cells in which 
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NF-κB activation is attenuated, antioxidants are not expressed, ROS is not scavenged and 
JNK phosphatases therefore inhibited, resulting in prolonged JNK activation and cell death 
induction. Although prolonged JNK1 activation is required for TNF-induced cell death, 
prolongation of its activity alone in the absence of concomitant TNF stimulation is not 
sufficient to kill cells, indicating that JNK1 targets specific components of TNFR1 signalling 
to allow TNF-induced cell death to occur.  
JNK1-deficient hepatocytes are resistant to TNF plus cycloheximide (CHX)-induced cell 
death and the absence of JNK1 delayed lethality caused by removal of IKKβ by four days, 
underscoring the physiological relevance of an NF-κB (IKKβ-mediated) and JNK crosstalk 
(Chang et al, 2006). The mechanism of JNK-mediated cell death induction has remained an 
open question for several years since a JNK-related target gene has not been identified. 
However, the observation that c-FLIP levels were stabilised in JNK1 deficient cells following 
TNF stimulation combined with the finding that JNK1 (and not JNK2) was able to 
phosphorylate and activate the HECT E3 ligase Itch provided new mechanistic insight to this 
conundrum (Gao et al, 2004). JNK1-mediated Itch activation was shown to induce 
ubiquitination and subsequent proteasomal degradation of c-FLIP, in particular c-FLIPL. 
Reduced levels of c-FLIP were unable to prevent caspase-8/FADD complex formation and 
caspase-8 processing, which ultimately resulted in cell death (Figure 6). Consistently, Itch or 
JNK1deficiency in mice protects them from TNF-induced acute liver failure due to c-FLIP-
mediated protection. Given that Itch phosphorylation is a reversible process, prolonged JNK1 
activation is required to maintain Itch in an active state allowing for complete c-FLIP 
degradation. Taken together, c-FLIP levels, which are controlled on the transcriptional 
(NF-κB induction) and post-translational (JNK1-mediated degradation) level, are critical 
determinants deciding about the output of TNF-induced signalling.  
1.4.2.3 Complex IIA versus Complex IIB 
Complex II-mediated cell death can be executed in cells lacking substantial NF-κB activity, 
due to the inability to up-regulate anti-apoptotic factors (Muppidi et al, 2004). Thus, the 
balance between TNF-induced survival and cell death can be shifted to the latter in cells 
displaying mutations in the NF-κB-activating arm. Based on the dependency of c-FLIP levels 
for TNF-induced cell death, complex II can be subdivided in complex IIA and complex IIB 
(Wang et al, 2008). As mentioned before, most cells are resistant to TNF-induced cell death 
and rather induce pro-survival signalling. However, IAP antagonist-mediated down-regulation 
of cIAPs and CHX-induced inhibition of protein translation enforced complex IIB and IIA 
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formation, respectively, thereby allowing TNF-induced cell death to occur. Internalisation of 
complex I from the membrane induced conformational changes in RIP1 and TRAF2, which 
allowed TRADD to dissociate and to form complex IIA with caspase-8 and FADD. The 
activity of complex IIA depends on c-FLIP levels, which are regulated by TNF-induced JNK 
and NF-κB signalling and are negatively modified by CHX.  
In contrast, complex IIB formation depends on the presence of RIP1, which has been shown 
to possess, based on its ubiquitination state, pro- as well as anti-apoptotic properties (Hsu et 
al, 1996; Stanger et al, 1995). TNF-RSC-recruited RIP1 in IAP antagonist-treated cells was 
not modified with ubiquitin and hence allowed efficient dissociation from the membrane and 
association with caspase-8/FADD. Thus, cIAPs prevent the recruitment of RIP1 to complex 
IIB (Bertrand et al, 2008). TRADD and TRAF2 were not found in complex IIB and TRADD 
knockdown was shown to even enhance SM-induced complex IIB formation and hence cell 
death (Wang et al, 2008).  Furthermore, c-FLIP levels did not alter complex IIB activity, 
indicating that the two secondary complexes apply diverse mechanisms and proteins for cell 
death execution. While the kinase domain of RIP1 is dispensable for pro-survival TNFR1 
signalling, it is required for cell death responses. Accordingly, caspase-8 interaction with 
FADD was strongly diminished when RIP1’s kinase domain was chemically inhibited or 
mutated (Degterev et al, 2008; Wang et al, 2008). 
Taken together, TNF can induce cell death via two distinct, caspase-8-involving pathways 
that are formed under diverse conditions. Complex IIA-induced cell death depends on the 
presence of TRADD and is controlled by c-FLIP levels, but independent of RIP1. In contrast, 
complex IIB is insensitive to inhibition by c-FLIP, is regulated by cIAPs and requires RIP1 
kinase activity.  
1.4.3 TNF-induced necroptosis 
Although the molecular signature of necroptosis is less well defined than the signalling 
pathways that induce apoptosis, a prominent function for RIP1 in death receptor-induced, 
caspase-independent cell death execution was demonstrated by Holler et al. in 2000 (Holler et 
al, 2000). However, the downstream mechanisms and description of other relevant factors 
remained poorly described. Accordingly, it remained obscure why some cells preferentially 
die by necroptosis, whereas others die by apoptosis. Performing a genome-wide siRNA 
screen, He et al. solved this mystery by identifying RIP3 as the determinant for cell death 
responses (He et al, 2009). They showed that cells expressing RIP3 were sensitive to TNF-
induced caspase-independent necroptosis, whereas those lacking RIP3 expression purely died 
1. Introduction 
33 
 
by apoptosis. Consistently, ectopic expression of RIP3 in RIP3-deficient cell lines rendered 
them susceptible to necroptosis, underscoring the importance of RIP3 in necroptotic 
responses. In contrast, cells expressing a RIP3 mutant lacking the kinase domain remained 
insensitive to necroptosis. However, necroptosis can only occur in RIP3-expressing cells if 
caspases are inhibited at the same time, indicating that caspase-8 blocks necroptosis (Figure 
6). In line with this observation, it was shown that a heterodimer of caspase-8 and c-FLIPL 
possessed stronger caspase-8 activity than a caspase-8 homodimer in a cell free system 
(Micheau et al, 2002). Moreover, Oberst et al. recently described the inhibition of RIP1/RIP3-
mediated necroptosis by caspase-8/c-FLIPL heterodimers, therefore providing the missing link 
explaining why caspase-8 deficient mice are not viable (Oberst et al, 2011). Backcrossing 
Caspase-8-/- or Fadd-/- mice to Rip1-/- (Kaiser et al, 2011; Zhang et al, 2011) or Rip3-/- (Kaiser 
Figure 6: TNF-induced necrosome formation. Following TNF-RSC formation at the membrane, NF-κB and 
MAPKs are activated leading to the transcription of pro-inflammatory genes. In a negative feedback loop, 
NF-κB and MAPKs up-regulate the expression of CYLD and A20, which deubiquitinate RIP1 at the TNF-RSC, 
thereby allowing the formation of the cytosolic complex II and the termination of NF-κB/MAPK signalling. In 
TRADD-dependent secondary complexes, FADD and caspase-8 are recruited and activated, leading to apoptosis 
accompanied by RIP1 and RIP3 cleavage. Presence of IAP antgonists favours formation of a RIP1-dependent 
complex, whose function is independent of TRADD. The FADD-RIP scaffold induces activation of caspase-8 in 
a RIP1-dependent manner and leads to apoptosis. However, if caspase-8 activity is inhibited (indicated by the 
yellow star), RIP1 and RIP3 associate in a complex referred to as necrosome with FADD, caspase-8 and possibly 
TRADD, become activated and induce necroptosis. 
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et al, 2011¸ Oberst et al, 2011) mice rescued pre-natal liver failure-induced lethality of 
Caspase-8-/- or Fadd-/- mice. Besides its well characterised pro-apoptotic function required for 
immune homeostasis to prevent accumulation of abnormal T cell subsets, these studies 
demonstrate that the main function of caspase-8 during embryogenesis is to restrict 
RIP1/RIP3-dependent necrotic death rather than to induce apoptosis. However, Fadd-/- Rip1-/- 
double knockout mice died a few days after birth, consistently with the phenotype of Rip1-/- 
single knockout mice, indicating that, unlike RIP3, RIP1 also possesses pro-survival functions 
independent of its necroptotic activity. Inactivation of RIP1 and RIP3 by caspase-8/c-FLIP 
heterodimers inactivates these proteins by an as yet unresolved mechanism, most likely 
involving their proteolytic cleavage. Consequently, caspase-8 inhibition switches the cellular 
response from apoptotic to necroptotic cell death. 
RIP1 and RIP3 are quite similar in structure. Both contain a kinase domain, followed by a RIP 
homotypic interaction motif (RHIM), which is required for the interaction of both proteins 
following death receptor stimulation. However, unlike RIP3, RIP1 possesses a DD. TNF 
stimulation in the presence of caspase inhibitors and IAP antagonists induces complex IIB 
formation, which also includes RIP3. Closer examination revealed that the RIP3-pool 
interacting with RIP1 following TNFR1 activation was modified by phosphorylation. 
Although kinase-deficient RIP3 was still able to interact with RIP1 upon TNF stimulation, 
RIP3 phosphorylation was absent, indicating that RIP3 auto-phosphorylates following 
interaction with RIP1. Accordingly, inhibition of RIP1 kinase activity by its specific inhibitor 
necrostatin-1 (Degterev et al, 2005) prevented its interaction with RIP3 and hence necroptosis 
induction, indicating that RIP1 has to phosphorylate a target protein, most likely itself in order 
to interact with RIP3. 
As described in chapter 1.5.4, the DUB CYLD has been shown to remove K63- and linear 
poly-ubiquitin chains in vitro (Komander et al, 2009), and to be recruited to the TNF-RSC 
where it removes polyubiquitin chains from target proteins, including RIP1. As the 
ubiquitination state of RIP1 determines whether its function induces survival or cell death, it 
is not surprising that necroptosis is inhibited in CYLD-depleted cells (Hitomi et al, 2008; 
Wang et al, 2008). These findings define CYLD as an inhibitor of necroptosis. 
Although most work on necroptosis focused on TNF-induced cell death, TRAIL and CD95L 
were also shown to induce necroptosis in the absence of caspase-8 activity (Holler et al, 
2000). While FADD was completely required for caspase-dependent and -independent 
TRAIL- and CD95L-mediated cell death in Jurkat T cells, Fadd-/- T cells were even more 
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sensitive to TNF-induced cell death, indicating an anti-necroptotic function of FADD in 
TNFR1 signalling. However controversially, TNF-induced necroptosis was blocked in Fadd-/- 
fibroblasts (Lin et al, 2004), suggesting the presence of different necroptosis-inducing 
complexes (so-called necrosomes) in different cell types. Accordingly, the strict requirement 
of TRADD for TNF-induced necroptosis is under debate. Some studies showed the absence of 
apoptosis and necroptosis in Tradd-/- cells, supporting an indispensable role for TRADD in 
both types of cell death (Ermolaeva et al, 2008; Micheau & Tschopp, 2003). In contrast, 
TRADD was not detected in IAP antagonist-induced, TNF-dependent complex II and siRNA-
mediated TRADD knockdown even enhanced complex II formation in some cell types, 
arguing against a crucial role for TRADD in complex II formation and activity (Declercq et 
al, 2009; Wang et al, 2008). Thus, it currently appears that necroptosis is a highly stimulus- 
(presence of IAP antagonists, CHX) and cell type-dependent process. 
The signalling events that occurre down-stream of RIP1-RIP3 interaction and are implicated 
in necroptosis execution are still poorly defined. RIP3 has been described to interact with 
glycogen phosphorylase (PYGL), glutamate-ammonia ligase (GLUL) and glutamate 
dehydrogenase 1 (GLUD1), thereby increasing their enzymatic activities and promoting a 
considerable metabolic burst (Zhang et al, 2009). Additional respiratory substrates are 
generated due to increased glycogenolysis and glutaminolysis, resulting in over-generation of 
ROS, which subsequently triggers mitochondrial membrane permeabilisation (MMP) and 
hence necroptosis. However, scavenging of ROS failed to prevent necroptosis in some cell 
lines (including HT-29), suggesting ROS as a mediator of necroptosis in some, but certainly 
not all cell types (He et al, 2009).  
Several viruses were shown to produce proteins capable of inhibiting caspase-8, thereby 
preventing the host cells from undergoing apoptosis and clearing the viral infection. In 
scenarios where apoptotic responses are inhibited, RIP3-mediated necroptosis is believed to 
act as a back-up mechanism to eliminate virus-infected cells. Cells dying by necroptosis 
release danger-associated molecular patterns which then, together with the viral antigens, 
function as endogenous adjuvant to boost an efficient immune response. Consistently, 
although Rip3-/- mice are viable and develop normally, they fail to control viral infection, 
most likely due to impaired necroptosis-mediated activation of innate, and consequently, 
adaptive immunity (Cho et al, 2009; He et al, 2009; Zhang et al, 2009). These results 
demonstrate that necroptotis possesses in-vivo relevance.  
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Taken together, although the signalling molecules used in the three death receptor systems are 
redundant, the outcomes of TNF versus TRAIL/CD95L signalling are very diverse and 
strongly depend on the cellular context. cIAPs have been described as critical determinants of 
cellular fate and their absence has been shown to shift the balance towards cell death in all 
three systems. However, more in-depth analyses are required to resolve the pathways in order 
to target them in various human diseases. 
  
1.5 The ubiquitin system 
Post-translational modifications of proteins constitute a major mechanism by which cells 
regulate and fine-tune signalling outputs initiated by various stimuli. In the 1950s’, 
phosphorylation was the first mechanism identified to regulate enzymatic activities (Burnett 
& Kennedy, 1954). Kinase-mediated phosphorylation describes the covalent attachment of a 
phosphate group to serine, threonine or tyrosine residues of target proteins, thereby ultimately 
altering their electrostatic properties. By changing the allosteric conformation of proteins, 
phosphorylation allows for the recruitment of down-stream proteins and/or activation or 
inactivation of target proteins, thereby contributing to signal propagation. Phosphorylation is a 
complex, reversible process that involves more than 500 protein kinases, whose activites are 
counteracted by approximately 120 phosphatases which remove phosphate groups (Manning 
et al, 2002).  
Ubiquitination was discovered in the late 1970’s as part of an energy-dependent protein-
degradation system (Ciechanover et al, 1978), in which covalent conjugation of ubiquitin, at 
that time referred to as ATP-dependent proteolysis factor (APF-1), to lysine residues of target 
proteins was shown to be essential for their proteasomal degradation (Ciechanover et al, 1980; 
Hershko et al, 1980; Wilkinson et al, 1980). Shortly afterwards, the concept of ubiquitin-
mediated degradation was confirmed in vivo (Ciechanover et al, 1984; Finley et al, 1984). It 
was well accepted for nearly two decades that ubiquitination was solely associated with 
degradation. However, in 1995 Spence et al. were the first to report a protein turnover-
independent function of ubiquitin (Spence et al, 1995), suggesting non-proteolytic functions 
of ubiquitin. This was the starting point to extend ubiquitin research and led to the 
identification of numerous alternative functions including trafficking, DNA damage repair 
and kinase activation (Yang et al, 2010).  
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1.5.1 Ubiquitin chain formation 
Ubiquitin is a highly conserved protein of about 8.5 kDa expressed in all eukaryotes from 
yeast to mammals (Makarova & Koonin, 2010). It is encoded by four individual genes, either 
as linear polyubiquitin chain, or as fusion protein with a ribosomal subunit (Finley et al, 
1987). Processing of these pre-cursors generates a 76 amino-acid mature globular protein, 
which can be attached to lysine residues of target proteins. Ubiquitin possesses seven internal 
lysine residues (K6, K11, K27, K29, K33, K48 and K63) and all of them can be used for 
ubiquitin chain assembly (Ikeda & Dikic, 2008). Additionally, the amino-terminal methionine 
(M1) of ubiquitin can be connected to its C-terminal Glycine (G76), thereby generating so 
called head-to-tail linear ubiquitin chains. Most interactions between ubiquitin and target 
proteins are due to a prominent hydrophobic surface patch centred on isoleucine 44 (Ile44) of 
ubiquitin. Given that all lysine residues reside on different surfaces pointing in different 
directions (except of K63 which is spatially close to the N-terminal amino group of M1), 
ubiquitin-binding proteins exhibit different affinities for the differentially linked ubiquitin 
chains. This chain-type selectivity of ubiquitin receptors hence explains the physiological 
differences induced by the different types of ubiquitin chain linkages. 
  
Figure 7: The ubiquitin system. a) Ubiquitin initially gets activated in an ATP-consuming manner by an E1
and is then passed onto the reactive cysteine residue of an E2 conjugating enzyme. Subsequently, ubiquitin gets 
either transferred to the reactive cysteine of a HECT E3 enzyme, which then transfers it to a lysine residue of a 
target substrate or the E2 cooperates with a RING-box E3 which confers target selectivity and the E2 directly 
attaches ubiquitin to the target. b) Target proteins can be modified by mono-ubiquitination, multi-mono-
ubiqutination or polyubiquitination. Polyubiquitin chains can be of homotypic nature, i.e. the ubiquitin chains 
contain only one linkage type, or of heterotypic nature, in which the polyubiquitin chain has alternating linkage 
types or is branched, i.e. two or more lysine residues of the same ubiquitin molecule are elongated. 
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The HECT and RING family of E3 ligases 
Generation of mono- or polyubiquitin chains is mediated by a concerted action of three 
enzymes referred to as E1, E2 and E3 (Figure 7a). Initially, ubiquitin is activated by a 
ubiquitin-activating enzyme (E1) in an ATP-dependent manner creating a thioester bond 
between its conserved cysteine residue and the C-terminal carboxy group of monomeric 
ubiquitin. Subsequently, ubiquitin is transferred to the active site of a ubiquitin-conjugating 
enzyme (E2), which is recruited by the C-terminal ubiquitin-fold domain of E1. Finally, an 
isopeptide bond between the C-terminus of ubiquitin and the ε-amino group of a lysine 
residue within a target protein is catalysed by a ubiquitin ligase (E3) (Kerscher et al, 2006). 
Up to date, two E1s, about 50 E2s and more than 600 E3s have been described in the human 
genome (Bhoj & Chen, 2009).   
Classically, E2s are thought to determine linkage specificity whereas E3s confer substrate 
specificity bringing E2s in close proximity to target proteins. E2s contain a core UBC 
(ubiquitin conjugating) domain of approximately 140 amino acids including an invariant 
cysteine residue at the active site. Some E2s have been described to possess unique linkage 
specificity, including CDC34 and Ubc13/Uev1a which exclusively generate K48- and K63-
linked ubiquitin chains, respectively (Hofmann & Pickart, 1999; Petroski & Deshaies, 2005). 
Preferential interactions between these particular E2s and ubiquitin which position the lysine 
residue of the ubiquitin to be conjugated in a distinct orientation most likely account for this 
specificity (Eddins et al, 2006; Petroski & Deshaies, 2005; VanDemark et al, 2001). On the 
contrary, E2s including those of the UbcH5 family are promiscuous and are capable of 
generating ubiquitin chains of different linkage types (Kim et al, 2007).  
E3 ubiquitin ligases can be categorised in three classes based on their structure and function: 
homology to E6AP C-terminus (HECT), really interesting new gene (RING) and closely 
resembling U-Box E3s. HECT E3s possess highly conserved cysteine residues that initially 
accept ubiquitin molecules from E2s and subsequently transfer them to lysine acceptors in 
target proteins or to lysine residues of growing ubiquitin chains. In contrast, RING E3s lack 
enzymatic activity and rather function as adaptors bridging between E2s and target proteins 
facilitating the transfer of ubiquitin from E2s directly to targets. Some RING E3s including 
cIAPs and TRAFs contain substrate modules to directly function as E3, whereas others form 
part of multi-protein complexes (e.g. the SCFβTrCP complex). 
Rachel Klevit and collegues recently described a novel RING-HECT hybrid mechanism 
which is utilised by a sub-group of RING-type E3s referred to as RING-in-between-RING 
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(RBR) E3s (Wenzel et al, 2011). RBR E3s are characterised by a canonical Cys3HisCys4-type 
RING domain (RING1), followed by two conserved Cys/His-rich Zn2+-binding domains, an 
in-between RING (IBR) and a RING2 domain (Marin et al, 2004). While the RING1 domain 
is responsible for binding to an E2 enzyme, a conserved cysteine residue in the RING2 motif 
possesses catalytic activity. Similar to HECT E3s, this cysteine residue accepts ubiquitin from 
the E2 and forms a stable thioester bond before ubiquitin is transferred to the target. Thus, 
RBRs combine characteristics of both, RING and HECT E3s.  
1.5.2 Physiological role of different ubiquitin chain linkages 
As mentioned above, all seven lysine residues as well as the amino-terminus can be employed 
in ubiquitin chain formation as shown by mass-spectrometric analysis of total cell extracts 
(Peng et al, 2003).  Only recently, quantitative analyses in budding yeast revealed that K48-
linked chains are the most abundant, accounting for 29% of all ubiquitin linkages in the cell. 
Interestingly, presence of K11-linked chains was nearly as frequently detected as K48 
linkages (28%). 17% of all linkages were conjugated via K63, whereas K6 (11%), K27 (9%), 
K29 (3%) and K33 (3%) linkages were present in relatively low abundance (Xu et al, 2009b). 
Since His-tagged ubiquitin was employed in this study, linearly linked ubiquitin chains could 
not be detected. Though these results indicate that all chain types serve physiological 
functions in vivo, more systematic analyses are required to understand the significance of each 
chain type during development or stress-induced signalling. 
Though hundreds of papers have been published on ubiquitin during the past decade, most 
cover the functions, structures and physiological roles of K48-, K63- and mot recently also 
M1-linked ubiquitin chains. In contrast, recent studies just started to explore the character of 
other, “non-conventional” chains. These analyses revealed that not only the topology, but also 
the length of a given ubiquitin chain is able to regulate the signalling output, therefore placing 
ubiquitination as a central mechanism in signal regulation. 
According to its position within the ubiquitin molecule, ubiquitin chains linked via the various 
internal lysine residues adopt different conformations. K48-linked ubiquitin chains form 
rather rigid, compact structures, in which the single ubiquitin monomers are tightly packed 
against each other and the Ile44 patches not exposed. In contrast, K63- and M1-linked 
ubiquitin chains adopt a rather flexible, extended, open conformation, forming no contacts 
between the individual ubiquitin molecules apart from the linkage itself. The Ile44 patches are 
exposed and capable of adopting different positions due to a relatively high flexibility in the 
ubiquitin chain. Hence, the only characteristic structural difference between these two chains 
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is constituted in the linkage itself. The peptide bond in linear chains with a methionine 
branching off is slightly more constrained as compared to more flexible isopeptide chains 
linked through lysine residues (Komander et al, 2009). Recently Virdee et al. solved the 
structure of K6-ubiquitin chains, which form an asymmetric, compact structure distinct from 
all other ubiquitin chains (Virdee et al, 2010). Additionally, the conformation of K11-chains 
is also unique among the ubiquitin linkages since the contacts between isopeptide-linked 
ubiquitin moieties are entirely polar and do not involve the hydrophobic ubiquitin surface 
patch around Ile44 (Bremm et al, 2010). 
Apart from poly-ubiquitination, proteins can be modified with a single ubiquitin molecule on 
a single lysine residue (mono-ubiquitination) or on several lysine residues (multi-mono-
ubiquitination; Figure 7b). (Multi)-mono-ubiquitination of surface receptors induces their 
internalisation and lysosomal degradation or recycling to the cell surface (Haglund et al, 
2003). Furthermore, mono-ubiquitination of histones or the DNA sliding clamp PCNA 
(proliferating-cell nuclear antigen) was described to serve important functions during the 
DNA damage response (Alpi et al, 2008; Sigismund et al, 2004). Since mono-ubiquitination 
of certain substrates is sufficient to induce their proteasomal degradation (Shabek et al, 2009), 
the substrate’s affinity for the proteasome must be just high enough to allow the degradation 
process to initiate. It has also been suggested that distinct E2s might be involved in generation 
of mono- and poly-ubiquitination, respectively (Windheim et al, 2008).  
As pointed out earlier, classical ubiquitin chains linked via K48 are solely associated with 
proteasomal degradation (Hershko & Ciechanover, 1998). Ubiquitin Binding Domains 
(UBDs; discussed in the next chapter) play important functions for the delivery and 
recognition of K48-modified substrates to the proteasome and its subsequent hydrolysis, 
which occurs from the distal end of the ubiquitin chain (Lee et al, 2010). 
Besides K48, linkages via the K63 residue constitute the best studied and described form of 
ubiquitin chains. Groundbreaking work at the end of the 20th century by the groups of Pickart 
and Chen showed that the E2 complex consisting of Ubc13 and Uev1A specifically utilised 
K63 to elongate ubiquitin chains (Deng et al, 2000; Hofmann & Pickart, 1999). This type of 
chain serves non-degradative functions and has been implicated in NF-κB and JNK activation. 
In the IL-1 and TLR pathways, TRAF6 serves as major E3 that, in combination with 
Ubc13/Uev1a specifically and uniquely conjugates K63-linked ubiquitin chains to target 
proteins, including IRAKs, NEMO but also TRAF6 itself. Knockout of either TRAF6 (in 
particular its RING domain) or Ubc13 abolished IL-1- and TLR-induced IKK and MAPKs 
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activation (Conze et al, 2008; Lamothe et al, 2007; Walsh et al, 2008; Yamazaki et al, 2009; 
Yin et al, 2009). Furthermore, using an elegant ubiquitin replacement strategy in which 
endogenous ubiquitin was knocked out and replaced by a mutant lacking K63, Xu et al. 
demonstrated the necessity of K63-linked ubiquitin chains generated by Ubc13/Uev1a in IL-1 
signalling (Xu et al, 2009a). However surprisingly, formation of K63-linked ubiquitin chains 
was dispensable for TNF-induced NF-κB activation, which relied on the activity of UbcH5 
family members rather than Ubc13. This study demonstrated for the first time that different 
pathways, though utilising similar components, differentially rely on the formation of distinct 
ubiquitin chain types. Consequently, the old model in which long K63-linked poly-ubiquitin 
chains function as recruitment and activation platform for the TAK1/TAB and IKK 
complexes has to be revised, at least with respect to TNF signalling.  
Intriguingly, the linear ubiquitin chain linkage has recently been described to be involved in 
TNF-induced NF-κB and MAPK activation, i.e. linear ubiquitin chains (Gerlach et al, 2011; 
Haas, 2008; Ikeda et al, 2011; Tokunaga et al, 2011; Tokunaga et al, 2009). Unlike all other 
linkage types, linear chains do not utilise the ε-amino group of an internal lysine residue for 
chain propagation, but rather fuse the α-amino group of the M1 residue of ubiquitin to the C-
terminal carboxy-group on G76 of the incoming ubiquitin. Though linear and K63-linked 
ubiquitin chains adopt similar conformations, the chemistry of the bonds between individual 
ubiquitin monomers (peptide vs. isopeptide bond) and the topology of the area surrounding 
the respective bonds clearly distinguish these two linkage types from another. As described in 
the next chapter, ubiquitin binding domains specifically bind to K63- or linear ubiquitin chain 
linkages, respectively, thereby dictating down-stream signalling. 
Artificial conjugation of tetra-ubiquitin to the N- or C-terminus of various proteins induced 
their degradation (Zhao & Ulrich, 2010), suggesting that the position and/or length of the 
linear chain within a target determines its functional outcome. Binding of specific UBDs (see 
chapter 1.5.3) to linear ubiquitin chains possibly mask them from binding to the proteasome 
and hence from proteasomal degradation. Thus, although linear chains might mark proteins 
for degradation under certain circumstances, they also function as signalling molecules that 
work by recruiting factors involved in sigal transduction. Consistently, free linear ubiquitin 
chains are rapidly cleaved by isopeptidase T, which binds to the C-terminus of ubiquitin, 
thereby disassembling ubiquitin chains (Reyes-Turcu et al, 2006). However, attachment of 
linear chains to target proteins blocks the C-terminus, thereby preventing isopeptidase T from 
hydrolysing linear chains.   
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A variety of proteins involved in diverse cellular signalling processes are modified with K11-
linked ubiquitin chains (Xu et al, 2009b), suggesting its physiological importance in various 
pathways. The major function of K11-chains is attributed to proteasomal degradation 
(Baboshina & Haas, 1996; Jin et al, 2008). Accordingly, attachment of K11-linked ubiquitin 
chains to cyclin B1 promoted by the E3 anaphase-promoting complex (APC/C) led to its 
proteasomal degradation, therefore suggesting a role for K11 in cell cycle regulation (Jin et al, 
2008). A prominent function of K11-chains in proteasomal degradation is further supported 
by the finding that K11-chains associate with the proteasome (Baboshina & Haas, 1996) and 
accumulate upon chemical inhibition of the proteasome (Xu et al, 2009b).  
Although a heterodimeric complex of BRCA1 and BARD1 was capable of forming K6-linked 
ubiquitin chains in vitro (Morris & Solomon, 2004; Wu-Baer et al, 2003), a physiological 
function for this chain type has not been identified yet. However, since BRCA1 is associated 
with DNA damage repair and since it is frequently mutated in breast cancer, K6-linked 
ubiquitin chains are likely involved in DNA repair. 
Analysing the function of K27-, K29- and K33-linked ubiquitin chains proves a challenging 
task owing to their close proximity within the ubiquitin molecule and hence formation of 
small tryptic-digest fragments during mass-spectrometry. Albeit accounting for approximately 
10% of all ubiquitination events in yeast, no physiological function has so far been reported 
for K27-linked ubiquitin chains. In contrast, at least three independent E3s were described to 
generate K29-linked ubiquitin chains and predominantly associated its function with 
lysosomal degradation of substrates (Chastagner et al, 2006; Johnson et al, 1995; You & 
Pickart, 2001). Furthermore, conjugation of K29- as well as K33-linked ubiquitin chains to 
members of the AMP-activated protein-kinase (AMPK)-related family of protein kinases has 
been reported to inhibit their activity (Al-Hakim et al, 2008). However, the exact mechanism 
of inhibition remains elusive and requires further research.  
In vitro, ubiquitin chains of mixed linkages (so called heterotypic chains) as well as branched 
chains in which several lysine residues of the same ubiquitin molecule are elongated can be 
formed. However, their existence and relevance in vivo remains to be shown. 
1.5.3 Ubiquitin Binding domains 
Similar to SH2-domain-containing proteins that are recruited to phosphorylated sites, 
ubiquitin chains also serve as platform for the recruitment of UBD-containing proteins also 
referred to as ubiquitin receptors. Approximately 200 proteins containing one or several 
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UBDs have been identified. Non-covalent interactions between ubiquitin and UBDs control a 
variety of physiological processes, including protein degradation, receptor trafficking, cell-
cycle progression, DNA repair, autophagy and apoptosis (Kirkin et al, 2009; Raiborg & 
Stenmark, 2009; Wickliffe et al, 2009; Winget & Mayor). As yet, five structural folds with 
more than 20 UBDs were identified (Dikic et al, 2009). Although ubiquitin is mostly 
composed of polar surfaces, most UBDs bind to a hydrophobic patch surrounding Ile44 of 
ubiquitin. Since ubiquitin chains linked via the different lysine residues adopt distinct 
conformations, the hydrophobic Ile44-containing patch is either embedded or faces outward, 
conferring a certain layer of specificity. 
UBDs are commonly α-helical structures, zinc fingers, are similar to the Ubc-domain present 
in E2s or assume pleckstrin homology (PH) folds (Chen & Sun, 2009). Given a rather low 
binding affinity in the micro- to millimolar range for UBDs to ubiquitin (Winget & Mayor), 
additional interactions between the ubiquitinated target protein and the ubiquitin receptor are 
required for sufficient specificity and affinity.  
Some UBDs were shown to specifically interact with a certain type of ubiquitin linkage. For 
instance, Husnjak et al. demonstrated preferential binding of the proteasome receptor Rpn13 
via its pleckstrin-like receptor for ubiquitin (pru) domain to K48-linked di-ubiquitin (Husnjak 
et al, 2008).  
Accordingly, the Npl4 zinc finger (NZF) of TAB2 and TAB3 selectively binds to K63-linked 
ubiquitin chains (Kulathu et al, 2009; Sato et al, 2009), providing a possible mechanism of 
recruitment of the TAK1/TAB complex to various signalling platforms. Precisely, two distinct 
sites of the NZF domain bind adjoining ubiquitin molecules at the hydrophobic Ile44 patch 
without contacting the K63-linker region (Kulathu et al, 2009; Sato et al, 2009). Due to steric 
constraints in the linker region of linear chains preventing their wrapping around NZF 
domains, linkage specificity is warranted.  
NEMO and ABIN1-3 (A20 binding inhibitor of NF-κB) are critically linked with NF-κB 
activation and termination, respectively. Together with optineurin, NEMO and ABINs possess 
a type of UBD referred to as UBAN (UBD present in ABINs and NEMO). All five proteins 
specifically bind to linear ubiquitin chains (Komander et al, 2009; Rahighi et al, 2009). 
Although NEMO was originally identified as a K63-interacting protein (Ea et al, 2006; Wu et 
al, 2006), recent reports have provided biophysical proof that its affinity for linear chains was 
about 100-fold higher. Furthermore, competition experiments revealed NEMO to solely bind 
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to linear chains when offered a mixture of K48-, K63- and M1-linked tetra-ubiquitin chains 
(Komander et al, 2009).  
Crystallographic analyses showed that two UBAN domains of NEMO form a parallel 
symmetric dimer, in which each UBAN domain interacts with one linear di-ubiquitin, 
revealing a 2:2 complex (two UBANs interacting with two di-ubiquitins). The NEMO UBAN 
directly contacts the residues involved in the linkage between two ubiquitin molecules, 
thereby explaining why NEMO specifically interacts with linear linkages, despite the fact that 
K63- and linear ubiquitin chains adopt similar overall conformations (Rahighi et al, 2009). 
Deletion or mutation of NEMO’s UBAN domain led to impaired IKK and TAK1 activation 
by a variety of stimuli (Rahighi et al, 2009). Intriguingly, mutations in the UBAN have been 
identified in humans suffering from X-linked ectodermal dysplasia and immunodeficiency 
(Vinolo et al, 2006), further underscoring a physiological importance of linear ubiquitin 
binding by NEMO. NEMO binding to linear chains alters its conformation, thereby providing 
a possible mechanism translating to auto-activation of IKKβ. While these data clearly show 
the necessity of NEMO’s binding to ubiquitin chains, its role as ubiquitin acceptor being 
modified with ubiquitin chains itself remains elusive. Although several studies reported on the 
ubiquitination of NEMO with different linkage types and several potential acceptor lysines 
have been mapped (e.g. K285, K277, K309, K399), the contribution of the distinct linkage 
types and ubiquitination sites for signal propagation have not yet been confirmed (Tokunaga 
et al, 2009). It has been assumed that NEMO ubiquitination induced a conformational change, 
leading to oligomerisation and subsequent auto-phosphorylation of IKKβ (Tang et al, 2003). 
Thus, although IKK activation is doubtlessly the central mechanisms leading to NF-κB 
activation, the precise mechanisms are yet to be determined. 
NEMO also possesses a C-terminal NZF domain, which has been shown to bind equally well 
to K63-, K48- and M1-linked ubiquitin chains (Bloor et al, 2008; Cordier et al, 2009a; Wu et 
al, 2006). Although a fusion protein containing both the NZF and UBAN domain binds by an 
order of magnitude more tightly to K63-linked chains in vitro (Cordier et al, 2009a), it is not 
clear whether this also translates into differential binding in vivo. However, initial binding of 
NEMO to K63- and possibly K11-linked ubiquitin chains (Dynek et al, 2010) generated upon 
stimulation might allow for a transient, weak recruitment of the IKK complex to a signalling 
platform. Subsequent generation of linear chains on NEMO but also other possible targets 
might strengthen the interaction, allowing for conformation-induced IKK activation or 
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phosphorylation by simultaneously recruited and activated TAK1. Thus, a concerted action of 
ubiquitin chains of different linkage specificity allows for strong, persistent signalling. 
ABIN-1, which was initially identified in a yeast-two-hybrid screen as A20-interactor 
(Heyninck et al, 1999) and was shown to specifically bind to linear ubiquitin chains via its 
UBAN domain (Rahighi et al, 2009), also serves critical roles in immune responses but, 
unlike NEMO, is rather required for their termination. Consistently, overexpression of 
ABIN-1 resulted in inhibition of TNF-induced NF-κB activation (Heyninck et al, 2003). In 
contrast, Abin1-/- cells did not show any severe abnormalities with regard to ex vivo NF-κB 
activation, possibly due to a certain degree of redundancy between ABIN-1, ABIN-2 and 
ABIN-3. However, ABIN proteins clearly show some non-redundant functions given that 
ABIN-1 knockout mice died during embryogenesis due to TNF-dependent fatal liver 
apoptosis (Oshima et al, 2009). Although the mechanism remains elusive, deletion of the 
UBAN domain from ABIN-1 sensitised cells to TNF-induced cell death through increased 
complex II formation (Oshima et al, 2009). Furthermore, replacing endogenous wild-type 
ABIN-1 by a mutant lacking the UBAN domain led to auto-immunity in mutant knock-in 
mice (Nanda et al, 2011). Thus, the ability of ABIN-1 to bind to linear ubiquitin chains 
prevents auto-immune pathologies by on the one hand terminating NF-κB and MAPKs 
signalling and on the other hand inhibiting pro-inflammatory cell death.  
Generation of eight possible ubiquitin linkage types combined with the presence of a variety 
of UBDs with different specificity confers a high level of complexity, which tightly regulates 
the localisation and function of hundreds of proteins in diverse cellular processes. Depending 
on whether UBDs are located in proteins involved in proteasomal degradation, endocytosis, 
vesicle-trafficking or signal transduction, ubiquitination leads to proteasomal degradation, 
lysosomal destruction or non-proteolytic signalling outputs, respectively. Thus, the fate of a 
given cell and generation of down-stream signals are dictated by the kind of ubiquitin chain 
recognised by its specific UBDs. Units of ubiquitin-dimers are thought to confer UBD 
binding specificity. However, little is known about the regulation of the length of ubiquitin 
chains in vivo and its influence on UBD recruitment. It will be of great interest to decode the 
ubiquitin network and identify which chain types attached to which target proteins are 
decisive for the different signalling outputs. 
1.5.4 Deubiquitinases 
Opposing the effect of ubiquitin ligases, the human genome contains nearly 100 
deubiquitinases (DUBs) that are capable of removing ubiquitin chains of different linkages 
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from target proteins (Skaug et al, 2009). DUBs can be subdivided in 5 classes based on their 
structural motifs: ubiquitin C-terminal hydrolases (UCHs), ubiquitin-specific proteases 
(USPs), ovarian tumour proteases (OTUs) and Josephins that act as cysteine proteases as well 
as the zinc-dependent JAB1/MPN/MOV34 metalloproteases (JAMMs) (Reyes-Turcu et al, 
2009). USPs constitute the largest class of DUBs with more than 50 members. 
A20 belongs to the OTU family (Evans et al, 2004) and is one of the best characterised DUBs 
that was initially identified as a TNF-target gene in human umbilical vein endothelial cell 
(HUVEC) (Opipari et al, 1990). While its expression level is rather low in most unstimulated 
cells, it gets rapidly up-regulated in an NF-κB-dependent fashion by a variety of stimuli. Only 
thymocytes and peripheral T lymphocytes show high expression of A20 per se, which 
conversely becomes down-regulated following T cell activation (Tewari et al, 1995). A20 
functions as a ubiquitin-editing enzyme in TNFR1 signalling by removing K63-linked, and 
possibly other types of ubiquitin chains and simultaneously adding K48-linked ubiquitin 
chains to RIP1, targeting it for degradation. Remarkably, A20 does not possess a RING or 
HECT domain but mediates ubiquitination via its fourth zinc finger domain (ZnF4), thereby 
presenting a new type of E3 ubiquitin ligase domain. Thus, A20 occupies a dual function as 
ubiquitin-editing enzyme capable of removing (DUB activity) and adding (E3 ligase activity) 
ubiquitin chains in a controlled, sequential manner. Since RIP1 does not play a major function 
in TLR and IL-1 signalling, other mechanisms have to exist explaining the negative 
regulatory function of A20 in these pathways. Only recently, Shembade et al. reported A20 to 
disrupt the association of E2-E3 enzymes including binding of the E3 TRAF6 to the E2s 
Ubc13 and UbcH5c (Shembade et al, 2010). Thus, A20 utilises a variety of mechanisms to 
terminate signalling initiated by distinct stimuli.  
As a result of excessive, uncontrolled NF-κB signalling, A20-/- mice die pre-maturely due to 
multi-organ inflammation and cachexia (Lee et al, 2000). Cells derived from A20-deficient 
animals exhibited elevated, prolonged TNF- and IL-1-induced IKK activation and were 
hypersensitive to TNF-induced cytotoxicity, suggesting A20 as negative regulator of NF-κB 
signalling possessing anti-apoptotic functions (Heyninck et al, 1999; Jaattela et al, 1996; 
Opipari et al, 1992; Song et al, 1996). However, the function of A20 is not limited to TNF 
since back-crossing A20 knockout mice to Tnf-/- or Tnfr1-/- mice did not revert the 
spontaneous inflammatory phenotype (Boone et al, 2004). Moreover, Rag-/- A20-/- double 
knockout mice were also not rescued, indicating that the inflammation was independent of the 
adaptive immune system (Lee et al, 2000). However, concomitant loss of MyD88, an adaptor 
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protein commonly used in TLR signalling, rescued A20-/- animals from lethality (Turer et al, 
2008), indicating that TLRs are implicated in manifestation of inflammatory lesions.  
A20 does not preferentially cleave K63-linked ubiquitin chains in vitro (Lin et al, 2008), 
suggesting that (i) this might not be the preferred target linkage in vivo or (ii) that it needs to 
cooperate with distinct proteins conferring selectivity for this type of chain. Indeed, A20’s 
activity depends on a variety of proteins including Tax 1 binding protein 1 (TAX1BP1), Itch 
and RING finger protein 11 (RNF11). TAX1BP1, Itch and RNF11 knockout cells all present 
with hyperactivated NF-κB signalling and it was shown that the function of A20 depended on 
these proteins. TNF-induced interaction of RNF11, Itch and TAX1BP1 is a pre-requisite for 
A20 recruitment to RIP1 (Iha et al, 2008; Shembade et al, 2007; Shembade et al, 2008; 
Shembade et al, 2009). Thus, A20 forms a multi-protein complex involved in negative 
regulation of NF-κB signalling induced by a variety of stimuli.  
ABIN-1 is another molecule crucially linked to A20’s inhibitory function. Following TNFR1 
activation and formation of linear ubiquitin chains on NEMO and RIP1 (Gerlach et al, 2011), 
ABIN-1 functions as adaptor to recruit A20 in close proximity to these molecules. 
Subsequently, A20 deubiquitinates NEMO and RIP1, thereby terminating TNF-induced 
signalling (Mauro et al, 2006). However, an A20-binding-deficient mutant of ABIN-1 was 
still capable of inhibiting NF-κB activation, suggesting the existence of A20-independent 
mechanisms. Presumably, ABIN-1 competes with other proteins required for NF-κB 
stimulation for binding to the complex, thereby dampening complex stability.   
The USP family member CYLD was initially discovered as tumour suppressor given its 
frequent mutations in benign tumours of skin appendage (Bignell et al, 2000). Counteracting 
ubiquitination of TRAF2 and NEMO, CYLD negatively regulates NF-κB, JNK and p38 
signalling (Brummelkamp et al, 2003; Kovalenko et al, 2003; Trompouki et al, 2003). Loss of 
CYLD did not only increase NF-κB signalling, but also enforced c-Jun amino-terminal kinase 
(JNK) and p38 activation, most likely due to maintained ubiquitination of TRAF2 and NEMO 
(Zhang et al, 2006). However, its activity is quite distinct from A20, since it is thought to 
rather inhibit spontaneous signalling and its activity needs to be overcome to allow TNF-
induced signal propagation. IKK was suggested to phosphorylate CYLD, thereby inhibiting 
its DUB activity, allowing TNF-induced signals to proceed prior to their termination by A20 
(Reiley et al, 2005). Conversely, A20 is part of a negative feedback loop whose expression 
initially needs to be induced prior to accomplishing its inhibitory function. Thus, CYLD and 
A20 serve precise, temporarily distinct roles in inhibiting NF-κB. Furthermore, CYLD and 
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A20 possess different ubiquitin linkage specificities; A20 preferentially hydrolyses K48-
linked ubiquitin chains, whereas CYLD specifically cleaves linear chains and has some, albeit 
reduced activity towards K63-linked ubiquitin chains in vitro (Komander et al, 2008; 
Komander et al, 2009; Lin et al, 2008). However, these activities might be different in vivo 
when these proteins function together with adaptors, as in the case for A20.  
USP21 and Cezanne (cellular Zn finger anti-NF-κB) were also described as negative 
regulators of TNF-induced signalling, though the exact mechanisms remain elusive (Enesa et 
al, 2008; Evans et al, 2001; Xu et al, 2010). However interestingly, Cezanne was implicated 
in hydrolysis of K11-linked ubiquitin chains. At the time when K48- and K63-linked 
ubiquitin chains were the only linkage types regarded important for cell signalling, the 
development of a complex system of at least four DUBs with non-redundant functions 
remained puzzling. However, considering recent reports describing the presence of at least 
four different ubiquitin chain types on RIP1 (Gerlach et al, 2011), evolution of such an 
intricate scheme is a lot more intuitive. Each ubiquitin chain type formed on RIP1 or other 
TNF-RSC components needs to be removed to terminate an inflammatory signal and to 
prevent the development of auto-immune pathologies. This demand is warranted by a highly 
controlled termination system, in which each component (DUB) fulfils its precise, temporally 
and spacially-controlled function.  
Taken together, the ubiquitin network comprises a complex system that we are just starting to 
understand. Considering the association of frequent mutations of the ubiquitin-mediated 
signalling cascade with the occurrence of certain diseases, interfering with the perturbation of 
the ubiquitin network or with the consequences thereof might constitute a starting point for 
the development of novel therapeutic strategies to treat these diseases.  
 
1.6 The Linear Ubiquitin Chain Assembly Complex (LUBAC) 
1.6.1 HOIL-1, HOIP and SHARPIN 
Following identification of ubiquitination in the early 80s’, generation of ubiquitin chains was 
thought to be solely mediated via one of the ε-amino groups of one of the seven internal 
lysine residues. However, in 2006, Kirisako et al. described that the α-amino-group of 
ubiquitin can also be utilised for chain elongation by covalently attaching it to the carboxy-
terminus of the following ubiquitin (Kirisako et al, 2006). This activity was attributed to a 
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complex consisting of HOIL-1 (heme-oxidised iron-regulatory protein 2 ubiquitin ligase-1; 
also known as RBCK1) and HOIP (HOIL-1 interacting protein; also known as RNF31), 
which was therefore referred to as linear ubiquitin chain assembly complex, LUBAC. Only 
recently, we and others found that LUBAC does not only consist of HOIL-1 and HOIP, but 
includes SHARPIN (SHANK-associated RH-domain-interacting protein) as a third 
component, which will be discussed in this thesis (Gerlach et al, 2011; Ikeda et al, 2011; 
Tokunaga et al, 2011).  
Since ubiquitin genes are encoded as linear precursors which are rapidly processed to 
monomers by DUBs, the existence of linear ubiquitin chains has been known for years. 
However, recent proteomic approaches revealed only very low steady-state levels of linear 
ubiquitin conjugates in cells (Dammer et al, 2011). Thus, identification of an E3 ligase 
complex capable of de novo assembly of these chains from mono-ubiquitin moieties was 
somehow surprising. However, research efforts during the past years by our lab and others 
showed that linear ubiquitin chains generated by LUBAC are required for certain aspects of 
cell signalling and indeed play an important physiological role in the prevention of 
inflammation.  
HOIL-1 and HOIP are both members of the RBR family, a subgroup of the RING finger 
protein family (Marin et al, 2004). HOIL-1 was initially discovered as ubiquitin ligase for 
heme-oxidized IRP2 (Yamanaka et al, 2003) that contains, besides its C-terminal RBR, an 
NZF domain responsible for binding to ubiquitin as well as an N-terminal Ubiquitin-like 
domain (UBL) (Tokunaga et al, 2009; Ikeda et al, 2011).  
In addition to its C-terminal RBR domain, HOIP possesses a ZF domain, followed by two 
NZFs and a ubiquitin-associated (UBA) domain (Hicke et al, 2005). The UBA domain of 
HOIP and the UBL domain of HOIL-1 mediate stable interaction of both proteins. 
Surprisingly, although a mutant consisting only of the UBA of HOIP was able to directly bind 
to HOIL-1, no interaction of this mutant with ubiquitin could be observed (Kirisako et al, 
2006). Thus, the UBA of HOIP does not seem to be essential for binding to ubiquitin, but is 
both sufficient and required to form a complex with HOIL-1. Instead, the second NZF motif 
confers binding capacity to ubiquitin.  
SHARPIN does not possess any enzymatic activity, but sequence analyses revealed a similar 
structure to HOIL-1, i.e. presence of a C-terminal UBL domain followed by an NZF motif. 
Additionally, SHARPIN contains an N-terminal coiled-coil domain of so far unknown 
function. Initially, SHARPIN was identified as a protein interacting with SHANK, a 
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component of postsynaptic density in dendritic spines, sites of neuronal connectivity in the 
hippocampus (Lim et al, 2001). SHARPIN forms homodimers that facilitate SHANK cross-
linking, suggesting a possible function of SHARPIN in neuronal signalling. 
Initially, Kirisako et al. demonstrated that HOIL-1 and HOIP form a high molecular weight 
complex of approximately 600 kDa that possesses ubiquitin ligase activity in vitro (Kirisako 
et al, 2006). The catalytic activity of HOIL-1 is dispensable for linear ubiquitin chain 
formation, which solely depends on a functional RBR domain of HOIP (Haas et al, 2009; 
Tokunaga et al, 2009). Here, the RING1 domain of HOIP is thought to bind to E2s, whereas 
the RING2 motif confers enzymatic activity. Although HOIL-1 does not confer linear 
ubiquitin ligase activity to LUBAC, it was shown to ubiquitinate a number of proteins with 
K48-linked ubiquitin chains, including IRP2, the transcription factors Bach1 and interferon 
regulatory factor-3 (IRF3) as well as TAB2 and TAB3 (Ishikawa et al, 2005; Tian et al, 2007; 
Yamanaka et al, 2003; Zenke-Kawasaki et al, 2007). Targeting TAB2/3 for proteasomal 
degradation, HOIL-1 might negatively interfere with NF-κB activation in a LUBAC-
independent manner. However, given that this study was based on overexpression of HOIL-1 
and taking into account that Hoil-1-/- mice showed defects in NF-κB activation (Tokunaga et 
al, 2009), it is unlikely that HOIL-1 has a negative regulatory function in vivo. HOIL-1 and 
HOIP were shown to bind to activated conventional protein kinases (PKCs) and ubiquitinate 
them in vitro. Since degradation of activated PKCs was decreased in HOIL-1-deficient cells, 
linear ubiquitination was associated with proteasomal degradation at that time (Nakamura et 
al, 2006).  
We and others showed that SHARPIN is also part of this high molecular weight complex and 
that SHARPIN-HOIP or SHARPIN-HOIL-1-HOIP complexes are also capable of linear chain 
formation in vitro. Thus, HOIP is the central component of the LUBAC complex conferring 
catalytic activity. However, HOIP alone is unable to fulfil its activity, indicating that it 
requires at least one binding partner, i.e. HOIL-1 or SHARPIN to act as an E3 ubiquitin 
ligase. Furthermore, the stoichiometry of the 600 kDa complex needs to be resolved in order 
to understand whether only tripartite complexes exist in vivo, or whether HOIP-SHARPIN 
and HOIP-HOIL-1 sub-complexes form that might target diverse proteins for ubiquitination. 
In contrast to the initial observation that linear ubiquitination triggers proteasomal degradation 
(Kirisako et al, 2006), recent work by our group and others conclusively showed that 
LUBAC-mediated linear chain formation is rather required for proper NF-κB and MAPK 
activation in a variety of signalling pathways (Gerlach et al, 2011; Ikeda et al, 2011; 
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Tokunaga et al, 2011). As demonstrated in this thesis, LUBAC regulates the balance of TNF-
induced pro-survival signalling and cell death induction (see Results section).  
LUBAC is capable of forming linear chains with a variety of E2s, challenging the classical 
view that the E2 is primarily responsible for conferring linkage specificity. Moreover, 
LUBAC even forces E2-25K, an E2 described to uniquely catalyse K48-ubiquitin chain 
formation (Chen & Pickart, 1990), to generate linear chains. As proposed by Wenzel et al., 
LUBAC and other RBR family proteins utilise a RING-HECT hybrid mechanism that allows 
the E3 to confer linkage specificity independently of the E2s (Wenzel et al, 2011). Thus, 
LUBAC overrides E2-encoded linkage preference and determines linkage specificity. 
Consistently, LUBAC is unable to generate poly-ubiquitin chains in vitro with versions of 
ubiquitin, in which the amino-terminus is masked by a tag (Gerlach et al, 2011, Kirisako et al, 
2006). Thereby, it can be concluded that LUBAC exclusively forms linear (and not lysine-
conjugated) ubiquitin chains.  
1.6.2 Chronic proliferative dermatitis (cpdm) 
Mice harbouring a loss of function mutation in the Sharpin gene spontaneously develop 
chronic proliferative dermatitis (cpdm), an autosomal recessive, systemic inflammatory 
disorder at about four to six weeks of age. Deletion of a single base pair in the 3’end of exon1 
encoding the coiled-coiled region of SHARPIN leads to a frame shift in the open reading 
frame predicted to cause a premature stop codon at position 624 and hence generation of a 
non-functional protein (Seymour et al, 2007). Although the skin is the organ that is affected 
most obviously, cpdm mice present with multi-organ inflammation including other epithelia, 
e.g. in the mouth, oesophagus and forestomach, but also in liver, lungs and several joints. The 
skin of these mice displays signs of hyperplasia, hyperkeratosis and parakeratosis that are 
accompanied by infiltration of inflammatory cells including macrophages, mast cells and 
granulocytes (Gijbels et al, 1995a; Gijbels et al, 1996). Increased ICAM-1 and E-Selectin 
expression on basal keratinocytes and endothelial cells of dermal blood vessels might account 
for this increased infiltration. Besides increased keratinocyte proliferation resulting in 
thickening of the dermis, elevated levels of keratinocyte cell death have also been reported in 
cpdm mice. However, cpdm mice are not born with these lesions but develop them with age, 
with the first alterations being macroscopically visible three to four weeks after birth. Once 
severe pruritus and scaling manifest, the condition of the mice worsens as demonstrated by 
significant weight loss, growth retardation and formation of self-inflicted wounds, entailing 
the necessity to cull the animals ten to twelve weeks after birth. Only recently, Xia et al. 
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demonstrated a role of SHARPIN in bone metabolisms, explaining the observed growth 
retardation phenotype (Xia et al, 2010).  
Transfer of haematopoietic cells from cpdm mice to irradiated syngeneic mice did not induce 
the development of skin lesions, indicating that haematopoietic cells do not account for the 
skin pathogenesis observed in cpdm mice. In contrast, skin grafts transferred from cpdm or 
wild-type mice to cpdm, nude or wild-type mice revealed maintenance of the donor phenotype 
(Gijbels et al, 1995b). These results suggest that the pathology of cpdm mice is a result of a 
disorder in the dermis caused by local factors and not a cause of systemic defects or defects of 
the immune system. 
Apart from inflammatory lesions, mice also show developmental abnormalities as assessed by 
defective organisation of lymphoid tissues. In particular, cpdm mice are completely devoid of 
Peyer’s patches and lack well-formed follicles, germinal centres and follicular dendritic cells 
in the spleen, lymph nodes and nasal-associated lymphoid tissues (HogenEsch et al, 1999), 
resulting in impaired B cell development without affecting  T cell responses. In spite of a 
defective B cell population, absolute numbers of B cells and CD4+ and CD8+ T cells are 
unchanged. In contrast, total numbers of white blood cells in peripheral blood are 7-fold 
increased with an even 40-fold rise in eosinophil counts (HogenEsch et al, 2001), causing 
splenomegaly and lymphadenopathy in cpdm mice. This accumulation is mediated by 
increased TH2 cytokine production observed in skin homogenates of mutant mice. In 
particular, levels of interleukin-4 (IL-4), -5, -13 and granulocyte macrophage colony-
stimulating factor (GM-CSF) were shown to be up-regulated in cpdm samples, whereas no 
differences in TNF and IL-10 could be observed. Furthermore, cpdm-derived splenocytes 
activated with Concanavalin A (ConA) produced less interferon-γ (IFNγ), but more IL-13 and 
IL-5, further underscoring a dysbalanced cytokine response in the absence of SHARPIN.  
Steady-state serum levels of the immunoglobulins (Ig) IgG, IgA and IgE in cpdm mice are 
significantly lower as compared to wild-type, whereas IgM levels remain normal. 
Furthermore, production of antigen-specific antibodies of all isotypes upon antigenic 
challenge is severely decreased, indicating a function of SHARPIN in humoral immune 
responses, particularly in Ig class switching.   
Treatment of mutant mice with IL-12 completely abolished thickening of the epidermis and 
development of skin abnormalities (HogenEsch et al, 2001). Most likely, IL-12 induced 
T cells and natural killer (NK) cells to produce IFNγ and to inhibit the production of TH2 
cytokines, as assessed by decreased IL-5 secretion. IL-5 is a cytokine critically linked to 
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eosinophil homeostasis as it promotes maturation of eosinophils in the bone marrow, 
sensitises them to chemokines and enhances their survival in tissues (Stern et al, 1992; 
Yamaguchi et al, 1988). Treatment of cpdm mice with neutralising anti-IL-5 antibodies or 
crossing to Il-5-/- mice reduced eosinophil numbers to normal levels. However, the severity of 
dermatitis was not changed, indicating that eosinophils do not account for manifestation of 
inflammatory skin lesions and that their accumulation in cpdm mice is rather a consequence 
of the inflammation than causative for it (Renninger et al, 2009).  
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1.7 Aims of the project 
We recently reported on the development of a highly sensitive modified tandem-affinity 
purification (moTAP) method which can be used to purify receptor signalling complexes with 
high purity and selectivity (Haas et al, 2009). Analysis of the TNF-RSC revealed a 
stimulation-dependent recruitment of two novel components, HOIL-1 and HOIP, which form 
a ubiquitin ligase complex capable of generating linear poly-ubiquitin chains (Kirisako et al, 
2006). Additionally, this mass-spectrometric analysis determined SHARPIN as a third novel 
constituent of the TNF-RSC. This thesis aims at identifying the function of SHARPIN in 
TNFR1 signalling and at answering the following questions: 
 
1. How is SHARPIN recruited to the TNF-RSC? 
 2. What is the functional consequence of SHARPIN deletion on TNF-induced NF-κB 
 and MAPK signalling? 
3. Is SHARPIN required to prevent TNF-induced cell death, and if so what is the 
mechanism of sensitisation? Is there a difference in signalling output between 
SHARPIN-deficient as compared to HOIL-1-deficient cells? 
 
TNFR1, CD95 and TRAIL-R1/R2 are members of the TNFR superfamily that are able to 
induce proliferation as well as cell death following receptor crosslinking by their respective 
cognate ligands TNF, CD95L and TRAIL. Given that the signalling outputs of all three 
receptor-ligand systems rely on similar down-stream molecules, I also analysed and compared 
the functions of SHARPIN, HOIP and HOIL-1 in the CD95l/CD95 and TRAIL/TRAIL-R1/2 
systems. Thereby I aimed at answering the following questions: 
 
1. Are SHARPIN, HOIL-1 and HOIP required for CD95L- and TRAIL-induced pro-
survival signalling? 
2. Are SHARPIN, HOIL-1 and HOIP required for preventing CD95L- and TRAIL-
induced cell death? 
3. What is the mechanism of sensitisation to death ligand-mediated cell death in the 
absence of one of the LUBAC components? 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
All reagents used in this study were purchased from the following companies unless stated 
otherwise: Amersham Biosciences, AppliChem, Becton Dickinson, Gerba, Merck 
(Calbiochem), Invitrogen, Pierce, Roche, Roth and Sigma/Aldrich (Fluka). All chemicals 
were purchased in pA quality unless indicated otherwise. 
2.1.2 Specific inhibitors 
COMPLETE Protease Inhibitor Cocktail  Roche 
Phosphatase Inhibitor Cocktail   Sigma/Aldrich 
Necrostatin-1      Sigma/Aldrich    
Q-Val-Asp(non-O-methylated)-OPh (QVD) R&D systems 
TNFR2-Fc (Enbrel)     Pfizer 
2.1.3 Buffers and solutions 
Blocking Buffer     5 % milk powder 
       0.05 % Tween-20 in PBS 
 
Carbonate Coating Buffer (pH = 9.5)  8.4 g NaHCO3 
       3.56 g Na2CO3   
 
Citrate Buffer      0.025 M citric acid (pH = 4.5) 
 
ELISA Assay Buffer     0.5 % BSA 
       0.05 % Tween-20 in PBS  
 
ELISA Substrate Solution    10 ml Citrate Buffer 
 10 µl H2O2 
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       10 mg OPD  
 
FACS buffer      1 x PBS 
       5% FCS (v/v) 
       0.05% NaN3 (w/v) 
 
Freezing medium (for cells)    90% FCS (v/v) 
       10% DMSO (v/v) 
 
HBS (2x, pH = 7.0)     50 mM HEPES 
       280 mM NaCl 
       1.5 mM Na2HPO4 x 2 H2O 
 
IP-lysis Buffer     30 mM Tris-Base (pH 7,4) 
       120 mM NaCl 
       2 mM EDTA 
       2 mM KCl 
       10% Glycerol (v/v) 
       1% Triton X-100 (v/v) 
       COMPLETE protease-inhibitor cocktail  
 
Luciferase Assay Buffer A (pH = 7.8)  20 mM HEPES 
       33.3 mM DTT 
       8.0 mM MgCl2 
       130 µM EDTA 
       530 µM ATP 
       470 µM Luciferin 
       270 µM Coenzyme A 
 
Luciferase Assay Buffer B (pH = 5.0)  15 mM Natriumpyrophosphate 
       7.5 mM NaOAc 
       400 mM NaSO4 
       10 mM CDTA 
       25 µM APMBT 
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       1% Methanol (v/v) 
       2 µM Benzyl-Colenterazin 
 
MOPS Running Buffer (pH = 7.7)   50 mM MOPS 
       50 mM Tris-Base 
       3.5 mM SDS 
       1.0 mM EDTA 
 
PBS (pH = 7.4)     137 mM NaCl 
       8.1 mM Na2HPO4 
       2.7 mM KCl 
       1.5 mM KH2PO4 
 
PI buffer      1 µg/mL Propidium Iodide in PBS 
 
Pull-down buffer     150 mM NaCl 
       50 mM Trizma Base  (pH 7.5) 
       5 mM DTT 
       0.1% NP-40 (v/v) 
 
Stripping Buffer (pH = 2.3)    50 mM Glycin in H2O  
 
TAE buffer (10x)     400 mM Tris/HCl 
       200 mM Acetic Acid 
       10 mM EDTA 
 
TB buffer      10 mM Pipes 
       55 mM MnCl2 
       15 mM CaCl2 
       250 mM KCl 
 
  
Transfer Buffer     192 mM Glycin 
       25 mM Tris-Base 
  2. Materials and Methods 
58 
 
       0.01 % EDTA 
       20% Methanol (v/v) 
 
Wash Buffer      0.05% Tween-20 in PBS (1x) 
2.1.4 Antibodies 
Table 2.1: Unconjugated antibodies  
(WB: Western blotting; IP: immunoprecipitation) 
 
Antibody Isotype Source Application 
A20 (59A426) rabbit Imgenex WB 
ABIN1 Sheep Gift by Philipp Cohen WB 
Actin (A5441) mIgG1 Sigma WB 
Bid (#2002) rabbit Cell signalling WB 
Caspase-3 rabbit Axxora WB 
Caspase-8 (ALX-804-429) mIgG2b Axxora Life Science WB 
Caspase-8 ratIgG1 Axxora Life Science WB, IP 
Caspase-8 (C20) goat Santa Cruz IP 
Caspase-9 mIgG1 MBL WB 
cIAP1/2 Pan (MAB3400) mIgG2a R&D Systems WB 
FLAG (M2) mIgG1 Sigma WB, IP 
IκBα (44D4) rabbit Cell signalling WB 
JNK (56G8) rabbit Cell Signalling WB 
Myc (9E10) mIgG1 Abcam WB 
pIkBα (5A5) mIgG1 Cell Signaling WB 
pJNK (98F2) rabbit Cell Signalling WB 
p38 (7D6) rabbit Cell signalling WB 
p65 (A) rabbit Santa Cruz WB 
PARP1 (C-2-10) mIgG1 Biomlo WB 
pp38 (3D7) rabbit Cell signalling WB 
RIP1 (#610459) mIgG2a BD WB 
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RIP3 rabbit Imgenex WB 
SHARPIN rabbit Gift by Ivan Dikic WB 
TNFR1 (ab19139) rabbit Abcam WB 
TRADD (H-278) mIgG1 Santa Cruz WB 
TRAF2 (C-20) rabbit Santa Cruz WB 
Ubiquitin (#07-375) Rabbit Millipore WB 
V5 (sV5-10) mIgG1 Sigma WB, IP 
 
Table 2.2: Conjugated antibodies 
 
Antibody Source Application 
Goat-anti-mIgG1-HRP Southern Biotech WB 
Goat-anti-mIgG2a-HRP Southern Biotech WB 
Goat-anti-mIgG2b-HRP Southern Biotech WB 
Goat-anti-mIgM-HRP Southern Biotech WB 
Goat-anti-rabbit-IgG-HRP Southern Biotech WB 
Goat-anti-rat-HRP Southern Biotech WB 
Rabbit-anti-goat-IgG-HRP Santa Cruz WB 
 
2.1.4.1 HOIL-1, HOIP ans SHARPIN antibodies 
Polyclonal anti-HOIP serum was obtained by immunising rabbits with two peptides 
(CEDFQNWKRMNDPEYQAQ-CONH2 and CGDPEKQRQDKMREEG-CONH2) coupled 
to KLH. Monoclonal HOIL-1 antibodies (2D2) were generated from 8-week-old BALBc mice 
immunised with recombinant full length GST-tagged HOIL-1 protein. The monoclonal 
antibody recognising human SHARPIN was generated from 8-week-old Balb/c x C57BL6 
mice immunised with KHL-coupled peptide (GPDAEAQLRRLQLSADC). 
2.1.5 Cell culture Media and Additives 
Dulbecco’s Modified Eagle Medium Invitrogen, Karlsruhe; Germany 
Dulbecco’s PBS    Invitrogen, Karlsruhe; Germany 
RPMI 1640     Invitrogen, Karlsruhe; Germany  
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Opti-MEM® Reduced Serum Medium Invitrogen, Karlsruhe; Germany 
Keratinocyte Serum Free Media (KSFM) Invitrogen, Karlsruhe; Germany  
Ampicillin     Roth, Karlsruhe; Germany 
Penicillin/Streptomycin   Invitrogen, Auckland; New Zealand 
Gentamycine     Cambrex Bio Whittaker, Verviers; Belgium 
Hygromycin B    Boehringer Mannheim, Mannheim; Germany 
G418 (Geneticin®)    Invitrogen, Karlsruhe; Germany 
Zeocin      Invitrogen, Karlsruhe; Germany 
Sodium Pyruvate    Invitrogen, Karlsruhe; Germany 
Hypoxanthine Thymidine (HAT)  Invitrogen, Karlsruhe; Germany 
Trypsin/EDTA solution   Invitrogen, Karlsruhe; Germany 
β-mercaptoethanol    Invitrogen, Karlsruhe; Germany 
2.1.6 Beads for protein precipitation 
Anti-Myc agarose    Sigma-Aldrich, Munich; Germany 
anti-V5 Agarose (clone V5-10)  Sigma-Aldrich, Munich; Germany 
FLAG M2 affinity Gel   Sigma-Aldrich, Munich; Germany 
Protein G Sepharose    GE Healthcare, Munich; Germany 
2.1.7 Kits and Ready-to-Use Solutions 
ABsolute QPCR ROX Mix   ABgene, Epsom; UK 
BCA Protein assay    Perkin Elmer, Wellesley; United States 
Chemiluminescent Substrate   Perkin Elmer, Wellesley; United States 
IL-6 ELISA      eBioscience, Frankfurt; Germany 
Perhydrol® 30 % H2O2   Merck, Darmstadt; Germany 
QIAprep Maxi Kit    Qiagen, Hilden; Germany 
QIAprep Spin Mini Kit   Qiagen, Hilden; Germany 
QIAquick Gel Extraction Kit   Qiagen, Hilden; Germany 
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RevertAidTM H Minus strand cDNA  Fermentas Life Science, St. Leon Rot; Germany 
synthesis kit 
Trizol reagent    Invitrogen, Karlsruhe; Germany 
TrypanBlue     Serva, Heidelberg; Germany 
2.1.8 Consumables 
Cell Culture Petri dishes   TPP, Trasadingen; Switzerland 
Cell Culture Test Plates (6-, 12-, 24-well) TPP, Trasadingen; Switzerland 
Round and flat bottom 96-well test plates TPP, Trasadingen; Switzerland 
Tissue Culture flasks (25, 75, 150 cm2) TPP, Trasadingen; Switzerland 
Falcons (15 ml and 50 ml)   TPP, Trasadingen; Switzerland 
Plastic pipettes (5 ml, 10 ml and 15 ml) Becton Dickinson, Heidelberg; Germany 
Pipette tips (0.1-10, 1-200, 101-1000 µl) StarLab, Ahrensburg, Germany 
Safe-Lock Reaction Tubes (1,5ml, 2 ml) Eppendorf, Hamburg; Germany 
Vivaspin Concentrator MWCO 10000 Sartorius, Goettingen; Germany 
PCR Tubes     StarLab, Ahrensburg; Germany 
96 well PCR plate    ABgene, Epsom; UK 
384 well PCR plate    ABgene, Epsom, United Kingdom 
Sealing foil     Roche, Mannheim; Germany 
NuPAGE® 4-12% Bis-Tris Gels  Invitrogen, Karlsruhe; Germany  
Hybond ECL Nitrocellulose Membrane Amersham Bioscience, Buckinghamshire; UK 
X-Ray film HyperfilmTM ECL  Amersham, Freiburg; Germany 
Whatman paper    Schleicher&Schuell, Maidstone; United Kingdom 
Polypropylene round bottom tube (5 ml) Becton Dickinson, Heidelberg; Germany 
Cuvette     Greiner Bio-One, Flacht; Germany  
Dialysis Tube     Roth, Karlsruhe; Germany 
PS- Test Tubes for FACS   Greiner Bio-One, Flacht; Germany   
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Cryogenic vials    Nunc, Wiesbaden; Germany 
F96 MaxiSorp Plates for ELISA  Nunc, Wiesbaden; Germany 
Cell Sieve (40 µm pore size)   Becton Dickinson, Heidelberg; Germany 
Vaccum driven Bottle Top filter (0.22 µm) Millipore, Billerica; United States 
50 ml Reagent Reservoir   Corning Inc., Corning; United States 
Single-Use Syringe (5 ml, 30 ml, 50 ml) Terumo, Eschborn; Germany 
Single-Use Syringe (1 ml, 2 ml)  Becton Dickinson, Heidelberg; Germany 
Sterile filter (0.22 µm pore size)  Millipore, Billerica; United States 
Single-Use Scalpel    Feather, Osaka; Japan 
Single-Use Needles    Becton Dickinson, Heidelberg; Germany 
Glassware     Schott, Mainz; Germany 
2.1.9 Instruments 
Flow Cytometer FACSCalibur  Becton Dickinson, Heidelberg; Germany 
ABI Prism® 7900HT Sequence Detection  
System     Applied Biosystems, Foster City; United States 
Multiskan Ascent    Thermo Labsystems, Vantaa; Finnland 
Hyper Processor X-Ray film Developer Amersham Bioscience, Buckinghamshire; UK 
COBRA Auto-gamma counter  Packard, Ramsey; United States 
Blotting equipment X cell IITM  Novex, Bergisch Gladbach; Germany 
NanoDrop Spectrophotometer ND-1000 NanoDrop Technologies, Wilmington; USA 
Photometer Ultrospec 3100 pro  Amersham, Freiburg; Germany  
Äkta Prime     Amersham Pharmacia Biotech, Vienna; Austria 
Steri-Cult Cell culture bench   HERA Safe, Berlin; Germany 
Incubator Stericult 2000   Forma Scientific, Scotia; United States 
Millipore Super-Q water installation  Millipore, Billerica; United States 
Ice machine     Scotsman, Vernon Hills; United States 
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Microwave     AEG, Nuremberg; Germany 
Table Centrifuge Biofuge   Heraeus, Hanau, Germany 
Varifuge 3O-R    Heraeus, Hanau, Germany 
Multifuge 3S-R    Heraeus, Hanau, Germany 
Biofuge Stratos    Heraeus, Hanau, Germany 
Gene Amplification PCR system 9700 Applied Bioscience, Mumbai; India 
Power Supply for agarose gels  BioRad, Hercules; United States 
Light Microscope    Zeiss, Oberkochen; Germany 
Vortex      Heidolph, Schwabach; Germany 
Cryo 1°C Freezing container   Nalgene Labware, Neerijse; Belgium 
pH Meter     Mettler, Giessen; Germany 
Thermomixer compact   Eppendorf, Hamburg; Germany 
Freezer -20° C    Liebherr, Biberach; Germany 
Freezer -80° C    Forma Scientific, Marietta; United States 
GelSystem Flexi 4040   Biostep, Jahnsdorf; Germany  
Digital Camera    Olympus, Hamburg; Germany 
Pipettes (10 µl, 100 µl, 200 µl, 1 ml) Gilson, Bad Camber; Germany 
Pipetboy     Integra Bioscience, Fernwald; Germany 
Multichannel pipettes    Micronic Systems, McMurray; United States 
2.1.10 Software 
CellQuest ProTM version 4.02  Becton Dickinson, Heidelberg; Germany 
Vector NTI     Invitrogen, Karlsruhe; Germany 
Microsoft® Excel 2003   Microsoft, Redmont; United States 
Microsoft® Powerpoint 2003   Microsoft, Redmont; United States 
Microsoft® Word 2003   Microsoft, Redmont; United States 
Universal Probe Library Assay Design  
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Centre      Roche, Mannheim; Germany 
Sequencing     Imperial College London, London, UK 
ND1000 V3.3.0    NanoDrop Technology; Wilmington; USA  
Ascent Software Version 2.6   Thermo Labsystems, Vantaa; Finnland  
SDS 2.1     Applied Biosystems, Foster City; United States 
 
2.2 Methods of Cell Biology 
2.2.1 Cell lines 
2.2.1.1 HEK293T cells 
HEK293T cells were generated by transformation of human embryonic kidney (HEK) cell 
cultures with sheared adenovirus 5 DNA (Graham et al, 1977). HEK293T cells are highly 
transfectable. The expression of the SV40 large T-antigen facilitates the extra chromosomal 
replication of plasmids bearing the SV40 origin of replication. 
2.2.1.2 HeLa cells 
The HeLa cell line was isolated from an adenocarcinoma of the cervix of a patient named 
Henrietta Lacks in 1952. It is the first human epithelial cancer cell line established in long-
term cell culture (Scherer et al, 1953). HeLa cells have a hypertriploid chromosome number 
(3n+), 20 clonally abnormal chromosomes and contain multiple copies of HPV type 18 
(HPV18), integrated at specific sites (Chen, 1988; Popescu et al, 1987). 
2.2.1.3 Jurkat cells 
The Jurkat cell line was first established from the peripheral blood of a 14-year old boy 
suffering from T cell leukemia in the late 1970s (Schneider et al, 1977).  
2.2.1.4 MCF-7 cells 
The human breast carcinoma cell line MCF-7 was first described in 1973 by Brooks and 
colleagues (Brooks et al, 1973). 
2.2.1.5 Mouse Embryonic Fibroblasts (MEFs) 
MEFs were generated from E15 embryos in accordance with standard procedures and were 
infected with SV40 large T antigen-expressing lentivirus. For the generation of HOIL-1-/- 
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MEFs, cells were additionally infected with Cre-expressing lentivirus and selected by addition 
of 2 µg/mL puromycin. 
2.2.1.6 U937 
The human monocytic cell line U937 was derived from a patient with generalised histiocytic 
lymphoma and was first described in 1976 by Sundstrom and Nilsson (Sundstrom & Nilsson, 
1976). 
2.2.2 Cell culturing conditions 
All adherent cell lines were cultured in a 10% CO2-humidified atmosphere at 37 °C. 
HEK293T, HeLa and MEF cell lines were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 5% foetal bovine serum. MCF-7 cells were cultured in 
DMEM containing 5% foetal bovine serum, 1% pyruvate and 0.1% human insulin. Cells were 
detached with a 1 x PBS/trypsin (Invitrogen) solution before they reached confluence. 
All suspension cell lines were maintained in RPMI supplemented with 10% FBS at 5% CO2 
(37 °C) at a density of ~ 1x106 cells/mL. Cell density was determined with a Neubauer 
chamber slide.  
2.2.3 Freezing and thawing of eukaryotic cells 
For freezing, approximately 2.5 x 106 cells were re-suspended in FCS containing 10% DMSO, 
transferred to cryogenic vials and frozen down in an isopropanol box to -80° C. For long-term 
storage, cells were transferred to liquid nitrogen at -196 °C.  
Frozen cells were thawed in a water bath at 37 °C. To get rid of the DMSO, cells were spun 
down with a centrifuge and re-suspended in fresh medium.  
2.2.4 Generation of primary keratinocytes 
The skin of the tails from 10 day-old mice was incubated in keratinocyte serum free medium 
(KSFM) supplemented with bovine pituitary extract, epidermal growth factors (Invitrogen) 
and gentamicin (50 µg/mL) containing 2.1 U/mL dispase II (in 50 mM HEPES and 150 mM 
NaCl, pH 7.4) at 4 °C overnight. The following day, the epidermis was separated from the 
dermis and keratinocytes extracted from the epidermis using Tryp LE express Trypsin 
(Invitrogen) under constant agitation using a P1000 pipette at room temperature for 15 min. 
Subsequently, cells were centrifuged for 10 min, keratinocytes re-suspended in growth factor- 
supplemented KSFM and seeded on 12-well or 96-well plates, respectively. Medium was 
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changed the next day to remove cells that have not attached. Five days later, keratinocytes 
were used for the respective assays. 
2.2.5 Transfection of adherent cells 
MCF-7 and HeLa cells were transfected with FuGene 6 (Roche Applied Science) according to 
the manufacturer’s protocol. 
HEK293T cells were transfected by the calcium phosphate method. HEK293T cells were split 
1:3 the day before transfection to obtain ~60% confluence. For transfection of a 10 cm2 dish, 
20 µg plasmid DNA and 50 µl CaCl2 (2M) were added to 450 µl H2O. Subsequently, the 
DNA/CaCl2 solution was gently mixed with 500 µL 2xHBS. Following 30 min incubation at 
room temperature, the transfection mixture was gently added drop-wise to the cell medium.  
For production of recombinant proteins secreted into the cell culture supernatant, the 
supernatant was harvested 48 hrs and 96 hrs post-transfection.  
2.2.6 Lentiviral infection of eukaryotic cells 
2.2.6.1  Production of recombinant viruses 
HEK293T cells were used for the production of recombinant, lentiviral particles using the 
calcium phosphate method (see chapter 2.2.5). The transfection mixture containing 28 µg of 
the packaging vector pCMV-dR8.91 (HIV_Gag, HIV_Rev), 12 µg of the envelope pMD2G 
(VSVG) and 40 µg of the shRNA plasmid (pLKO.1) to be packed was added drop wise to the 
cells. Following 48 and 96 hrs incubation at 37° C, the lentivirus-containing cell supernatant 
was collected. 
Lentiviral particles were then used to generate cell lines in which the gene of interest was 
stably silenced. Briefly, target cells were spin-infected in the presence of 5 µg/mL polybrene 
(2000 x g, 4 hrs, RT) and infected cells selected with 2 µg/mL puromycin. Knockdown 
efficiency was controlled by Western Blotting and qPCR. 
2.2.6.2 Generation of stable knockdown or overexpressing cells 
HOIL-1-specific shRNAs were obtained from the RNAi consortium (TRC). The sequence for 
stable knockdown of HOIL-1 was 5'-CCACAACACTCATCTGTCAAA-3´ 
(TRCN0000007599), RHS408 was used as control shRNA. For stable HOIP knockdown, the 
shRNA coding sequence (5’-AGACAAGGTTGAAGATGATAT-3‘) from the pGeneClip 
vector (SA Biosciences) was cloned into pTWEEN-GFP. To excise HOIL-1 from targeted 
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HOIL-1 MEFs, cells were infected with Cre-expressing virus. The respective cDNA 
sequences of HOIL-1 and SHARPIN were cloned into the pCIGW vector and the cDNA 
sequence of wild-type or mutant HOIP into the pCIGW vector in order to over-express the 
respective proteins.  
2.2.7 siRNA-mediated Knock-down 
Transient knock-down of target genes was achieved by siRNA obtained from 
ThermoScientific using Dharmafect as transfection agent. Briefly, per six-well, 1.5 µL 
Dharmafect were mixed with 200 µL DMEM not containing FCS for 10 min at RT. 
Subsequently, 2.2 µL siRNA (20 µM) were added and incubated for 30 min at RT. 2 x 106 
cells were transfected with the transfection mixture. 
2.2.8 Inducible Protein Expression in MEF cell lines 
An inducible lentiviral system was used for the induction of cIAP1 in cIAP1/2 double 
knockout MEFs using 20 nM 4-hydoxy-tamoxifen (4-HT) for 20 hrs (Mace et al, 2008). The 
cell line was kindly provided by John Silke.  
2.2.9 cIAP1/2 degradation using SMAC mimetics 
SMAC-83 (SM-83) was synthesised and kindly provided by Pierfausto Seneci and Leonardo 
Manzoni (Cossu et al, 2009). To obtain efficient cIAP1/2 degradation, HeLa cells were pre-
treated with 100 nM SM-83 for 2 hrs. 
2.2.10 Quantification of Cell Death and Cell Viability 
Cell death was assessed by propidium Iodide uptake. Briefly, 5 x 104 cells were seeded per 
12-well and cells pre-treated the next day in the presence or absence of 10 µM Q-Val-
Asp(non-O-methylated)-OPh (QVD) or 30 µM necrostatin-1 (NEC-1) for 1 hr before addition 
of the respective death ligand. 24 or 48 hrs later, the percentage of cell death was assessed by 
propidium Iodide up-take using flow cytometry (FACS Calibur). Alternatively, 1 x 104 cells 
were seeded per 96-well, cells treated the next day and cell viability measured by Cell Titer 
glo (Promega) 24 hrs later according to the manufacturer’s instructions.  
2.2.11 Determination of clonogenic survival 
1 x 104 cells were seeded per 12-well and stimulated with the respective death ligand the 
following day. Six days later, cells were washed with PBS and fixed in 3% formaldehyde in 
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PBS for 10 min at RT. Subsequently, cells were incubated with crystal-violet for 15 min at 
RT and washed with PBS. 
2.2.12 Flow cytometry 
For flow cytometry, up to 5 x 105 cells per staining were initially incubated for 10 min on ice 
with FACS buffer containing Fc-Receptor blocking abtiody (CD16/32) to block unspecific 
binding. Depending on the efficiency of the antibodies, different dilutions of the antibody 
were prepared in FACS buffer. Typically, 5 µg/mL primary, 3 µg/mL secondary and 1 µg/mL 
tertiary antibody were used. If the primary antibody was not directly conjugated to a distinct 
fluorescent dye, cells were washed three times with FACS buffer before the next antibody 
was applied. To control for specific binding of the antibody, isotype controls were used. 
Surface expression of distinct proteins was then assessed by flow cytometry using a FACS 
Calibur. 
 
2.3 Methods of Molecular Biology 
2.3.1 DNA digestion and restriction analysis 
For the sequence-specific cleavage of DNA molecules samples were incubated with 
restriction endonucleases (Fermentas FastDigest®) for 1 hr at 37 °C.  
2.3.2 Agarose gel electrophoresis of nucleic acids 
Agarose gels in TAE buffer were used to analyse Plasmid DNA and DNA fragments. DNA 
was mixed with 1 x DNA loading buffer, loaded onto 1-2 % (w/v) agarose gels and ran at 130 
V for 40 min in 1 x TAE buffer. To determine the size of the loaded DNA fragments, a 
marker containing DNA fragments of defined molecular sizes (Smart Ladder) was also 
applied. DNA bands were visualized by incubation in a solution containing 0.5 µg/ml 
ethidium-bromide for 15 min. UV light with a wavelength of λ = 254 nm enabled 
visualization of DNA fragments. 
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2.3.3 Gel extraction of DNA fragments 
Isolation of DNA fragments from agarose gels was achieved using the QIAquick Gel 
Extraction kit (Qiagen) according to manufacturer’s instructions. DNA was eluted 30-50 µL 
and used in further applications. 
2.3.4 Ligation of DNA fragments 
The optimal ratio for ligation between linearised vector and insert is in the range of 1:3 to 1:5. 
The concentrations of both components were estimated by intensity comparison of the bands 
in agarose gels. Appropriate volumes were mixed with ligase buffer, polyethylenglycol (PEG) 
and 2 U T4-ligase (NEB) in a total volume of 20 µl. The reaction was carried out in a PCR 
machine using a cycle ligation program overnight; alternately 10 min at 10 °C, 30 min at 
30 °C. 
2.3.5 Transformation of competent E. coli bacteria and Isolation of Plasmid DNA 
Competent bacteria E.coli TOP 10 F’ (Invitrogen) were thawed on ice and incubated with 
1-10 ng plasmid DNA or the ligation product for 30 min on ice. Heating at 42° C for 90 sec 
and subsequent cooling on ice for 3 min permeabilised the bacterial membrane and allowed 
the DNA to enter the cell. 300 µl SOC medium were added, the bacteria shacked for 30 min at 
37 °C and then plated on LB agar plates containing the respective antibiotic to select for 
positive clones. The next day, single clones were picked, grown in 5 mL LB Amp medium 
overnight at 37 °C and the plasmids isolated with the QIAprep Miniprep Kit (Qiagen).  
2.3.6 Polymerase Chain Reaction (PCR) 
All PCRs were done in a volume of 50 µl, containing 1-50 ng plasmid- or cDNA as template. 
The synthetic oligonucleotides were designed with 40-60% GC content, no internal structure 
or complementarities at the 3’-ends. Annealing temperatures were chosen ~5-10°C lower than 
the melting temperature Tm. A typical PCR reaction contained 200 µM dNTP, 2.5 U 
Polymerase, 1 x Polymerase Buffer and 0.4 µM Primer.  
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2.3.7 Quantitative PCR 
2.3.7.1 RNA purification 
Total RNA from cells was isolated using Trizol (Invitrogen) according to the manufacturer’s 
instructions. Trizol was removed by addition of 0.2 ml chloroform followed by isopropanol 
precipitation. The concentration and purity of RNA was determined with a ND-1000 
Spectrophotometer (NanoDrop). 
2.3.7.2 cDNA preparation 
5 µg of total RNA were transcribed into cDNA using the RevertAidTM H Minus first strand 
cDNA synthesis kit (Fermentas) according to the manufacturer’s instructions. 
2.3.7.3 Quantitative Real-time PCR  
Quantitative Real-time PCR (qPCR) was performed with the ABI PRISM 7900 HT Sequence 
Detection System (Applied Biosystems) using the ABsoluteTM QPCR ROX Mix (ABgene). 
The ProbeFinder software (Roche) was used to design the optimal assay, comprising the 
respective labelled probe of the Universal ProbeLibrary (Roche) and gene-specific primers. A 
specific probe-primer mix was prepared for each gene investigated: 
Specific Probe    0.44 µl 
5’ and 3’ Primer mix (10 pmol/µl)  1.76 µl 
H2O      6.4 µl 
cDNA (diluted 1:10)     4.4 µl 
2 x qPCR ROX Mix      13 µl 
The qPCR reaction was performed in double determination (each time 11 µl) according to the 
following thermal cycling program: 
Initiation    50 °C for 2 min 
Enzyme activation   95 °C for 15 min 
Denaturation    95 °C for 15 sec 
Annealing/Extension   60 °C for 60 sec 
After normalisation on basis of the housekeeping genes, relative differences in mRNA levels 
were assessed based on the cycling threshold (C(t)) determined by the PE Biosystems ABI 
7900 sequencer software and the relative quantification calculated. 
40 cycles 
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The following Primers and Probes were used: 
Table 2.3: Oligonucleotide sequences and corresponding Probe numbers according to the 
Roche Universal Probe Library. 
 
Name Forward Primer 5’-3’ ReversePrimer 5’-3’ Probe number 
GAPDH aaattcaacggcacagtcaa  gtagcccaagatgcccttc 38 
A20 gctcaactggtgtcgtgaag atgaggcagtttccatcacc 21 
HOIL-1 tctccccaacacaggacatc aaatggtgacggtgtgcat 88 
HOIP cccagtgtcaccagaccttc cctcacaactccgtcctctg 52 
ICAM-1 cccacgctacctctgctc gatggatacctgagcatcacc 81 
IκBα acgagcaaatggtgaaggag atgattgccaagtgcagga 38 
TNF tgcctatgtctcagcctcttc gaggccatttgggaacttct 49 
FLIP cttcgctcccaaaattgagt tccacaaatcttggctctttact 50 
 
2.4 Methods of Biochemistry 
2.4.1 Determination of protein content 
To determine the protein concentration of cell lysates, the bicinchoninic acid (BCA)-
containing protein assay was applied according to the manufacture’s protocol (Pierce). 1-5 µl 
of the lysate were incubated in 100 µl BCA solution at 60 °C for 15 min, followed by 
measuring light absorption at 560 nm in a Multiskan Ascent (Thermo Labsystems). 
2.4.2 Precipitation of Receptor Signalling Complexes 
Cells were stimulated with the respective death ligand for different time periods. His-FLAG 
tagged TNF (HF-TNF, referred to as TNF in the subsequent chapters), moTAP-TRAIL 
(3xFLAG-Precission-Avi tag; referred to as TRAIL) and Fc-CD95L (referred to as CD95L) 
were used. TNF and TRAIL were produced in bacteria and subsequently purified based on 
standard procedures; CD95L was produced in HEK293T cells, the supernatant collected and 
the protein content quantified. Following stimulation, cells were washed twice with ice-cold 
PBS and lysed in 1 mL IP-lysis buffer/cell dish at 4 °C for 35 min. The detergent-insoluble 
fraction was then pelleted by centrifugation (13.000 rpm, 30 min) and the cell lysates 
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transferred to a new tube. Equal amounts of protein were subjected to precipitation with 
10 µL of the respective antibody-coupled beads at 4 °C overnight. Briefly, anti-FLAG 
coupled M2 beads (Sigma-Aldrich) were used for the immune-precipitation of the TNF-RSC 
and TRAIL-DISC and Protein G beads for the CD95 DISC. Alternatively, to precipitate any 
other component from the lysates, 1 µg of the antibody of interest was coupled to 10 µL 
Protein G beads per sample. Beads were washed five times the next day in IP-lysis buffer. In 
the last step, beads were completely aspirated and dried, re-suspended in 20-40 µL 2 x LDS 
buffer and incubated at 75 °C for 10 min. 
2.4.3 Protein interaction studies 
For in vivo interaction studies, 7.5 x 106 HEK293T cells were transfected with 5-10 µg of the 
respective DNA plasmids by standard calcium phosphate transfection (see chapter 2.2.5). 
Cells were harvested 24 hrs post transfection and lysed in 1 ml IP-lysis buffer supplemented 
with 1% Triton X-100 for 30 min at 4 °C. Subsequently, lysates were centrifuged at 
13.000 rpm for 30 min. Immuno-precipitations with the respective antibody-coupled beads 
were performed at 4 °C overnight. Beads were washed five times with IP-lysis buffer and the 
proteins were eluted in 30 µl 2 x LDS sample buffer. Precipitated proteins were analysed by 
Western blotting.  
2.4.4 Ubiquitin pull-down assay 
10 µg of purified GST-tagged protein were incubated with glutathione-sepharose resin in 
600 µl Pull-down buffer (PDB) at 4 °C for 6 hrs. Beads were washed three times with PDB 
and incubated at 4 °C overnight with 2 µg ubiquitin tetra-ubiquitin chains of different linkage 
in 450 µl PDB. Beads were washed five times with PDB the next day and binding of the 
respective ubiquitin chains types to the GST-tagged proteins analysed by Western blotting. 
2.4.5 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Separation of proteins was performed based on the method by Laemmli (Laemmli, 1970) 
using 4-12% Bis-Tris-NuPAGE gels from Invitrogen. Samples were mixed with SDS-Sample 
buffer and heated for 10 min at 75 °C. The SeeBlueTM Plus2 Pre-Stained marker (Novex) was 
used as a molecular weight standard. The electrophoretic separation was carried out at a 
constant voltage of 100 V for 10 min and subsequently 180 V for 60 min. Depending on the 
molecular sizes of the proteins of interest, MES (proteins < 40 kDa) or MOPS buffer 
(> 40 kDa) was used. 
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2.4.6 Western blotting 
Western blotting was performed using the NOVEX gel-system based on the method of 
Towbin (Towbin et al, 1979). Proteins from SDS-PAGE gels were transferred onto 
nitrocellulose membranes (Amersham Pharmacia) by application of a current of maximum 
160 mA (30 V) per gel for 2 hrs. Afterwards, membranes were incubated for at least 15 min 
with blocking buffer at room temperature to occupy non-specific protein binding sites. 
Subsequently, membranes were subjected to immune-probing with primary antibodies and 
secondary horseradish-peroxidase (HRP)-conjugated antibodies. Proteins were visualised 
using different ECL® detection systems (Amersham Biosciences). 
2.4.7 Stripping of Western blot membranes 
Nitrocellulose membranes containing transferred proteins were incubated with alternative 
antibodies if necessary. For that purpose, the already bound immunoglobulins were removed 
by incubating the nitrocellulose membranes with Stripping buffer at RT for 15 min. The 
acidic pH of the stripping solution leads to denaturation of the bound antibodies. 
Subsequently, the membranes were washed 4 - 6 times with PBST, followed by incubation in 
blocking solution and probing as described in 2.4.6. 
2.4.8 Enzyme-Linked Immuno Sorbent Assay (ELISA) 
Cells were stimulated for 24 hrs with the respective ligands and the cell supernatant collected 
afterwards. ELISA reactions were performed according to the manufacturer’s instruction. 
Briefly, 96-well plates were coated with anti-IL-6 or anti-TNF antibodies diluted in coating 
buffer at 4 °C overnight. Plates were washed three times and blocked with 200 µl/well Assay 
buffer at RT for 1 hr. Plates were then washed again and the supernatant applied at RT for 
2 hrs. In addition, distinct concentrations of recombinant IL-6 or TNF were applied to prepare 
standard curves. Subsequently, the detection antibody was applied followed by Streptavidin-
HRP solution. Cytokine production was the visualised by the addition of ELISA substrate 
solution. The reaction was stopped with 100 µl 2 N H2SO4 and the absorbance measured at 
450 nm with a Multiskan Ascent. 
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2.5 Animal work 
2.5.1 Chronic proliferative dermatitis mice 
The cpdm mutation arose spontaneously in the breeding stock of inbred C57BL/KaLawRij 
mice in the specific pathogen-free-breeding facility of TNO Rijswijk, Netherlands. Mice with 
a mutation in the SHARPIN gene were obtained from the Jackson Laboratory and kept under 
conventional conditions. Mutation of the SHARPIN gene causes a chronic proliferative 
dermatitis (cpdm) phenotype which was initially described by HogenEsch et al. (HogenEsch 
et al, 1993). SHARPIN-deficient cpdm mice of both sexes were equally affected. As female 
cpdm mice do not breed and males become infertile with 6-8 weeks of age, heterozygous 
males and females were mated and mutant mice born with Mendalian ratio. Animals were 
housed in micro-isolator cages under pathogen-free conditions in the Burlington Danes barrier 
facility at Imperial College London. Animal experiments were done in accordance with the 
Animals (Scientific Procedures) Act 1986; all were approved by local ethical review. 
2.5.2 Conditional HOIL-1 mice 
Conditional HOIL-1 knockout mice were generated at the Walter and Eliza Hall Institute 
(WEHI) in Melbourne, Australia. These mice contain a targeted cassette in which exon 1 and 
exon 2 of HOIL-1 are flanked by loxP sites and HOIL-1 can hence be excised by crossing 
these animals to tissue-specific Cre-expressing mice (Figure 8). Alternatively, isolated cells 
can be infected with Cre-expressing lentivirus to generate Hoil-1-/- cells. 
 
2.5.3 Enbrel administration 
Ten day old, lesion free cpdm animals were injected twice weekly with 125 µg Enbrel 
(Etanercept; Pfizer) in 100 µl saline solution and monitored for skin lesion development. If 
lesions were too severe, mice were culled according to standard procedures. This experiment 
was conducted together with Eva Rieser. 
Figure 8: Schematic representation of the targeted allele used to generate conditional Hoil-1-/- mice.  
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3.  Results  
3.1 Functional analysis of SHARPIN in TNFR1 signalling 
3.1.1 SHARPIN is a novel constituent of the TNF-RSC and forms a stimulation-
independent complex with HOIL-1 and HOIP 
We recently reported on the mass-spectrometrical identification of HOIL-1 and HOIP as new 
components of the TNF-RSC (Haas et al, 2009). Apart from HOIL-1 and HOIP, SHARPIN 
was the only other previously unknown component for which peptides were detected by this 
approach. The data obtained by mass-spectrometry could be confirmed by a kinetic analysis 
using Western blotting, in which a stimulation-dependent recruitment of SHARPIN to the 
TNF-RSC peaking between 5-15 min following receptor engagement and declining after 
30 min was observed in different cell lines of human and murine origin (Figure 9). As 
previously described, RIP1, cIAP1/2, TRAF2 and TRADD were rapidly recruited being 
detectable in the TNF-RSC as early as 2 min following TNF administration and declined over 
Figure 9: SHARPIN forms part of the native TNF-RSC. a) Hela and b) MEF cells were stimulated with 
1 µg/mL TNF for the indicated times and the receptor complex precipitated. Post-lysis, 0.5 µg TNF was added to 
the unstimulated samples to pull down non-stimulated receptors. The isolated RSCs were immunoblotted with the 
indicated antibodies. A representative experiment of three independent experiments is shown. * marks unspecific 
bands. 
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time once complex II forms (Micheau & Tschopp, 2003). In contrast, A20 expression, which is 
low in unstimulated cells, had to be induced by NF-κB and MAPK signalling prior to its 
recruitment to the TNF-RSC (Opipari et al, 1990), hence peaking in the TNF-RSC 1-2 hrs 
following stimulation. 
Interestingly, SHARPIN was recruited to the TNF-RSC with similar kinetics as compared to 
the previously identified HOIL-1 and HOIP. Although SHARPIN does not possess a RING 
domain or any other catalytic activity, its structure closely resembles HOIL-1 given the 
presence of a C-terminal NZF motif and a UBL domain (Figure 10a). It was therefore next 
analysed whether the three proteins interacted with each other. As demonstrated in Figure 10b, 
SHARPIN formed a stimulation-independent complex with HOIL-1 and HOIP whose 
composition did not change following TNF stimulation. Consistently, immuno-precipitation of 
any of the three components resulted in co-precipitation of the other two in a variety of cell 
lines including monocytic U937 (Figure 10c) and Jurkat T cells (Figure 10d). Stimulation of 
U937 cells with TNF or Jurkat cells with the ionophore A23187 and PKC activator PMA did 
not change the interaction of SHARPIN with HOIL-1 and HOIP, indicating that the three 
proteins associate as a pre-formed tripartite complex in the cytoplasm. Consistently, 
overexpression experiments showed that SHARPIN interacted with both HOIL-1 and HOIP but 
Figure 10: SHARPIN forms a stimulation-independent tripartite complex with HOIL-1 and HOIP. a)
Schematic domain structure of SHARPIN, HOIL-1 and HOIP. b), c) U937 cells were stimulated with 1 µg/mL 
TNF for indicated times and the lysates were subjected to precipitation with the indicated antibodies. d) Jurkat 
cells were stimulated with 200 ng/mL A23187 and 10 ng/mL PMA for the indicated times and lysates were 
subjected to SHARPIN pull-down.  
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that its interaction with HOIL-1 was increased in the presence of HOIP, indicating that HOIP 
mediates binding of HOIL-1 to SHARPIN (Figure 11a).  This notion was further supported by 
the finding that an interaction of endogenous HOIL-1 with endogenous SHARPIN was barely 
visible in cell lysates which have been depleted for HOIP (Figure 11b), suggesting that HOIL-1 
and SHARPIN were unable to directly interact but are part of the same complex due to 
concomitant interaction with HOIP.  
NF-κB was only activated by a combination of HOIP with SHARPIN and/or HOIL-1, but not 
by overexpression of SHARPIN and HOIL-1 (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga 
et al, 2011), indicating that HOIP is the catalytic active component of the tripartite complex. 
Considering this result, the interaction between SHARPIN and HOIP was studied in this thesis 
by mapping the domains responsible for the interaction. Overexpression of a mutant form of 
SHARPIN lacking the UBL domain strongly attenuated its binding to HOIP, whereas a mutant 
lacking the NZF domain was still capable of interacting with HOIP. Thus, similar to HOIL-1, 
SHARPIN utilises its UBL domain to bind to HOIP (Figure 12a).  
  
Figure 11: HOIP facilitates the interaction between HOIL-1 and SHARPIN. a) HEK293T cells were 
transfected with the indicated plasmids and half of the lysates were subjected to V5 (HOIL-1) or myc (SHARPIN) 
immunoprecipitation, respectively.  b) HeLa cells were silenced for HOIP expression and lysates were 
subsequently further depleted by HOIP precipitation. Depleted lysates were subjected to HOIL-1 pull-down and 
immunoblots were analysed as indicated. ctr = control; HOIP refers to samples in which HOIP has been silenced 
by HOIP-specific siRNA. 
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Next, the domain within HOIP necessary for binding to SHARPIN was determined. Different 
HOIP mutants were co-expressed in the presence of wild-type SHARPIN, which was pulled 
down via its N-terminal myc-tag. As shown in Figure 12b, a HOIP mutant lacking the RING 
domains was sufficient to interact with SHARPIN. Albeit showing slightly decreased binding 
affinity, a HOIP mutant lacking the UBA domain was still capable of interacting with 
SHARPIN, indicating that this domain was also not required for the interaction of HOIP and 
SHARPIN, but might contribute to the strength of the asscociation of both proteins. In contrast, 
a HOIP mutant containing only the N-terminal part of HOIP comprising the ZF and NZF 
domains was sufficient to bind to SHARPIN, indicating that the interaction between SHARPIN 
and HOIP was primarily mediated via their UBL and zinc finger domains, respectively.  
HOIL-1 and HOIP are capable of binding to ubiquitin chains of different linkage specificity 
using their NZF domains (Haas et al, 2009; Tokunaga et al, 2009). To analyse whether 
SHARPIN was also able to bind to ubiquitin, different SHARPIN mutants were overexpressed 
 
Figure 13: SHARPIN binds to 
ubiquitin via its NZF domain.
HEK293T cells were transfected with 
the indicated SHARPIN mutants and the 
lysates incubated with ubiquitin-coupled 
agarose beads. Binding of SHARPIN to 
ubiquitin was assessed by Western blot 
analysis. 
 
Figure 12: SHARPIN and HOIP interact via their UBL and NZF domains, respectively. a) HEK293T cells 
were transfected with the indicated plasmids and lysates were subjected to V5-HOIP IP and the co-precipitation of 
SHARPIN mutants was analysed. b) Full length myc-tagged SHARPIN (wt) was co-expressed with the indicated 
HOIP mutants, cell lysates were subjected to myc-precipitation and co-precipitation of HOIP was analysed. 
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in HEK293T cells and the lysates incubated with ubiquitin-coated beads. As shown in Figure 
13, SHARPIN bound to ubiquitin via its NZF domain. Taken together, SHARPIN interacts via 
its UBL with HOIP and via its NZF domain with ubiquitin. 
HOIP alone was unable to produce linear ubiquitin chains in vitro. However, addition of either 
HOIL-1, SHARPIN or a combination thereof activated the ubiquitin ligase activity of HOIP 
(Gerlach et al, 2011). Therefore, the terminology linear ubiquitin chain assembly complex 
(LUBAC) should be expanded to the tripartite complex consisting of HOIP, HOIL-1 and 
SHARPIN.  
 
3.1.2 SHARPIN is recruited to the TNF-RSC in a cIAP1/2-dependent manner and 
stabilises the receptor signalling complex 
HOIL-1 and HOIP are recruited to the TNF-RSC in a TRADD/cIAP1/2/TRAF2-mediated 
manner, independently of NEMO and RIP1 (Haas et al, 2009). Given that SHARPIN forms a 
tripartite complex with HOIP and HOIL-1, it was not surprising that the recruitment of 
SHARPIN to the TNF-RSC was also diminished in cIAP1/2-depleted MEFs or HeLa cells in 
which cIAP1/2 were degraded by the addition of the IAP antagonist SM-83 (Figure 14). 
Figure 14: SHARPIN is recruited to the TNF-RSC via cIAPs. a) MEFs of the indicated genotype were 
stimulated with 1 µg/mL HF-TNF for 10 min or left untreated and the TNF-RSC precipitated. 0.5 µg was added 
post-lysis to unstimulated samples. b) HeLa cells were pre-treated with 100 nM SM-83 for 2 hrs before cells were 
stimulated with TNF. Immunoblots were analysed with the indicated antibodies. 
3. Results 
 
80 
 
Moreover, SHARPIN was not recruited to the TNF-RSC of cIAP1/2 double knockout MEFs 
reconstituted with a cIAP1 mutant unable to form RING homodimers (F610A) and hence 
lacking catalytic activity (Mace et al, 2008). In contrast, reconstitution of cIAP1/2 double 
knockout MEFs with an inducible cIAP1 wild-type construct restored SHARPIN recruitment to 
the TNF-RSC. Considering that cIAP1 re-expression did not reach wild-type expression levels 
and RIP1 was hence not fully ubiquitinated, SHARPIN and HOIL-1 recruitment to the TNF-
RSC were only partially restored as compared to wild-type cells (Figure 15). However, when 
compared to the inactive mutant of cIAP1, both proteins were clearly recruited. These results 
indicate that cIAP activity is required and sufficient for LUBAC recruitment to the TNF-RSC. 
This result is in line with a report by Mahoney et al. who showed that cIAP1 and cIAP2 
possess redundant functions in TNF signalling and that the presence of one cIAP protein was 
sufficient for proper TNFR1 signal transduction (Mahoney et al, 2008). Furthermore, these data 
show that the ubiquitin-forming activity of cIAPs rather than their mere presence was required 
to recruit LUBAC to the TNF-RSC.  
  
Figure 15: SHARPIN is recruited to cIAP-generated chains. cIAP1/2 double knockout MEFs were 
reconstituted with wild-type (wt) cIAP1 or the dimerisation mutant F610A lacking enzymatic activity using 
4-hydroxy-tamoxifen for 16 hrs. Cells were stimulated with TNF and analysed as previously described. 
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Conversely, overexpression of SHARPIN together with HOIP stabilised the TNF-RSC as 
indicated by enhanced cIAP1/2, RIP1, TRAF2 and IKKα recruitment to, and prolonged 
retention in the TNF-RSC (Figure 16), which was not due to increased expression of the 
respective proteins (data not shown and Haas et al, 2009). Knockout experiments in which 
single components of the TNF-RSC were individually depleted showed the significance of each 
protein for NF-κB and MAPK activation and revealed that the formation of a stable TNF-RSC 
is a pre-requisite for efficient NF-κB and MAPK activation (reviewed in Silke & Brink, 2010). 
Therefore, stabilisation of the TNF-RSC by prolonged and enforced recruitment of TNFR1 
signalling adaptors by LUBAC allows for efficient TNF-induced target gene transcription and, 
consequently proliferation and cell survival.  
  
Figure 16: SHARPIN contributes to stabilisation of the TNF-RSC. The TNF-RSC was precipitated from TNF-
stimulated HeLa cells stably overexpressing SHARPIN and HOIP or HOIL-1 and HOIP. Protein complexes were 
subjected to Western blot analysis and were immunoblotted with the indicated antibodies. Overexpression of 
SHARPIN, HOIL-1 and HOIP was verified in the Input (right panel). 
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3.1.3 SHARPIN stabilises the tripartite LUBAC complex 
To analyse the function of SHARPIN in TNF-induced signalling, MEFs from chronic 
proliferative dermatitis (cpdm) mice were generated. These mice harbour a spontaneous a 
single base pair deletion in the SHARPIN gene, which leads to the abrogation of SHARPIN 
expression (see chapter 1.6.2). The macroscopically most obvious alterations observed in cpdm 
mice include an approximately three to four-fold increase in the spleen weight and the 
generation of prominent skin lesions starting at four to six weeks following birth (Figure 17). 
Surprisingly, apart from completely lacking SHARPIN expression, cpdm-derived MEFs also 
exhibited reduced protein levels of HOIL-1 and HOIP (Figure 18a). HOIL-1 is usually 
expressed in two variants as assessed by the appearance of a double band on Western Blot 
analyses, indicating a modification of HOIL-1. However, the upper band was completely 
absent in cpdm-derived cells, similar to cells with siRNA-mediated silenced HOIP expression 
(Haas et al, 2009). The mRNA levels of both proteins were even slightly enhanced in cpdm-
derived MEFs, suggesting that SHARPIN-mediated down-regulation of HOIL-1 and HOIP was 
not regulated on the transcriptional level (Figure 18b). Thus, SHARPIN is required for 
stabilisation of HOIL-1 and HOIP on the protein level, underscoring the existence of a tripartite 
complex. However, in the absence of SHARPIN a dimeric complex of HOIL-1 and HOIP still 
existed as assessed by HOIL-1 pull-down experiments (Figure 18c, d). These data indicate the 
possibility of forming dimeric complexes in the absence of the third component, but also show 
that for optimal LUBAC expression all three proteins are required. Furthermore, depletion of 
one component, e.g. SHARPIN, does not promote formation of dimeric complexes but rather 
leads to degradation of a major portion of HOIL-1 and HOIP proteins. 
  
Figure 17: SHARPIN-deficient cpdm mice. a) SHARPIN deletion results in the development of a severe skin 
pathology accompanied by retarded growth. Representative photograph of 7-week old wild-type (wt) and cpdm
mice is shown. b) Representative image of the spleens of these mice and the respective spleen weight (n=4). 
3. Results 
 
83 
 
To analyse whether the function to stabilise the tripartite LUBAC was restricted to SHARPIN, 
fibroblasts from embryos in which exon 1 and exon 2 of the HOIL-1 gene were flanked by loxP 
sites were generated and analysed. Subsequently to infection with a Cre-expressing virus, 
HOIL-1 was efficiently excised by recombination in the antibiotic-selected cells (Figure 19a). 
These cells will be referred to as Hoil-1-/- MEFs in the following chapters. As shown in Figure 
19b, similar to cpdm-derived cells, Hoil-1-/- fibroblasts also presented significantly lower levels 
of HOIP and SHARPIN as compared to wild-type MEFs, indicating that all three proteins were 
required to stabilise the tripartite LUBAC and that deletion of one component resulted in 
significant, albeit incomplete, loss of the other two proteins. Treatment with the proteasome 
inhibitor MG132 only marginally increased the levels of the remaining two components in both 
SHARPIN- and HOIL-1-deficient cells, indicating that other mechanisms than proteasomal 
degradation account for the down-modulation (data not shown). This observation is in line with 
the data obtained by the group of K.Iwai (personal communication). 
Figure 18: Loss of SHARPIN destabilises HOIL-1 and HOIP on the protein level, but still allows for their 
interaction. Protein and mRNA levels from three independently generated wt and cpdm MEF lines were subjected 
to a) Western blot analysis or  b) quantitative PCR (n=3). Data are presented as mean ± SEM. c) SHARPIN-
deficient cpdm MEFs were subjected to immunoprecipitation with control (ctr) or HOIL-1-specific antibodies and 
immunoblotted as indicated. d) MEFs were left unstimulated or treated with 1 µg/mL TNF for 5 min. Equal 
amounts of precipitated HOIL-1 complexes were compared by immunoblot. pIκB was used as control to check for 
cell activation. 
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3.1.4 HOIP allows for the recruitment of LUBAC to the TNF-RSC 
Given that SHARPIN forms a stimulation-independent complex with HOIL-1 and HOIP, the 
question arises as to which degree the individual three components contribute to the 
recruitment of the tripartite complex to the TNF-RSC. To address this question, the TNF-RSC 
was initially precipitated from cpdm-derived MEFs and analysed for the recruitment of the 
other two LUBAC components. As shown in Figure 20, despite presenting significantly 
decreased protein levels of HOIL-1 and HOIP, both proteins were still recruited to the TNF-
Figure 19: Loss of HOIL-1 destabilises HOIP and 
SHARPIN protein levels. a) HOIL-1 deficient cells 
were generated by infection of MEFs obtained from 
conditional floxed HOIL-1 embryos (see 2.5.2) by 
infection with a Cre-expressing virus. b) The 
expression of SHARPIN, HOIP and HOIL-1 was 
analysed by Western blot in MEFs of the indicated 
genotypes. 
Figure 20: HOIP and HOIL-1 are recruited to the TNF-RSC in the absence of SHARPIN. Wt and cpdm-
derived MEFs were stimulated with 1 µg/mL for the indicated times and the TNF-RSC analysed by Western blot. 
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RSC following TNF treatment, indicating that the tripartite LUBAC complex is not recruited to 
the TNF-RSC via SHARPIN. Interestingly, although the overall composition of the TNF-RSC, 
as assessed by levels of TNF-RSC-recruited cIAP1/2 and RIP1, was not severely disturbed at 
early time points following stimulation, significantly less ABIN-1, which is known to 
specifically bind to linear ubiquitin chains (Rahighi et al, 2009), was recruited to the TNF-RSC 
in cpdm-derived MEFs. This result suggests that linear ubiquitination at the TNF-RSC is 
strongly diminished in the absence of SHARPIN. 
Next, HeLa cells were used in which the expression of HOIL-1 was stably silenced by lentiviral 
delivery of HOIL-1-specific shRNA (Haas et al, 2009). Despite the high knockdown efficiency, 
down-regulation of HOIL-1 only marginally diminished the recruitment of HOIP and 
SHARPIN to the TNF-RSC (Figure 21). Interestingly, in contrast to only minor alterations in 
the recruitment of cIAP1/2 and RIP1, the levels of ABIN-1 at the TNF-RSC were strongly 
diminished in the absence of HOIL-1, indicating that ABIN-1 requires HOIL-1- (Figure 21), as 
well as SHARPIN-imparted linear ubiquitination (Figure 20) for its recruitment.  
 
  
Figure 21: HOIL-1 is dispensable for the 
recruitment of HOIP and SHARPIN to the TNF-
RSC. The TNF-RSC was precipitated from HeLa 
cells in which the expression of HOIL-1 was stably 
silenced by shRNA. The composition of the TNF-
RSC was analysed by Western Blotting using the 
indicated antibodies. 
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Lastly, the expression of HOIP was transiently silenced in wild-type MEFs and the composition 
of the TNF-RSC analysed. As compared to a lack of HOIL-1 or SHARPIN, a decrease in HOIP 
expression severely diminished the recruitment of HOIL-1 and SHARPIN to the TNF-RSC 
(Figure 22). However, their recruitment was not completely absent, most likely due to an 
incomplete knockdown of HOIP and consequently the presence of residual amounts of HOIP at 
the TNF-RSC following stimulation. Taken together, these data support a major function for 
HOIP not only for the linear chain forming activity of LUBAC, but furthermore for the 
recruitment of the tripartite LUBAC to the TNF-RSC.   
 
 
  
Figure 22: HOIP is required for the recruitment of LUBAC to the TNF-RSC. HOIP expression was silenced 
in wild-type MEFs for 72 hrs and the TNF-RSC analysed as previously described. 
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3.1.5 SHARPIN is required for proper TNF-induced NF-κB and MAPK activation 
Having identified the mechanism of recruitment, the functional consequences of SHARPIN 
deficiency were next analysed in the context of TNF-induced signalling. As shown in Figure 
23a, cpdm-derived fibroblasts stimulated with 50 ng/mL TNF showed impaired 
phosphorylation and hence degradation of IκBα, the characteristic hallmarks of NF-κB 
activation. Furthermore, TNF-induced JNK activation was also severely attenuated as assessed 
by reduced levels of phosphorylated JNK1 and JNK2. This experiment was done in three 
independently generated MEF cell lines and all of them resulted in the same outcome, 
underscoring the reproducibility of these results. Additionally, to rule out any disturbances 
resulting from immortalisation of the cells by large T antigen infection, primary keratinocytes 
from the tails of ten-day old cpdm mice that have not yet developed any obvious skin lesions 
were generated. These primary murine keratinocytes also exhibited reduced levels of TNF-
induced IκBα phosphorylation and degradation as well as reduced levels of JNK1/2 
phosphorylation when compared to wild-type control keratinocytes (Figure 23b), confirming 
the results obtained in transformed MEF cell lines. Interestingly, levels of HOIL-1 and HOIP 
were also diminished in cpdm-derived keratinocytes, supporting a cell-type independent 
function of SHARPIN in stabilisation of LUBAC.    
  
Figure 23: SHARPIN is required for full NF-κB and JNK1/2 activation. a) Large T antigen transformed wild-
type (wt) and cpdm-derived MEFs or (b) primary keratinocytes from 10-day old lesion free mice were stimulated 
with 50 ng/mL TNF and the lysates subjected to immnuoblotting with the indicated antibodies. 
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Besides NF-κB and JNK, p38 activation was also reduced in cpdm-derived fibroblasts as 
assessed by diminished phosphorylation of p38 (Figure 24a). To confirm this result, a kinase 
assay was performed in which TNF-stimulated lysates were subjected to immunoprecipitation 
using an anti-pp38 antibody and subsequently incubated with the p38 target protein ATF2. As 
shown in Figure 24b, phosphorylation of ATF2 was severely attenuated in cpdm-derived cells, 
indicating that SHARPIN is required for efficient activation of the p38 MAPK pathway. In 
contrast, no obvious defect in TNF-induced ERK1/2 activation has been observed (Figure 23a 
and 24b). On the contrary, levels of phosphorylated ERK1/2 were even slightly enhanced in 
unstimulated SHARPIN-deficient MEFs and did not significantly alter between wild-type and 
cpdm-derived cells following TNF stimulation. 
  
Figure 24: TNF-induced p38 activation is diminished in the absence of SHARPIN. a) MEFs of indicated 
genotypes were stimulated with 100 ng/mL TNF and were lysates analysed by Western Blot. b) Alternatively, 
cells were stimulated with 50 ng/mL TNF and equal protein levels subjected to pp38 immunoprecipitation 
followed by a kinase assay. p38 activity was assessed by phosphorylation of its substrate ATF2. Actin served as 
loading control.  
 
Figure 25: HOIL-1 
knockdown in cpdm-derived 
MEFs further diminishes, but 
does not completely abrogate
NF-κB activation. HOIL-1 
expression was transiently 
silenced in cpdm-derived MEFs 
for 72 hrs and cells subsequently 
stimulated with 50 ng/mL TNF. 
Non-targeting siRNA was used 
as control. Lysates were 
immunoblotted with the 
respective antibodies. 
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Although a strong defect in NF-κB activation was observed in cpdm-derived MEFs, NF-κB 
signalling was not completely absent. HOIL-1 and HOIP were still recruited to the TNF-RSC 
in cpdm-derived MEFs (Figure 20) and were possibly active at the TNF-RSC. To test the 
influence of residual HOIL-1 levels on NF-κB activation, its expression in cpdm-derived 
fibroblasts was down-regulated by siRNA and the effects on TNF-induced signalling 
monitored. As shown in Figure 25, siRNA-mediated silencing of HOIL-1 further decreased 
phosphorylation and degradation of IκBα, however it did not completely prevent it despite the 
depletion of HOIL-1 being very efficient. These data indicate that LUBAC is required to enable 
full activation of NF-κB, but that it is not essential. Hence, LUBAC-indepenent mechanisms of 
NF-κB activation are likely to exist. 
Figure 26: Absence of SHARPIN diminishes and delays TNF-induced p65 nuclear translocation. a) Cells 
were stimulated with 50 ng/mL TNF for the indicated times, fixed, stained and analysed by confocal microscopy. 
Green: p65, blue: nuclei (DAPI), turquoise: overlay. b) Quantification of nuclear p65. 30 nuclei from three 
independent experiments were analysed with the Leica Application Suite for p65 stained nuclear area. Data are 
presented as mean ± SEM; n=3. 
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Phosphorylation of IκBα induces its proteasomal degradation and hence liberation of p50/p65 
heterodimers allowing them to translocate to the nucleus and drive transcription of TNF target 
genes. To analyse whether defects in cpdm-derived cells present at the level of IκBα 
phosphorylation/degradation translated into diminished NF-κB translocation, cells were stained 
for p65 location. Indeed, less p65 was detected in the nucleus of TNF-stimulated cpdm-derived 
fibroblasts as compared to their wild-type controls (Figure 26). Furthermore, translocation of 
p65 from the cytoplasm of cpdm MEFs to the nuclei was only detected 30 min following 
stimulation, whereas strong p65 staining was already apparent in the nuclei of wild-type control 
MEFs after 15 min, indicating that NF-κB activation is diminished and delayed, albeit not 
completely obliterated in the absence of SHARPIN.  
Next, the influence of SHARPIN deficiency on the transcription of TNF target genes was 
analysed. Therefore, cpdm-derived and their wild-type control MEFs were stimulated for 
various times with TNF. Subsequently, RNA was extracted, equal amounts of RNA were 
transcribed into cDNA and the expression levels of the target genes ICAM-1, A20, TNF and 
IκBα  were quantified by real-time PCR (RT-PCR). GAPDH served as internal control and was 
used for normalisation. Whereas mRNA levels for TNF, ICAM-1 and A20 were basically not 
induced following TNFR1 stimulation in cpdm-derived MEFs, IκBα was transcribed, albeit to 
a lesser degree (Figure 27). This result is consistent with a recent report by Tay et al. who 
showed that the threshold for the expression of some TNF target genes including IκBα is 
relatively low, whereas others require strong NF-κB activation or concerted actions of NF-κB 
and MAPKs to be transcribed (Tay et al, 2010). Hence, reduced levels of NF-κB activation 
observed in cpdm-derived MEFs were sufficient to allow for the expression of IκBα. However, 
Figure 27: TNF-induced 
gene transcription is 
impaired in cpdm-derived 
MEFs. MEFs were stimulated 
with 50 ng/mL TNF for the 
indicated times and mRNA 
expression of the indicated 
TNF target genes was 
determined by quantitative 
PCR (wt  ■ and cpdm  □). 
GAPDH served as internal 
control and was used for 
normalisation.  
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A20, ICAM-1 and TNF, which also rely on MAPK-activated transcription factors, were not 
induced due to concomitant defects in stimulating the JNK and p38 MAPK pathways in 
SHARPIN-deficient cells (Figure 23 and 24). 
In line with this result, HeLa cells, in which the expression of SHARPIN, HOIL-1 and HOIP 
was transiently silenced by RNA interference (RNAi) showed strong defects in TNF-induced 
MAPK activation, whereas phosphorylation and degradation of IκBα were hardly affected 
(Figure 28a). This effect is likely to be due to residual levels of the respective protein that has 
been silenced given the strong effect on TNF-induced IκBα degradation observed in 
SHARPIN-deficient cpdm and Hoil-1-/- MEFs. Alternatively, HeLa cells might differentially 
depend on LUBAC-mediated TNF-induced signalling output as compared with fibroblasts, 
suggesting that the influence of linear ubiquitination is cell-type specific. Hence, these date 
support a major function of LUBAC in MAPK signalling in cells of different origin and 
underline the notion that LUBAC-independent mechanisms of NF-κB activation exist.   
As previously described, HOIL-1 deficiency also led to decreased TNF-induced NF-κB 
responses (Tokunaga et al, 2009). Furthermore, JNK and p38 activation were also decreased in 
Hoil-1-/--derived fibroblasts (Figure 28b). However, and in contrast to cpdm-derived cells, basal 
levels of ERK1/2 were not increased in the absence of HOIL-1 and TNF-induced ERK1/2 
activation was attenuated as compared to wild-type cells. This is the first indication of different 
signalling outputs induced by HOIL-1 as compared to SHARPIN deficiency.  
Figure 28: HOIL-1 is required for full NF-κB and MAPK activation a) HOIL-1, SHARPIN and HOIP 
expression were transiently suppressed in HeLa cells by RNAi for 72 hrs. Cells were stimulated with 50 ng/mL 
TNF and signalling responses analysed with the indicated antibodies. b) Hoil-1-/- MEFs were treated accordingly. 
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3.1.6 Loss of SHARPIN sensitises to TNF-induced cell death 
Although TNF primarily activates proliferation and cell survival, it can also induce cell death 
under certain conditions. Since the first TNF response, i.e. gene activation, is diminished in the 
absence of SHARPIN or HOIL-1, it was next analysed whether cell death responses were 
altered in LUBAC-component-deficient cells. Initially, the TNF-sensitive breast cancer cell line 
MCF-7 was used, in which the three LUBAC components were transiently silenced by siRNA. 
Although a function for HOIL-1 and HOIP in the regulation of cellular responses has been 
demonstrated, the influence of SHARPIN in the context of cell death execution remained 
undefined (Haas et al, 2009; Tokunaga et al, 2009). As shown in Figure 29, knockdown of 
HOIL-1, and in particular HOIP and SHARPIN, significantly reduced cell viability, indicating 
that all three LUBAC components are required to control the TNF-induced signalling output.  
Considering that residual amounts of the respective protein to be targeted by siRNA might 
influence the system, cell death responses in a genetic clean system of knockout fibroblast cell 
lines were assessed. Absence of SHARPIN significantly reduced cell viability upon treatment 
with TNF. Whilst wild-type fibroblasts were completely resistant to TNF-mediated cell death, 
cell viability of cpdm-derived cells was severely diminished even in the presence of low 
concentrations of TNF (Figure 30a). Although addition of cycloheximide (CHX) increased the 
extent of TNF-mediated cell death in cpdm-derived MEFs quite substantially (data not shown), 
CHX and hence the inhibition of protein translation was not required for cell death execution 
by TNF when SHARPIN was absent.  
Figure 29: LUBAC deficiency sensitises to TNF-induced cell death. a) The expression of HOIP, SHARPIN and 
HOIL-1 was transiently silenced in MCF-7 cells for 72 hrs. b) These cells were then stimulated with increasing 
concentrations of TNF and cell viability was assessed by Cell Titer Glo analyses. n=2 ± STDEV. 
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Subsequently, the type of death by which cpdm-derived cells were killed by TNF was analysed. 
It was determined whether it could be blocked by the pan-caspase inhibitor Q-Val-Asp(non-O-
methylated)-OPh (QVD) or by the RIP1 kinase inhibitor necrostatin-1. Due to its ability to 
irreversibly bind to the catalytic centre of caspases, QVD blocks their activity, thereby 
preventing apoptosis. Necrostatin-1 on the other hand interacts with RIP1 to inhibit its kinase 
function, thereby preventing necrosome formation and activation, which is a pre-requisite for 
necroptosis (reviewed in Vandenabeele et al, 2011). To rule out any clonogenic artefacts, five 
independent transformed as well as primary MEF cell lines were generated from cpdm embryos 
and their cell death responses analysed. TNF-induced cell death in cpdm-derived fibroblasts 
was partially inhibited by QVD or necrostatin-1 alone and best by a combination thereof, 
indicating that the cell death observed in cpdm-derived cells is partially apoptotic and partially 
necroptotic (Figure 30b,c). Moreover, long-term survival in TNF-treated cpdm-derived cells 
was severely decreased as assessed by the analysis of clonogenic survival (Figure 30d). 
 
Figure 30: SHARPIN-deficient cells are sensitive to TNF-induced cell death, which is partially necroptotic 
and partially apoptotic in nature. a) Wt and cpdm-derived MEFs were stimulated with increasing concentrations 
of TNF and cell viability was measured by Cell Titer Glow. Large T antigen transformed (b) or primary (c) MEFs 
were stimulated with 100 ng/mL TNF in the presence of 10 µM QVD (Q), 30 µM necrostatin-1 (N) or a 
combination thereof and cell death assessed by PI incorporation. n=5 ± SEM. d) 2x104 transformed MEFs were 
seeded per six-well, stimulated with TNF and clonogenic survival assessed 6 days later. 
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SHARPIN deficiency in cpdm mice results in the generation of severe skin lesions 
characterised by immune cell infiltration and hence inflammation (Gijbels et al 1996; 
HogenEsch et al, 2001). Increased keratinocyte apoptosis in the skin of these mice has been 
described (Liang & Sundberg, 2011). To analyse whether the increase in keratinocyte cell death 
might be TNF-dependent, TNF-mediated cell death responses in primary keratinocytes 
obtained from ten-day old, lesion-free cpdm mice as compared to wild-type control animals 
were analysed. Indeed, cell viability was decreased in keratinocytes from SHARPIN-deficient 
cpdm mice (Figure 31a). To assess the kind of death keratinocytes underwent when treated with 
TNF, keratinocytes were pre-incubated with QVD or necrostatin-1 before TNF was added. 
Similar to the results obtained in MEFs, TNF-induced loss of viability in cpdm-derived 
keratinocytes was partially rescued by QVD and also by necrostatin-1 (Figure 31b), indicating 
that TNF-induced cell death in keratinocytes was also partially apoptotic and partially 
necroptotic in nature.  
The appearance of skin lesions and inflammatory milieus throughout the body observed in 
cpdm mice were completely prevented by concomitant deletion of the Tnf gene (Gerlach et al, 
2011). Although heterozygous Tnf deficiency significantly delayed the onset of disease 
progression, cpdm;Tnf+/- mice developed dermatitis starting at about 30 weeks of age (data not 
shown). Interestingly, injection of Enbrel, a TNFR2-Fc fusion protein known to block the 
binding of endogenous TNF to TNF-Receptors, did not prevent or even delay the generation of 
skin lesions (data not shown), even though the treatment was started fifteen days after birth, i.e. 
at a time when no obvious skin lesions have developed. In these mice, dermatitis occurred with 
similar kinetics as compared to untreated cpdm mice. Thus, the cpdm inflammatory phenotype 
Figure 31: Primary cpdm-derived keratinocytes are sensitive towards TNF-induced cell death. a) Primary 
keratinocytes from ten-day old lesion free mice were treated with increasing concentrations of TNF or (b) with 
100 ng/mL TNF in the presence of 10 µM QVD (Q) or 30 µM necrostatin-1 (N) and cell viability assessed the 
following day. n=3 ± SEM. 
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is a TNF-driven disease which results from accumulating defects due to a deregulated TNF 
signalling output, most likely as a consequence of signals generated by necrotic cells in the skin 
and possibly other inflamed organs which were killed by TNF. 
In line with a report by Tokunaga et al., absence of HOIL-1 sensitised fibroblasts to TNF-
induced cell death (Tokunaga et al, 2009) and the level of TNF-induced cell death was 
comparable to the quantity of cell death obtained in the absence of SHARPIN (Figure 32a). 
This result is in contrast to the study presented by Ikeda et al. who demonstrated that Hoil-1-/- 
MEFs were not as sensitive towards TNF-induced cell death as cpdm-derived fibroblasts (Ikeda 
et al, 2011).  However, their study was based on fibroblasts obtained from full Hoil-1-/- mice 
whereas the results presented in this thesis were obtained by employing fibroblasts generated 
from conditional, floxed embryos, in which the Hoil-1 gene was excised ex vivo by Cre-
expressing viruses. However, the quality of cell death significantly altered in cpdm- as 
compared to Hoil-1-/- cells given that loss of HOIL-1-induced cell death was not inhibitable by 
necrostatin-1 alone, but rather relied on the activity of caspases. However, cell death obtained 
in Hoil-1-/--derived fibroblasts could not be completely inhibited by caspase-inhibition, 
indicating that another form of cell death apart from necroptosis and apoptosis might contribute 
to TNF-induced sensitisation in the absence of HOIL-1 (Figure 32b). Hence, despite the 
involvement of both proteins in the regulation of cell death responses, the nature of the ensuing 
cell death was completely different in the absence of SHARPIN as compared to HOIL-1. This 
result indicates that SHARPIN and HOIL-1 possess independent, non-redundant functions. 
Figure 32: TNF-induced cell death in Hoil-1-/- as compared to cpdm-derived fibroblasts is similar in 
quantity, but severely different in quality. a) Hoil-1-/- and cpdm-derived MEFs were stimulated with increasing 
concentrations of TNF and cell death analysed by PI incorporation. n=4 ± SEM. b) Cells of indicated genotype 
were pre-treated with 10 µM QVD (Q), 30 µM necrostatin-1 (N) or both in the presence or absence of 100 ng/mL 
TNF. n=4 ± SEM. An unpaired t-test using the GraphPad software was performed. * indicates p<0.05, ** indicates 
p<0.005. 
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In line with this finding, TNF-induced generation of apoptotic hallmarks, including cleavage of 
caspases and their down-stream substrates PARP-1 and Bid, significantly differed between 
cpdm- and Hoil-1-/--derived fibroblasts. As shown in Figure 33, TNF-treatment alone in the 
absence of CHX rapidly and strongly induced cleavage of caspase-8, caspase-3 and caspase-9 
to their active forms p17, p18 and p37/39, respectively and resulted in processing of Bid and 
PARP-1 in Hoil-1-/--derived cells. In contrast, these apoptotic features were only marginally 
visible in cpdm-derived cells treated with TNF alone. However, addition of CHX significantly 
enhanced the formation of typical apoptotic hallmarks in cpdm-derived cells, but not in Hoil-1-/- 
cells. This result further underscores that cells undergo a differential kind of death in the 
absence of SHARPIN or HOIL-1, respectively and support the notion that the activity of HOIP 
is alternatively driven by SHARPIN- and HOIL-1-containing LUBAC complexes.  
Taken together, these results show that loss of SHARPIN, and also HOIL-1, result in a cell 
death-favouring deregulation of TNF-induced signalling and suggest that the inflammatory 
phenotype observed in cpdm mice is due to increased susceptibility to endogenous TNF-
induced cell death which is necroptotic in nature. In contrast, though absence of HOIL-1 
sensitised cells to TNF-induced death to a similar degree as SHARPIN deficiency, the nature of 
Figure 33: Apoptotic responses significantly alter in Hoil-1-/- MEFs as compared to cpdm-derived cells.
Fibroblasts of the indicated genotypes were incubated with 100 ng/mL TNF in the absence (left panel) of presence 
(right panel) of 0.5 µg/mL cycloheximide (CHX) for the indicated times and analysed as indicated. 
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this cell death was however characterised by rapid caspase cleavage involved in apoptotic, non-
immunogenic responses, thereby providing a possible explanation as to why the phenotype of 
Hoil-1-/- mice does not resemble the one observed in cpdm mice. Hence, these results strongly 
suggest that HOIL-1 is implicated in the inhibition of apoptosis, whereas the SHARPIN-driven 
linear ubiquitination activity of HOIP instead prevented necroptotic cell death induction by 
TNF. 
 
3.1.7 Loss of SHARPIN promotes complex II formation 
TNF-induced NF-κB and MAPK activation were strongly diminished in cpdm cells, which 
rather succumbed to cell death following TNFR1 engagement. In contrast to the TRAIL and 
CD95L systems, TNF does not induce cell death at the receptor proximal level. Instead, the 
receptor signalling complex disintegrates and forms an intracellular secondary complex, 
referred to as complex II (Micheau & Tschopp, 2003). Complex II is a consequence of the 
membrane-associated complex I and forms with a delayed kinetic with respect to complex I 
formation and NF-κB and MAPK activation, which are already apparent a few minutes after 
TNF stimulation. Since these pathways generally induce the transcription of anti-apoptotic 
genes including c-FLIP and Bcl-2 family members, they are able to inhibit caspase-8 activation 
Figure 34: Loss of SHARPIN induced strong complex II formation. a) TNFR1 expression is not changed in 
the absence of SHARPIN. Shaded: isotype, black: wt, dotted: cpdm. b) SHARPIN expression was silenced in 
HeLa cells for 96 hrs. Cells were stimulated with 500 ng/mL TNF in the presence of 0.5 µg/mL CHX for the 
indicated times and complex II was precipitated with anti-caspase-8 (C20; Santa Cruz) antibodies. 
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and hence cell death induction. However, under certain conditions when proteins involved in 
pro-survival signalling are mutated, inhibited or absent, complex II formation is increased, 
thereby subjecting cells to death. 
To investigate the mechanism resulting in cell death execution in cpdm-derived cells I initially 
monitored the expression level of TNFR1 on the surface of SHARPIN-deficient MEFs by flow 
cytometry. As shown in Figure 34a, surface expression of TNFR1 was not affected by loss of 
SHARPIN, indicating that levels of TNFR1 are unlikely to be causative for deregulated TNF 
signalling outputs present in cpdm-derived as compared to wild-type MEFs. 
Next, the formation of complex II was analysed in HeLa cells in which SHARPIN had been 
transiently silenced by specific siRNA oligonucleotides. Cells were stimulated for two and four 
hours respectively to allow complex II formation to occur and the complex was then 
precipitated via caspase-8. Caspase-8 does not form part of the membrane-proximal TNF-RSC, 
therefore allowing specific pull-down of the secondary complex. Depletion of SHARPIN 
resulted in significantly increased formation of complex II as assessed by increased interaction 
of caspase-8 with RIP1 and TRADD (Figure 34b). Furthermore, cleavage of RIP1 to a 42 kDa 
fragment was enhanced when SHARPIN expression was suppressed by siRNA. TNF-induced 
RIP1 cleavage at residue D324 is a caspase-8-dependent event that correlates with apoptosis 
execution (Lin et al, 1999). Thus, increased RIP1 cleavage in SHARPIN-depleted cells might 
Figure 35: Absence of any LUBAC component sensitises to TNF-induced cell death which is mediated by 
increased complex II formation. a) The indicated genes were down-regulated in HeLa cells by siRNA for 96 hrs 
and complex II analysed as previously described. b) Knock-down control. c) Hela cells were treated with TNF in 
the presence of 0.5 µg/mL CHX for 24 hrs and cell viability measured by Cell Titer Glo. n=3 ± SEM. 
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contribute to increased sensitivity towards TNF-induced cell death as compared to control cells. 
Accordingly, pronounced accumulation of the active p18 fragment of caspase-8 in SHARPIN-
depleted cells supports the notion that absence of SHARPIN facilitates formation of complex 
II, resulting in increased caspase-8 activity, thereby promoting enhanced RIP1 cleavage and 
apoptosis.  
Consistently with an increased susceptibility to TNF-induced cell death in HOIL-1- and HOIP- 
depleted cells (Figure 35c and Haas et al, 2009), stronger complex II formation was also 
detected in cell lines in which the expression of these two  proteins had been silenced (Figure 
35a, b). Again, increased interaction of caspase-8 with TRADD, RIP1 and also FADD was 
observed when one of the LUBAC components was transiently silenced by RNAi. 
Furthermore, caspase-8 activity was increased in these cells as assessed by accumulation of the 
cleaved N-terminal fragment of RIP1 and increased levels of the processed p43 c-FLIP 
fragment.  
Several components of the membrane-proximal TNFR1 complex I are known to also form part 
of complex II, including RIP1, TRADD and possibly TRAF2. Being recruited to the TNF-RSC 
in a stimulation-dependent manner, it was subsequently analysed whether LUBAC was a novel 
as yet unidentified component of this secondary complex. A shown in Figure 36, all three 
components were also identified in complex II following TNF stimulation in the presence of 
CHX in HeLa cells. Considering that cells were susceptible to TNF-induced cell death in the 
absence of SHARPIN, HOIL-1 or HOIP, this result suggests that LUBAC linearly ubiquitinates 
a yet to be identified target, possibly NEMO or RIP1 to inhibit complex II-induced cell death.  
 
Figure 36: LUBAC is part of the 
secondary complex II.  HeLa cells were 
stimulated with 500 ng/mL TNF in the 
presence of 0.5 µg/mL CHX for the 
indicated times and complex II was 
precipitated by anti-caspase-8 pull-down 
overnight. The immunoblot was analysed 
with the respective antibodies. 
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Levels of c-FLIP are one of the major determinants that decide between TNF-induced life and 
death of a cell and c-Flip-/- fibroblasts were shown to be TNF-sensitive, underscoring the 
significance of c-FLIP for cellular responses (Yeh et al, 2000). Surprisingly, c-FLIPL levels 
were significantly down-regulated in three independently generated, unstimulated cpdm-
derived fibroblast lines, indicating that the down-regulation was not due to clonal artefacts 
(Figure 37a). However, similar to HOIL-1 and HOIP, c-FLIPL down-regulation was not 
mediated on the transcriptional level since c-FLIP mRNA levels were even modestly enhanced 
in unstimulated cpdm-derived fibroblasts (Figure 37b). Although the mechanism resulting in 
the down-regulation of c-FLIP remains to be determined, decreased c-FLIP levels are likely to 
be involved in the sensitisation to TNF-induced cell death. In contrast, c-FLIP levels were not 
reduced but rather marginally increased in Hoil-1-/- cells (Figure 37c), demonstrating a further 
difference between SHARPIN and HOIL-1 deficiency, which might explain differential kinds 
of TNF-induced cell death. 
Taken together, these results show that SHARPIN and HOIL-1 regulate TNF-induced 
signalling outputs. Loss of one of these LUBAC components shifts the balance from TNF-
induced pro-survival signalling in favour of cell death execution. However, the quality of cell 
death obtained significantly alters in the absence of HOIL-1 as compared to SHARPIN 
deficiency. 
 
Figure 37: FLIP expression is decreased in cpdm but increased in Hoil-1-/- MEFs. a) Three different wild-tpye 
(wt) and cpdm-derived MEFs were analysed by immunoblot with the respective antibodies. b) Quantitative 
analysis of  HOIL-1, HOIP and c-FLIP mRNA expression in three different MEF lines. n=3 ± SEM. c)
Immunoblot of lysates from the indicated genotypes. 
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3.2 SHARPIN regulates TRAIL- and CD95L-induced signalling 
3.2.1 TRAIL- and CD95L-induced cell death responses 
3.2.1.1 Loss of SHARPIN sensitises cells to TRAIL-induced death 
TNFR1 belongs to the TNFR superfamily and, due to its death domain (DD), shares high 
homology to TRAIL-R1/2 and CD95. Although caspase-8, caspase-10, c-FLIP and FADD, 
which are not present in the TNF-RSC, were described as the central components of the 
TRAIL-R1/2 and CD95 DISCs, recent studies reported on the recruitment of RIP1, TRAF2 and 
cIAP1/2 to the TRAIL-R1/2 and CD95 DISCs (Geserick et al, 2009; Lin et al, 2000). Thus, the 
composition of the three receptor signalling complexes shares some degree of homology.  
Considering these similarities, it was next analysed whether LUBAC also affected TRAIL- and 
CD95L-induced signaling. As shown in Figure 38a, absence of SHARPIN sensitised cpdm-
derived MEFs to TRAIL-induced cell death. Whereas wild-type fibroblasts known to be 
completely TRAIL-resistant did not succumb to TRAIL-induced cell death, cpdm-derived 
Figure 38: Loss of SHARPIN sensitises to TRAIL-induced apoptosis. a) Wild-type (wt) and cpdm-derived 
MEFs were stimulated with increasing TRAIL concentrations and cell death analysed by PI incorporation. n=3 ± 
SEM. b) Cells were pre-incubated with 10 µM QVD (Q), 30 µM necrostatin-1 (N) or a combination thereof and 
cell death assessed by PI uptake. c) Primary keratinocytes from lesion-free mice were isolated, stimulated with 
increasing concentrations of TRAIL and cell viability assessed by Cell Titer Glo. n=2 ± STDEV. d) Clonogenic 
survival is decreased in SHARPIN-deficient cells. Cells were treated for 6 days. 
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MEFs died in a dose-dependent manner when incubated with TRAIL. Moreover, primary 
keratinocytes obtained from lesion-free cpdm mice were significantly more sensitive towards 
TRAIL-induced cell death as compared to wild-type control keratinocytes (Figure 38c).  
Intriguingly, in contrast to TNF-induced cell death, TRAIL-mediated cell death was purely 
apoptotic in nature and necrostatin-1 was unable to inhibit TRAIL-induced cell death (Figure 
38b). These data indicate that the signalling events occurring down-stream of TNFR1 and 
TRAIL-R (N.B. mice only express one death-inducing TRAIL-R) are diverse and involve the 
presence and activity of different down-stream proteins. Increased cell death in SHARPIN-
deficient fibroblasts translated into decreased clonogenic survival (Figure 38d), suggesting that 
SHARPIN is an inhibitor of TRAIL-induced apoptosis and that its absence, and hence the 
depletion of linear ubiquitin chains renders cells susceptible to TRAIL- induced cell death. 
 
3.2.1.2 Loss of SHARPIN increases CD95L-induced cell death 
The signalling complexes utilised by the TRAIL/TRAIL-R and CD95L/CD95 systems share 
high similarity and differences in the composition of the respective receptor-associated 
signalling complexes have so far not been identified. Therefore it was not surprising that cpdm-
derived fibroblasts also showed enhanced susceptibility towards CD95L-induced cell death 
(Figure 39a). Although wild-type cells also died when stimulated with high levels of CD95L, 
the amount of cell death obtained in SHARPIN-deficient MEFs was significantly higher and 
required lower doses of CD95L, indicating that SHARPIN is required to protect cells from 
CD95L-induced cell death. 
Figure 39: Loss of SHARPIN sensitises cells to CD95L-induced cell death. a) Cells were incubated with 
increasing concentrations of CD95L and cell death measured by PI incorporation. b) Cells were pre-incubated for 
1 hr with 10 µM QVD (Q), 30 µM necrostatin-1 (N) or a combination thereof and cell death was assessed by PI 
uptake. n=3 ± SEM. 
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To analyse the kind of cell death, i.e. apoptosis versus necroptosis, cpdm-derived fibroblasts 
were pre-incubated with QVD, necrostatin-1 or a combination thereof and the amount of cell 
death quantified by PI incorporation the next day. Surprisingly, however, CD95L-induced 
death was partially apoptotic and partially necroptotic and was most efficiently inhibited by a 
combined use of QVD and necrostatin-1 (Figure 39b). Thus, similar to the TNF system, but 
different from the TRAIL system, CD95L-mediated cell death relies on the proteolytic activity 
of caspases as well as on the kinase function of RIP1.  
According to the type of cell death TRAIL-treated cpdm-MEFs undergo, typical hallmarks of 
apoptotic cell death were readily detectable, including cleavage of Bid, PARP1 as well as 
initiator and executer caspases. In contrast, changes in XIAP protein levels were not detected, 
indicating that sensitivity towards TRAIL was not mediated via alterations on endogenous 
XIAP protein levels (Figure 40a). Furthermore, low concentrations of CD95L, which did not 
induce significant amounts of cell death in wild-type fibroblasts, also led to the formation of 
typical apoptotic hallmarks as shown by the cleavage of caspases, Bid and PARP, hence 
supporting a role for SHARPIN in the regulation of CD95L-induced cell death. 
Similar to the absence of SHARPIN, deletion of HOIL-1 also sensitised fibroblasts to TRAIL- 
and CD95L-induced death to similar degrees as compared to SHARPIN deficiency (Figure 41a, 
b). Hence, like SHARPIN, HOIL-1 protects cells from TNF-, but also from TRAIL- and 
Figure 40: Loss of SHARPIN induces typical hallmarks of apoptotis following TRAIL and CD95L 
stimulation. Fibroblasts of the indicated genotypes were treated with (a) 100 ng/mL TRAIL or (b) 100 ng/mL 
CD95L for the indicated times and lysates were subjected to immunoblot with the indicated antibodies. 
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CD95L-induced cell death, suggesting a prominent function of linear ubiquitin chains in the 
regulation of cell death responses. Additionally, clonogenic survival of Hoil-1-/- MEFs was 
similarly decreased as compared to cpdm-derived fibroblasts, indicating that both LUBAC 
components were equally required for TNF-, TRAIL- and CD95L-induced cell death inhibition 
and were hence involved in loss of clonogenic survival (Figure 41c).  
 
3.2.1.3 TRAIL- and CD95L-induced death in LUBAC-deficient cells is independent of TNF 
TRAIL and CD95L are capable of activating the NF-κB and MAPKs pathways and thereby 
inducing pro-survival signalling (Kavuri et al, 2011; Varfolomeev et al, 2005). TNF constitutes 
a prominent NF-κB and MAPK target gene whose expression can be induced by the activation 
of the TRAIL-R or CD95 systems. To rule out the possibility that TRAIL- and CD95L-induced 
apoptosis observed in cpdm and Hoil-1-/- MEFs was due to an autocrine production of TNF, 
cells of the different genotypes were stimulated in the presence of excessive doses of the 
TNFR2-Fc fusion protein Enbrel (30 µg/mL) to inhibit the potential binding of endogenous 
Figure 41: HOIL-1 and SHARPIN deficiency sensitise to TRAIL and CD95L-induced cell death 
independent of endogenous TNF production. a, b) cells were incubated with increasing concentrations of 
TRAIL (a) and CD95L (b) and cell death determined by flow cytometry. n=3 ± SEM. c) Clonogenic survival of 
cells of the indicated genotypes treated with 100 ng/mL TNF, 100 ng/mL TRAIL and 150 ng/mL CD95L for 
6 days. d) Cells were incubated with 100 ng/mL TNF, 100 ng/mL TRAIL or 150 ng/mL CD95L in the absence or 
presence of 30 µg/mL Enbrel (TNFR2-Fc) and cell death analysed the next day. 
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TNF produced following TRAIL or CD95L stimulation, respectively. As shown in Figure 41d, 
addition of the TNF blocker did not alter cell death responses in cpdm and Hoil-1-/- MEFs 
treated with TRAIL or CD95L, indicating that TRAIL- and CD95L-induced cell death occurred 
independently of TNF. Furthermore, the supernatants of cpdm and Hoil-1-/- fibroblasts treated 
with TRAIL and CD95L (in the presence of QVD and necrostatin-1 to inhibit cell death) did 
not contain levels of TNF that could be measured by ELISA (data not shown), indicating that 
autocrine TNF was unlikely to account for the levels of cell death induced by TRAIL and 
CD95L, respectively. In contrast, as expected, TNF-induced cell death was inhibited in cpdm 
and Hoil-1-/- MEFs in the presence of the TNFR2-Fc fusion protein, indicating that the inhibitor 
was indeed functional. Thus, the function of LUBAC is not limited to TNF-induced killing, but 
LUBAC also influences TRAIL- and CD95L death responses. 
 
3.2.1.4 LUBAC is required in other death-inducing signalling pathways 
In contrast to ligands of the TNFR superfamily that induce the extrinsic, apoptotic pathway, 
cell death can also be triggered from within the cell via the intrinsic pathway. Cellular exposure 
to exogenous stress including DNA-damaging agents results in activation of BH3-only family 
members which then induce mitochondrial alterations accompanied by cell death responses. 
Amongst the genotoxic stress inducers, cisplatin is known to crosslink the DNA in order to 
induce apoptosis, whereas etoposide induces DNA strand breaks by inhibiting the DNA 
unwinding enzyme topoisomerase II. Although both agents induced cell death in wild-type 
control fibroblasts when applied at high doses, LUBAC deficient cpdm- or Hoil-1-/- MEFs were 
more sensitive towards these stimuli (Figure 42). Especially low doses of etoposide that only 
marginally induced cell death in wild-type cells were sufficient to efficiently kill SHARPIN or 
Figure 42: Loss of SHARPIN and HOIL-1 sensitise to DNA damage-induced cell death. Cells of the indicated 
genotypes were incubated with increasing concentrations of (a) etoposide or (b) cisplatin for 48 hrs and cell death 
analysed by flow cytometry. n=3 ± SEM. 
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HOIL-1 deficient fibroblasts. In contrast, differences in cell death responses to cisplatin were 
not that pronounced between wild-type and LUBAC-deficient cells and were only apparent 
when cells were treated with low doses of cisplatin. These results are in line with a recent study 
showing that LUBAC interacted with NEMO following DNA damage and was involved in 
subsequent cellular responses (Niu et al, 2011). Thus, LUBAC is required for a variety of death 
responses, ranging from death ligands to genotoxic stress inducing agents. 
 
3.2.2 SHARPIN and HOIL-1 regulate pro-survival signalling by TRAIL and CD95L 
Although the major function of TRAIL and CD95L has been ascribed to cell death induction, 
both death ligands are also capable of activating pro-survival NF-κB and MAPK pathways 
(Kavuri et al, 2011; Varfolomeev et al, 2005). Considering that TNF-mediated NF-κB and 
MAPK signalling are deregulated in the absence of SHARPIN and HOIL-1, the influence of 
LUBAC on TRAIL- and CD95L-induced pro-survival pathway activation was analysed next. 
Thus, wild-type, cpdm and Hoil-1-/- cells were stimulated with TRAIL and CD95L and the 
phosphorylation patterns of IκBα, JNK1/2 and ERK1/2 analysed on Western Blot level. As 
Figure 43: TRAIL and CD95L-induced signalling is impaired in the absence of SHARPIN or HOIL-1. 
Cpdm-derived (a, b) or Hoil-1-/- (c, d) MEFs were stimulated with 100 ng/mL TRAIL (a, c) or 200 ng/mL CD95L 
(b, d) for  the indicated time points and the activation of NF-κB and MAPKs was analysed as compared to wild-
type (wt) MEFs. 
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shown in Figure 43, phosphorylation and degradation of IκBα was strongly diminished in 
cpdm-derived fibroblasts following TRAIL as well as CD95L stimulation. In contrast, the 
absence of SHARPIN on TRAIL-induced JNK1/2 activation was less pronounced and not 
consistent between individual experiments, suggesting that SHARPIN and hence linear 
ubiquitination played a minor role in TRAIL-induced JNK activation. CD95L-induced JNK1/2 
activation was slightly decreased in the absence of SHARPIN throughout all experiments, 
suggesting that SHARPIN is required for efficient JNK1/2 activation. In contrast, the ERK1/2 
MAPK pathway was slightly enhanced following TRAIL and CD95L stimulation in the 
absence of SHARPIN. As described earlier for TNF, basal levels of activated ERK1/2 were 
slightly enhanced in cpdm-derived cells, suggesting that increased basal ERK1/2 signalling 
might compensate for loss of SHARPIN. 
Although TRAIL- and CD95L-induced activation of NF-κB was also diminished in the absence 
of HOIL-1, the pattern of ERK1/2 activation in Hoil-1-/- MEFs differed from the one observed 
in cpdm-derived fibroblasts (Figure 43c and d). Most strikingly, basal levels of ERK1/2 
phosphorylation and hence activation were not increased in the absence of HOIL-1. 
Furthermore, similar to the TNF system, TRAIL- as well as CD95L-stimulation-dependent 
ERK1/2 phosphorylation were decreased in Hoil-1-/- MEFs as compared to control cells, 
indicating that HOIL-1 was required for TRAIL- and CD95L-induced ERK1/2 activation. 
Consistent with a different kind of cell death to which cpdm- and Hoil-1-/--derived cells 
succumb following TNF treatment, these data demonstrate that SHARPIN and HOIL-1 might 
also be differentially required for the regulation of non-apoptotic signalling pathways triggered 
by death ligands. 
Taken together, these results imply that HOIL-1 and SHARPIN are both required for the 
protection of cells from TRAIL- and CD95L-induced cell death. Similar to the TNF system, 
depletion of either of these LUBAC components also changed death ligand-induced NF-κB and 
MAPK activation. However, given that TRAIL and CD95L are rather weak inducers of pro-
survival signalling, the effects of HOIL-1 and SHARPIN depletion are unlikely to account for 
the observed sensitisation. 
 
3.2.3 LUBAC is recruited to the TRAIL and CD95 DISC 
Previous studies have shown that cIAP1/2 are required to confer resistance to TNF-, TRAIL- 
and CD95L-induced cell death (Bertrand et al, 2008; McEleny et al, 2004; Wang et al, 1998; 
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Wang et al, 2005). However, the mechanism of cell death inhibition by cIAPs is not completely 
resolved in the three death receptor systems given that cIAPs are poor direct inhibitors of 
caspase activity (Eckelman & Salvesen, 2006). Recently, we have shown cIAP1/2 to be 
required for LUBAC recruitment to the TNF-RSC (Haas et al, 2009 and Figure 14) and, as 
demonstrated in the previous chapter, LUBAC then shifts the balance of TNF-induced survival 
versus cell death in favour of the former. To analyse the mechanism by which LUBAC confers 
resistance to TRAIL- and CD95L-induced cell death, it was analysed whether LUBAC 
executes its activity at the level of the DISC. Hence, HeLa cells were stimulated for various 
times with TRAIL, the endogenous, stimulated receptors pulled out and the composition of the 
TRAIL-R1/R2 DISC analysed by Western blotting. As shown in Figure 44a, TRAIL binding to 
its receptors induced rapid recruitment of FADD and caspase-8 to the DISC. Caspase-8 then 
became ubiquitinated over time, a modification that has been linked to enhanced proteolytic 
activity (Jin et al, 2009). Furthermore, all three LUBAC components were detected in the 
Figure 44: LUBAC forms part of the TRAIL-R1/R2 DISC. a) HeLa cells were stimulated with 500 ng/mL 
moTAP-TRAIL for the indicated times and the DISC subsequently precipitated with anti-FLAG M2 beads. 
Immunoblots were analysed as indicated. b) Comparison between the TNF-RSC and TRAIL-R1/R2 DISC in 
HeLa cells stimulated with 500 ng/mL TNF or 500 ng/mL TRAIL, respectively. 
 
3. Results 
 
109 
 
TRAIL DISC, peaking 30-60 min following stimulation, indicating for the first time that 
LUBAC did not only form part of the TNF-RSC, but also of the TRAIL DISC (Figure 44a, b). 
Consistent with earlier reports (Geserick et al, 2009), cIAP1/2 and RIP1 were also recruited to 
the TRAIL DISC and modified by ubiquitin chains. Whereas RIP1 recruitment to the DISC 
was rather weak and occured with delayed kinetics, cIAP1/2 were already bound to the 
unstimulated receptor and got ubiquitinated over time. This is in agreement with a recent study 
by Sun et al., who reported on the binding of a complex consisting of cIAP1, DDX3 and 
glycogen synthase kinase-3 (GSK3) to unstimulated death receptors to confer resistance to the 
respective death ligand (Sun et al, 2008).  
Although LUBAC was apparently recruited to the TRAIL DISC, kinetics and particularly 
protein quantities were severely different from the TNFR1 system, in which a strong 
Figure 45: LUBAC forms part of the native CD95 DISC. HeLa cells were stimulated with 1 µg/mL Fc-CD95L 
for the indicated times and the native CD95 DISC precipitated with Protein G beads. Immunoblots were analysed 
as indicated. 
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recruitment occurred immediately following receptor engagement and declined after 15-30 min 
(Figure 44b). In contrast, LUBAC was recruited to the TRAIL DISC rather late peaking at 
approximately 30-60 min, when the TNF-RSC started to disassemble. Accordingly, severely 
reduced levels of other adaptor proteins including cIAP1/2 and RIP1 were recruited to the 
TRAIL DISC when compared to the TNF-RSC, indicating significant differences between 
these two systems despite employing similar adaptor molecules.  
Analogous to the TRAIL DISC, a stimulation- and time-dependent recruitment of LUBAC to 
the CD95 DISC was also detected. Again, LUBAC binding to the CD95 DISC severely 
differed from its association with the TNF-RSC, and became detectable only 30-60 min 
following receptor engagement (Figure 45). Similarly, RIP1 recruitment to the CD95 DISC 
also peaked approximately 60 min following stimulation when it became readily ubiquitinated. 
Furthermore, strong ubiquitination of caspase-8 was visible following CD95 trimerisation, 
which then allowed for strong processing of c-FLIPL to its p43 fragment. Taken together, 
although the composition of the TRAIL DISC, CD95 DISC and the TNF-RSC shares similarity 
with respect to the source of components recruited to these receptor complexes, the quality of 
the signalling complexes severely differs, allowing for a preferential induction of cell death or 
survival pathways, respectively. 
 
3.2.3.1 LUBAC is recruited to the CD95 and TRAIL DISC in a cIAP1/2-dependent manner 
We recently reported on the recruitment of LUBAC to cIAP1/2-generated ubiquitin chains in 
the TNF-RSC (Haas et al, 2009). The previous experiments showed that LUBAC was also part 
of the CD95 and TRAIL DISCs and moreover indicated the presence of cIAP1/2 as well as 
polyubiquitin chains attached to a variety of DISC constituents. It was therefore next analysed 
whether cIAP1/2 were also involved in the recruitment of LUBAC to the CD95 and 
TRAIL-R1/R2 DISCs, respectively. Pre-treatment of HeLa cells with SM-83 (Cossu et al, 
2009) efficiently induced auto-ubiquitination and hence degradation of cIAP1/2. In agreement 
with a recent report by Geserick et al., depletion of cIAP1/2 resulted in increased levels of 
RIP1 recruited to the TRAIL-R1/R2 DISC (Figure 46a), indicating that cIAP1/2 retain RIP1 in 
the cytoplasm, thereby preventing its pro-apoptotic/necroptotic activity (Geserick et al, 2009). 
Although caspase-8, c-FLIP and FADD recruitment to the DISC were not significantly affected 
by the absence of cIAP1/2, significantly less HOIP, SHARPIN and HOIL-1 were present in 
IAP antagonist-treated cells, indicating that, similar to the TNF-RSC, LUBAC recruitment to 
the TRAIL DISC was also cIAP1/2-dependent. 
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Accordingly, analysis of the endogenous CD95 DISC, which was precipitated via the Fc-
portion attached to the CD95L sequence, showed reduced levels of SHARPIN, HOIL-1 and 
HOIP in the absence of cIAPs (Figure 46b). Furthermore, and consistent with previous reports, 
(Geserick et al, 2009), RIP1 recruitment to the CD95 DISC was strongly increased in cIAP1/2-
depleted cells.  
Taken together, these data show that the mechanism of recruitment of LUBAC to the three 
death receptor signalling complexes is very similar. However, as pointed out before, significant 
differences exist regarding the quality and kinetics of the membrane-proximal complexes 
which then account for diverse signalling outputs. 
 
3.2.3.2 HOIL-1 absence alters the composition of the TRAIL and CD95 DISC 
Having shown that LUBAC was recruited to the TRAIL and CD95 DISCs, the question 
remained how LUBAC conferred resistance to these death stimuli and whether it acts at the 
level of DISC formation or down-stream of the DISC. To gain insight into the underlying 
Figure 46: LUBAC recruitment to the TRAIL and CD95 DISC is cIAP-dependent. HeLa cells were pre-
incubated with 100 nM Smac mimetic 83 (SM-83) or DMSO (D) for 2 hrs and subsequently stimulated with 
500 ng/mL TRAIL (a) or 1 µg/mL CD95L (b) and the endogenous DISCs precipitated with anti-FLAG or Protein 
G beads, respectively. Immunoblots were analysed as indicated. 
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mechanism, DISCs were analysed in HeLa cells in which HOIL-1 expression was stably 
suppressed by RNAi (Haas et al, 2009). Precipitation of the endogenous TRAIL DISC revealed 
that the absence of HOIL-1 and hence the formation of linear ubiquitin chains strongly altered 
the formation of the DISC with regards to caspase-8 levels and activity. As shown in Figure 
47a, the amount of caspase-8 at the DISC strongly increased in the absence of HOIL-1, and 
significantly more caspase-8 was modified with ubiquitin chains. Furthermore, caspase-8 
ubiquitination was also increased in the CD95 DISC of HeLa cells lacking HOIL-1 expression 
(Figure 47b). In accordance with Jin et al., increased levels of ubiquitinated caspase-8 
correlated with elevated enzymatic activity as assessed by enforced accumulation of the active 
p18 fragment, and hence increased TRAIL-induced cell death (Jin et al, 2008). Although this 
result is counter-intuitive given that LUBAC acts as an E3 involved in ubiquitin chain 
formation, it implies that caspase-8 is not a direct target of LUBAC but rather suggests that 
LUBAC modifies a yet to be identified protein, which in turn interferes with caspase-8 
ubiquitination and hence activation. Additional experiments will be required to solve the 
mechanism of LUBAC-mediated resistance to TRAIL-induced cell death.  
 
  
Figure 47: Caspase-8 ubiquitination is increased in the absence of HOIL-1 in the TRAIL-R1/R2 and CD95 
DISC. HeLa cells in which the expression of HOIL-1 was stably knocked down and control (ctr) cells were 
stimulated with (a) 500 ng/mL TRAIL or (b) CD95L for the indicated time and the DISCs precipitated and 
analysed as indicated. 
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3.3 Summary 
Signals emanating from the TNFR1 are quite diverse and can result in pro-survival signalling 
or cell death, respectively. Deregulated TNF signalling accounts for the generation of a 
variety of auto-immune diseases, indicating that proper signal transduction is required to 
allow tissue homeostasis. Thus, it is of great importance to understand the signalling pathways 
and functions of all relevant proteins involved in TNF-induced signal trasnsduction. 
Deciphering the complex code of signal generation and propagation induced by this cytokine 
might guide the future development of therapeutic agents capable of interfering with this 
process at a particular stage when it functions aberrantly, thereby terminating or enforcing the 
signal. 
In this study, the function of the linear ubiquitin chain assembly complex (LUBAC) with a 
particular focus on its component SHARPIN was analysed. SHARPIN forms a stimulation-
independent complex with HOIL-1 and HOIP that is recruited to the TNF-RSC as well as to 
the CD95 and TRAIL DISCs following stimulation with the respective ligands. Recruitment 
to either of these signalling platforms depends on the function of cIAP1/2, which attach 
ubiquitin chains to target proteins to which the tripartite LUBAC binds via HOIP.  
At the TNF-RSC, LUBAC confers stability and allows for full efficient induction of the 
NF-κB and MAPKs pathways, which subsequently induce a variety of target genes implicated 
in cell survival and proliferation. Loss of one of the LUBAC components is associated with 
reduced activation of these pro-survival pathways and instead results in TNF-induced cell 
death due to facilitated complex II formation. These results place LUBAC at a central position 
regulating the cellular fate of a cell in response to TNF. 
The function of LUBAC is not restricted to the TNF/TNFR1 system but involved in a variety 
of other pathways, including TRAIL and CD95L-induced signalling. Absence of one LUBAC 
component results in impaired activation of NF-κB and MAPKs and sensitises the cells to 
TRAIL- and CD95L-induced cell death, which is independent of TNF. LUBAC is recruited to 
the TRAIL and CD95 DISCs and its absence from these complexes results in increased 
ubiquitination and hence activity of caspase-8, indicating that LUBAC is implicated in DISC 
formation. 
Taken together, LUBAC is a new regulator of TNF-, TRAIL- and CD95L-induced signalling 
and loss of one of its components shifts the balance between life and death of a cell in favour 
of the latter. 
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4. Discussion 
Post-translational modifications constitute a major event capable of regulating and fine-tuning 
signalling outputs emanating from distinct signalling platforms. Due to their characteristic of 
being highly dynamic and largely reversible, post-translational modifications respond to 
alterations in the cellular microenvironment, thereby controlling the fate of a given cell. For a 
long time, phosphorylation was the major known form of post-translational modification 
regulated by a concerted action of kinases and phosphatases. A variety of human cancers is 
associated with deregulated phosphorylation, most commonly via mutations in the ras gene, 
which accounts for approximately 30% of all human cancers (Downward, 2003). Oncogenic 
mutation of ras leads to constitutive activation of the ERK1/2 and PI3K (phosphatidyl-
inositol-tris-phosphate kinase) pathways associated with cell proliferation, survival, 
angiogenesis and metastasis formation (reviewed in Hanahan & Weinberg, 2000).  
Apart from phosphorylation, ubiquitination is the post-translational modification system most 
intensively described in the past decade. It is regulated not only by E3 ubiquitin ligases and 
deubiquitinating enzymes (DUBs) attaching and removing ubiquitin moieties from target 
proteins, but also by proteins containing ubiquitin binding domains (UBDs). Deregulation of 
ubiquitin signalling is associated with the development of a variety of autoimmune disorders, 
indicating that tight control of ubiquitination, deubiquitination and recruitment of UBD 
signalling adaptor proteins is required for tissue homeostasis. 
In this thesis, I report the identification of a novel E3 ubiquitin ligase complex consisting of 
the previously described HOIL-1 and HOIP, which form a stable, stimulation-independent 
complex with SHARPIN (Figure 9). Given its ability to generate poly-ubiquitin chains 
connected via the N- and C-termini of ubiquitin molecules, respectively, this tripartite 
complex is referred to as linear ubiquitin chain assembly complex (LUBAC) (Gerlach et al, 
2011; Ikeda et al, 2011, Tokunaga et al, 2011). LUBAC is recruited to the TNF-RSC and the 
TRAIL- and CD95 DISC following stimulation with the respective ligand and is required for 
full NF-κB and MAPK activation. Absence of a LUBAC component shifts the balance from 
TNF- (and TRAIL- and CD95L-) induced pro-survival signalling towards cell death 
induction, thereby promoting an important function for LUBAC in the regulation of death 
receptor signalling.  
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4.1 SHARPIN is the third component of LUBAC and recruited to the TNF-RSC  
4.1.1 SHARPIN, HOIL-1 and HOIP stabilise the native TNF-RSC 
Signal transduction by members of the TNFR-superfamily relies on the concerted action of a 
variety of proteins including kinases, ubiquitin ligases, but also adaptor proteins required for 
the recruitment of these enzymatically active proteins. Using modified tandem affinity 
purification (moTAP) of the TNF-RSC combined with mass-spectrometry, our group recently 
reported the identification of HOIL-1 and HOIP (Haas et al, 2009), which together form a 
complex capable of generating linear ubiquitin chains in vitro (Kirisako et al, 2006). Apart 
from HOIL-1 and HOIP, the only other possible novel component we identified by mass-
spectrometry was SHARPIN, a protein that has not been associated with TNF signalling 
before. SHARPIN was recruited to the TNF-RSC in a variety of cell lines in a stimulation-
dependent manner with kinetics similar to those of HOIL-1 and HOIP (Figure 9). SHARPIN 
does not possess any enzymatic domain. However, a sequence alignment revealed the 
presence of UBL and NZF domains at the C-terminus of SHARPIN which are highly 
homologous to the N-terminus of HOIL-1. Furthermore, pull-down experiments in different 
cell lines in which HOIL-1, SHARPIN or HOIP were immuno-precipitated revealed that these 
three proteins form a stimulation-independent complex in the cytosol (Figure 10), suggesting 
the existence of a tripartite complex. The complex of HOIL-1 and HOIP has initially been 
described as LUBAC. However, complexes of SHARPIN-HOIP or SHARPIN-HOIL-1-HOIP 
were also able to form linear ubiquitin chains (Gerlach et al, 2011, Ikeda et al, 2011; 
Tokunaga et al, 2011), suggesting that the term LUBAC should be expanded to refer to a 
complex of HOIP, HOIL-1 and/or SHARPIN. 
HOIL-1 and HOIP are recruited to cIAP1/2-generated ubiquitin chains (Haas et al, 2009). 
Considering that SHARPIN forms a stimulation-independent complex with these two 
proteins, it was not surprising that its recruitment to the TNF-RSC was also dependent on the 
presence and activity of cIAP1/2 to form ubiquitin chains (Figure 14 and Figure 15). 
However, it still remains to be determined to which kind of ubiquitin chains LUBAC is 
recruited. We recently showed that HOIL-1, HOIP and SHARPIN preferentially bind to linear 
and K63-linked ubiquitin chains as compared with K48-associated ubiquitin moieties (Haas et 
al, 2009; Gerlach et al, 2011). However, the avidity of the individual LUBAC components for 
other ubiquitin linkages remains elusive. Dynek et al. showed that cIAP1 in combination with 
the E2 UbcH5 generates K11-linked ubiquitin chains on RIP1 following TNFR1 stimulation 
(Dynek et al, 2011). This finding is in line with our data demonstrating that RIP1 is 
 4. Discussion 
116 
 
simultaneously modified by at least four different ubiquitin linkages, i.e. linear, K48, K63 and 
K11 (Gerlach et al, 2011). Hence, it might well be possible that LUBAC is recruited to 
cIAP1-generated K11-linked ubiquitin chains attached to RIP1 or possibly other TNF-RSC 
constituents. Accordingly, the binding affinity of LUBAC to other ubiquitin linkages 
including K11 linkages has to be analysed. Generally, due to the limited availability of such 
tools, only the involvement of K48-, K63- and linear linked ubiquitin chains has been 
evaluated until now. However, the binding properties of UBDs to other ubiquitin-linkage 
types have not been examined. Recently, Dong et al. reported on a new method for the 
synthesis of distinct ubiquitin chains with high purity and yield which is likely to advance the 
field of ubiquitin research (Dong et al, 2011). Novel, improved technologies including 
advances in mass-spectrometry have identified the presence of a variety of other ubiquitin 
chain linkages in diverse signalling pathways, including K11- in cell cycle progression (Jin et 
al, 2008), K29- in Notch signalling (Chastagner et al, 2006; Chastagner et al, 2008) and 
K29/K33-linked ubiquitin chains in the control of AMPK-related kinases (Al-Hakim et al, 
2008). These data underline that the rather restricted view of the function of ubiquitination 
that was propagated during the last decade needs to be thoroughly revised.  
Similar to HOIL-1 and HOIP, SHARPIN also bound to ubiquitin chains in vitro (Figure 13). 
However, it remains to be determined whether this property is of any significance in vivo. 
Although genetic depletion of HOIL-1 or SHARPIN strongly impaired the protein expression 
levels of the other two LUBAC components (Figure 19), dimeric complexes of the remaining 
two LUBAC components were still recruited to the TNF-RSC (Figure 20 and Figure 21). In 
contrast, depletion of HOIP impaired the recruitment of HOIL-1 and SHARPIN to the TNF-
RSC (Figure 22), indicating that the recruitment of LUBAC to cIAP1/2-generated ubiquitin 
chains was mediated via HOIP. Depletion of the NZF domains from SHARPIN or HOIL-1, 
which impart ubiquitin binding (Figure 13 and Tokunaga et al, 2009), should not interfere 
with LUBAC recruitment and activity. However, Tokunaga et al. showed that overexpression 
of HOIP with a mutant of HOIL-1 lacking the NZF domain was unable to induce NF-κB 
activation (Tokunaga et al, 2009). Accordingly, a SHARPIN mutant lacking ubiquitin binding 
ability was unable to activate NF-κB when co-expressed with HOIP (Ikeda et al, 2011), Thus, 
although HOIL-1 and SHARPIN are dispensable for the recruitment of LUBAC to the TNF-
RSC, their respective ubiquitin binding properties are required to activate down-stream 
signals, possibly by anchoring the tripartite complex at the TNF-RSC. It will be interesting to 
determine whether a HOIP mutant lacking the NZF1 domain (which mediates ubiquitin 
binding) will completely abolish the recruitment of LUBAC to the TNF-RSC, supporting the 
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notion that LUBAC is recruited to the TNF-RSC by an interaction between HOIP and cIAP-
generated ubiquitin chains. The mere presence of LUBAC at the TNF-RSC is insufficient for 
TNFR1 signal transduction, which requires the linear ubiquitin-chain forming activity of 
HOIP (Haas et al, 2009). However, it is still unknown how HOIP itself gets activated 
following recruitment.  It might well be that components of LUBAC are ubiquitinated once 
recruited to the TNF-RSC, which subsequently results in HOIP activation. Alternatively, 
kinases might be implicated in LUBAC activation at the level of TNF-RSC formation by 
phosphorylation of one or more LUBAC components. Lastly, conformational changes of the 
tripartite complex occurring upon binding to cIAP-generated chains might account for 
activation of HOIP’s E3 ligase activity. Mass-spectrometrical as well as two-dimensional 
(2D)-gel analyses should guide in answering these questions.  
Once recruited to the TNF-RSC, LUBAC stabilises the complex and allows for efficient and 
prolonged retention of RSC-components as indicated upon overexpression of 
SHARPIN/HOIP or HOIL-1/HOIP complexes (Figure 16).  However, at this point it remained 
obscure as to how LUBAC contributes to complex stabilisation. Precipitating the endogenous 
TNF-RSC from U937 cells, RIP1 and NEMO were identified as two linearly ubiquitinated 
targets within the native TNF-RSC, thereby for the first time providing a mechanism by 
which LUBAC stabilises the TNF-RSC (Gerlach et al, 2011).  As yet, only NEMO and RIP1 
were found to be decorated with M1-linked ubiquitin chains. However, it is possible that other 
TNF-RSC components apart from NEMO and RIP1 are also linearly ubiquitinated following 
TNFR1 stimulation and might therefore also account for LUBAC-mediated TNF-RSC 
stabilisation and hence efficient signal transduction.  
The NEMO spot isolated from 2D-gels contained peptides for only one form of ubiquitin 
chain linkage, i.e. the linear linkage. According to the size of the protein spot that was 
analysed (approximately 60-70 kDa), NEMO (48 kDa) was assumed to be modified with a 
linear di-ubiquitin (14 kDa). Although no other ubiquitin signature peptides were identified in 
this analysis, it might be possible that NEMO migrating at another molecular weight and/or 
isoelectrical point contains a different ubiquitin signature. Therefore, a more detailed analysis 
of the moTAP-isolated TNF-RSC is required. Considering that the mechanisms leading to 
IKK activation remain poorly understood, the observation that NEMO is linearly 
ubiquitinated in the TNF-RSC, most likely at lysine residues K285 or K309 (Tokunaga et al, 
2009), suggests that these ubiquitin chains serve as platform for the recruitment of additional 
IKK complexes through binding of the UBAN domain of NEMO (Rahighi et al, 2009). 
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Increased oligomerisation of the IKK complex might result in trans-autophosphorylation of 
IKKβ and subsequent NF-κB activation. Additionally, attachment of linear ubiquitin chains to 
NEMO slightly changes the conformation of the UBAN domain (Rahighi et al, 2009), 
resulting in re-positioning of IKKα and IKKβ, thereby possibly activating the kinase 
activities. However, the significance of linear ubiquitination of NEMO has not yet been 
demonstrated. Once the lysine residue within NEMO carrying the linear di-ubiquitin is 
identified, mutation of this residue and monitoring of the signalling and cell death responses 
towards various stimuli should help to determine the biological relevance of this 
ubiquitination.  
In contrast to NEMO, four different ubiquitin signature peptides (K11, K48, K63 and linear) 
were identified in the same spot with RIP1-derived peptides. This indicates that RIP1 is 
simultaneously modified by at least four different kinds of ubiquitin chain linkages. Thus, our 
finding significantly changes the current view on TNFR1 signal transduction as it suggests 
that each particular chain serves a distinct function resulting in distinct signalling outputs. The 
concerted, spatio-temporal action of the various ubiquitin chains is required to assure proper 
signal transmission and hence to balance TNF-induced physiological outcomes.  
It has long been a matter of debate why so many diverse DUBs were recruited to the TNF-
RSC following stimulation to de-ubiquitinate RIP1. The discovery that at least four different 
ubiquitin linkage types are present on RIP1 suggests that DUBs of different linkage 
specificity are required to de-ubiquitinate RIP1 and to thereby terminate the signal. In this 
context, it is required to extend the analyses of DUB specificity from our limited view on 
K48, K63 and linear ubiquitin chains and also determine their activities on other linkage 
types. However, it might not be sufficient to analyse DUB specificities in vitro as it does not 
necessarily reflect the in vivo situation. A20 for instance preferentially cleaves K48-linked 
ubiquitin chains in vitro (Lin et al, 2008; Komander et al, 2009) but removes K63-linked 
ubiquitin chains attached to RIP1 in vivo (Wertz et al, 2004). Hence, the composition of the 
TNF-RSC has to be examined over time, with a special focus on the appearance and DUB-
mediated removal of ubiquitin chains of particular linkage types. 
So far, lysine K377 has been described as the only ubiquitin acceptor site in RIP1 (Ea et al, 
2006). However, it is so far unknown whether the four individual ubiquitin chain linkages we 
identified were only attached to this particular lysine residue and form branched chains or 
whether they were attached to additional lysine residues in RIP1. Once the lysine residue(s) 
has (have) been identified the function of each chain type should be analysed, i.e. whether it is 
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required for NF-κB, JNK1/2, p38 and ERK1/2 activation or cell death inhibition. Mutation of 
putative lysine residues and subsequent re-expression of these mutants in Rip1-/- cells should 
guide the identification of these particular functions. Alternatively, the TNF-RSC could be 
precipitated from cells expressing ubiquitin mutants in which one particular lysine residue has 
been exchanged and ubiquitin chains can hence not be prolonged via this particular lysine 
residue. Recently, Xu et al. applied this approach and showed that ubiquitin mutants lacking 
the K63-residue exhibited defects in IL-1-induced NF-κB activation but displayed normal 
TNF-induced responses, indicating that K63-linked ubiquitination is dispensable for TNF 
signalling but required in the IL-1 pathway (Xu et al, 2009). It will be interesting to determine 
the cellular responses in different mutants, thereby assessing which particular type of 
ubiquitin chain is required in which signalling pathway. Kinetic analysis of the TNF-RSC 
using the moTAP-2D-MRM (multiple reaction monitoring) mass spectrometry approach 
might help to identify which protein is modified with which ubiquitin chain at which stage 
following TNFR1 ligation and how this enables the spatio-temporally controlled activation 
and subsequent inactivation of the components of this complex. The development of ubiquitin 
chains of different length and linkage, of ubiquitin linkage-specific antibodies and ubiquitin 
sensors (e.g. TUBEs, tandem repeated ubiquitin entities) which specifically bind to certain 
ubiquitin linkage types in combination with advances in mass-spectrometry and microscopy-
based live cell imaging will be required to understand the complex, dynamic ubiquitin system. 
Accordingly, the AQUA (absolute quantification) technology will guide in the identification 
of the stoichometry of ubiquitin moieties on target proteins and will allow for quantification 
of ubiquitin chains of different linkages (Kirkpatrick et al, 2006).  
 
4.1.2 LUBAC-a tripartite complex? 
The identification of SHARPIN as endogenous, stimulation-independent interaction partner of 
HOIL-1 and HOIP raises the question of the stoichometry of this complex. It is currently 
unknown whether the three proteins form one tripartite complex or whether dimeric 
complexes with different target specificities exist. Although HOIL-1 possesses a RING 
domain, overexpression of HOIL-1 and SHARPIN was unable to induce NF-κB activation 
(Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 2011), indicating that these two 
proteins are unlikely to form an active complex involved in signal transduction. Accordingly, 
although a weak binding of HOIL-1 to SHARPIN was visible when both proteins were 
overexpressed, their interaction strongly increased in the presence of HOIP (Figure 11a), 
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suggesting that HOIP binds to both HOIL-1 and SHARPIN, thereby sequestering all three 
proteins in the same complex. It might be that the binding observed when HOIL-1 and 
SHARPIN were overexpressed was due to endogenous levels of HOIP. This notion is 
supported by the finding that an interaction of HOIL-1 with SHARPIN was barely detectable 
in cells depleted of HOIP (by siRNA and subsequent depletion with anti-HOIP antibodies; 
Figure 11b). However, a faint interaction between HOIL-1 and SHARPIN was still observed, 
raising the question whether this was due to remaining HOIP levels, a direct interaction 
between HOIL-1 and SHARPIN or mediated by a yet unidentified factor. To address this 
issue, HOIL-1 or SHARPIN should be precipitated from Hoip-/- cells and the proteins co-
precipitated analysed by unbiased proteomic approaches. If no interaction was observed, i.e. 
SHARPIN and HOIL-1 were unable to directly bind to each other, the existence of an 
endogenous, tripartite LUBAC complex would be confidently demonstrated.  
The protein levels of HOIP and HOIL-1 were severely diminished in the absence of 
SHARPIN and the levels of HOIP and SHARPIN in the absence of HOIL-1 (Figure 18a and 
Figure 19b). Down-regulation of HOIL-1 and HOIP was not due to defects in transcription 
given that their mRNA levels were even slightly enhanced in cpdm-derived cells (Figure 18b). 
Instead, all three proteins seem to be required to stabilise each other and the absence of one 
component induces rapid degradation of the others. According to the group of K. Iwai and my 
own observations, down-regulation of HOIP and HOIL-1 in cpdm-derived cells was only 
slightly prevented by treatment with the proteasome inhibitor MG132, indicating that 
proteasome-independent, as yet unidentified mechanisms account for their degradation.  
HOIL-1 generally occurs as a double band on Western blot, indicating that HOIL-1 is 
modified; based on the size difference between both bands, this second band is most likely a 
result of mono-ubiquitination of HOIL-1. However, similar to HOIP knockdown (Haas et al, 
2009), the upper band of HOIL-1 disappeared in cpdm-derived cells, indicating that the 
presence of both, HOIP and SHARPIN, was required for HOIL-1 modification. Although the 
significance of this modification on cell signalling remains undetermined, these results further 
underscore an interdependence between HOIL-1, HOIP and SHARPIN. Despite being present 
at decreased levels in cpdm-derived cells, HOIL-1 and HOIP were still able to interact in the 
absence of SHARPIN and to be recruited to the TNF-RSC (Figure 20), indicating that dimeric 
complexes can be formed. However, it remains to be determined whether these complexes are 
still active. In vitro ubiquitination assays so far showed that all three variants were able to 
form free linear poly-ubiquitin chains or attach linear ubiquitin chains to the target protein 
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NEMO, suggesting that dimeric complexes are sufficient for ubiquitination (Gerlach et al, 
2011; Ikeda et al, 2011; Tokunaga et al, 2011). However, in-vivo evidence that linear 
ubiquitin chains can still be formed in the absence of HOIL-1 or SHARPIN is still missing. 
To get insight into this conundrum, the TNF-RSC of Hoil-1-/- or cpdm MEFs should be 
analysed by mass-spectrometry and the presence of linear ubiquitin chains investigated. Such 
analyses would furthermore help to get a better understanding of a possible target specificity 
of SHARPIN/HOIP and HOIL-1/HOIP complexes, if these complexes indeed existed in vivo. 
However, considering decreased protein amounts of the remaining two LUBAC components 
in the absence of the third protein, it is highly likely that most of the endogenous LUBAC 
complexes are tripartite. Unlike SHARPIN-deficient cpdm mice which develop severe 
inflammatory and immunological disorders (HogenEsch et al, 1993; HogenEsch et al, 1999), 
Hoil-1-/- mice do not develop any prominent inflammatory lesions (Tokunaga et al, 2011; 
Tokunaga et al, 2009). Hence, although SHARPIN, HOIL-1 and HOIP seem to predominantly 
form a tripartite complex, SHARPIN might drive the E3 activity of HOIP towards other 
targets as compared to HOIL-1. Hence, HOIL-1 and SHARPIN do not functionally 
compensate each other but serve non-redundant roles in enabling particular functions of 
HOIP, thereby explaining phenotypic differences observed in cpdm and Hoil-1-/- mice. Taken 
together, all three proteins are required to stabilise each other and to properly position 
LUBAC in the TNF-RSC to enable both, HOIL-1- and SHARPIN-guided activities of HOIP 
by linearly ubiquitinating distinct targets.  
 
4.2 Identification of HOIL-1, HOIP and SHARPIN as novel components of the 
TRAIL and CD95 DISC 
Considering that SHARPIN forms a stimulation-independent complex with HOIL-1 and 
HOIP, which we recently reported as novel TNF-RSC components it was not surprising to 
also identify SHARPIN as previously unknown constituent of the TNF-RSC (Figure 9). In 
contrast, the discovery made in this thesis that HOIL-1, HOIP and SHARPIN also form part 
of the CD95 and TRAIL DISCs was surprising and represents the first description that linear 
ubiquitin chains play a role in death receptor signalling. Although significantly lower levels of 
LUBAC were recruited to these two signalling platforms with delayed kinetics when 
compared with the TNF-RSC, the identification of LUBAC at the DISC provides new aspects 
as to how these two pathways transmit their signals. However, a target protein for LUBAC 
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has so far not been identified in the CD95 and TRAIL DISCs. It will therefore be required to 
pull down vast amounts of these complexes and analyse them by mass-spectrometry for the 
presence of linear ubiquitin chains. First of all, it has to be verified that LUBAC recruitment 
to the DISC was indeed of functional significance and changed the composition of the DISCs. 
Pull down experiments revealed that caspase-8 was significantly more ubiquitinated in 
HOIL-1-depleted HeLa cells as compared with control cells following both TRAIL and 
CD95L stimulation (Figure 47). At first glance, this result appeared counterintuitive taking 
into account that LUBAC functions as an E3 ligase and one would therefore expect less 
ubiquitination in its absence. However, caspase-8 might not be a direct target of LUBAC, but 
LUBAC might rather ubiquitinate a yet unidentified target protein, which thereby inhibited 
caspase-8 ubiquitination. Once LUBAC is depleted or functionally inactive, the respective 
protein is not activated or even not recruited and caspase-8 ubiquitination is therefore not 
blocked anymore. In line with this thought, Jin et al. demonstrated that cullin3 poly-
ubiquitinates caspase-8 following TRAIL stimulation and that ubiquitination of caspase-8 is 
required to fully activate its proteolytic activity (Jin et al, 2009). Increased levels of caspase-8 
ubiquitination correlate with elevated levels of cell death, a scenario observed in LUBAC-
depleted cells (Figure 41). However, it will be of major importance to identify the target 
proteins of LUBAC in the CD95 and TRAIL DISCs, which might be involved in cullin3-
mediated caspase-8 inhibition. Alternatively, cullin3 recruitment to the DISC might be 
inhibited in the presence of LUBAC and reduced levels of cullin3 in the DISC causative for 
decreased levels of caspase-8 ubiquitination. To test this possibility, DISCs should be 
precipitated in LUBAC-proficient and -depleted cells and levels of cullin3 investigated. 
Moreover, it should be studied whether LUBAC activity is required to inhibit caspase-8 
ubiquitination or whether its mere presence is sufficient to sterically hinder it. Therefore, 
DISCs from cells expressing a HOIP mutant lacking enzymatic activity should be analysed 
and cell death responses monitored.  
Taken together, the identification of LUBAC as a novel component of the CD95 and TRAIL 
DISCs that blocks TRAIL- and CD95L-induced cell death defines linear ubiquitination as 
major regulator of cell death responses induced by a variety of TNFR superfamily members 
and highlights that linear ubiquitination has a much broader function than previously 
assumed. 
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4.3 LUBAC balances TNF-, TRAIL- and CD95L-induced signalling outputs 
4.3.1 LUBAC in TNFR1 signalling  
TNF is the key cytokine involved in the initiation of innate immune responses against 
invading pathogens and binding to its receptor TNFR1 generally associated with cell survival, 
proliferation and the expression of pro-inflammatory mediators. A variety of molecules have 
been implicated in the elucidation of a regulated, timely controlled signalling output by the 
TNFR1 system. In this thesis, SHARPIN, in addition to the previously described HOIL-1 and 
HOIP (Haas et al, 2009; Tokunaga et al, 2009), is defined as a previously unknown 
component of the TNF-RSC required for full activation of the NF-κB and MAPK pathways 
and its absence resulted in severe defects in TNF-induced  signalling. However, SHARPIN 
and HOIL-1 deficiency did not completely abolish the activation of NF-κB, JNK1/2 and p38 
but severely impaired their activation (Figure 23, Figure 24 and Figure 28). Consistently, 
transcription of the bona fide NF-κB target gene IκBα was only slightly decreased in the 
absence of SHARPIN (Figure 27). This finding is in line with a recent report by Tay et al. 
who demonstrated that some TNF target genes, including IκBα, require only weak signals to 
be transcribed, whereas others rely on the concerted action of NF-κB and MAPKs (Tay et al, 
2010). Hence, diminished activation of NF-κB in the absence of SHARPIN was sufficient to 
induce the transcription of IκBα, but the expression of other TNF target genes including A20, 
ICAM-1 and TNF itself was almost completely abrogated in the absence of SHARPIN due to 
concomitant defects in TNF-induced JNK1/2 and p38 activation. Considering that dimeric 
complexes of SHARPIN/HOIP or HOIL-1/HOIP still exist in the absence of HOIL-1 or 
SHARPIN, respectively, it might be possible that these remaining dimeric complexes were 
still capable of activating NF-κB and MAPKs. However, although HOIL-1 knockdown in 
cpdm-derived fibroblasts further decreased activation of these pathways, it did still not 
completely render them inactive, suggesting the existence of LUBAC-independent 
mechanisms of NF-κB and MAPK activation. In line with this notion, Hostager et al. recently 
demonstrated that B cells, in which the gene encoding HOIP was disrupted by somatic cell 
gene targeting, showed impaired, yet not completely absent CD40-induced activation of 
NF-κB and JNK1/2 (Hostager et al, 2011). Moreover, TNF-induced signalling in SHARPIN 
and HOIL-1 deficient cells did not phenocopy each other, indicating that both proteins have 
non-redundant functions. In particular, cpdm-derived MEFs showed elevated basal levels of 
phosphorylated ERK1/2, which were even slightly enhanced following TNF stimulation as 
compared with wild-type control cells (Figure 23a and Figure 24a). In contrast, basal levels of 
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phospho-ERK1/2 were not increased in Hoil-1-/- fibroblasts but even showed defects 
following TNFR1 engagement. The exact mechanism of TNF-induced ERK1/2 activation is 
only poorly understood, but seems to depend on the MAP3K Tpl2 (Eliopoulos et al, 2003). 
Although it remains to be determined at which stage Tpl2 is required for TNF signalling or 
whether any other molecules are implicated in TNF-induced ERK1/2 activation, these results 
indicate that HOIL-1 and SHARPIN differentially activate diverse signalling pathways, most 
likely by targeting different proteins for HOIP-mediated ubiquitination. However, the exact 
mechanisms and differences between SHARPIN- and HOIL-1-activated HOIP complexes 
need to be addressed in more detail.  
Although TNF generally results in cell activation and survival, it is also able to induce cell 
death if signal transmission is impaired. Consistently, SHARPIN-deficient cpdm-derived or 
Hoil-1-/- cells were sensitive to TNF-induced cell death, indicating that loss of linear 
ubiquitination shifts the balance from pro-survival signalling in favour of cell death execution. 
In this study, no obvious difference in cell death sensitivity between cpdm and Hoil-1-/- 
fibroblasts could be observed. This is in contrast to Ikeda et al. who suggested that absence of 
SHARPIN resulted in more cell death than absence of HOIL-1 (Ikeda et al, 2011). However, 
cell death was not quantified in the mentioned study and the presentation of the cell death 
results with a logarithmic scale was slightly misleading. Although a subtle delay in cell death 
induction was apparent, both cell types equally succumbed to cell death the following day, 
indicating that HOIL-1 and SHARPIN conferred a similar degree of resistance to TNF-
induced cell death. However, full knockout Hoil-1-/- MEFs were applied in the study by Ikeda 
et al. while fibroblasts obtained from embryos in which the Hoil-1 gene was flanked by loxP 
sites and excised following infection with a Cre-expressing virus were employed in this study. 
Hence, the differences between these two studies could also be due to the use of differentially 
generated fibroblasts, in which HOIL-1 was absent chronically as compared to inducibly. 
Fibroblasts or primary keratinocytes that die upon TNF stimulation in the absence of 
SHARPIN exhibited characteristics of apoptotic as well as necroptotic death as assessed by 
the ability of the RIP1 kinase inhibitor necrostatin-1 and the caspase inhibitor QVD to 
partially inhibit TNF-induced cell death (Figure 30 and Figure 31). However, cell death was 
not completely prevented when both inhibitors were applied simultaneously, indicating that 
either the inhibitors did not completely block caspases and RIP1 or that another form or 
pathway of cell death might be involved. Given that some cells die in a RIP1-independent, 
RIP3-dependent manner (Upton et al, 2010), it will be interesting to determine whether 
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knockdown, knockout or inhibition of the kinase activity of RIP3 in cpdm-derived cells 
renders them completely resistant to TNF-induced cell death. In contrast to the partial 
necroptotic nature of cell death in the absence of SHARPIN, the death obtained in Hoil-1-/- 
cells could not be blocked by necrostatin-1, but rather exhibited signs of apoptosis (Figure 
32). This is the first example showing a major difference between SHARPIN and HOIL-1 and 
supports the notion of different functions of HOIP-containing SHARPIN or HOIL-1 
complexes, which result in the generation of different phenotypes in mice. 
A major obstacle to working on necroptosis is the lack of a marker clearly identifying it as 
such; as yet, necroptosis is mainly identified based on the absence of apoptotic or autophagic 
markers in the early stages of cell death (Kroemer et al, 2009). Further complication arises 
from the occurrence of secondary necrosis at late stages of apoptosis due to inefficient 
clearance of apoptotic bodies. So far, necroptotic cells are mainly identified due to their 
ability to die in the presence of caspase inhibition or depletion and the dependency of cell 
death on the kinase activity of RIP1. However, the assessment of cell morphology is so far the 
only possibility to quantify the fractions of cells that undergo apoptosis versus necroptosis. 
While a staining for active caspase-3 represents a mean to biochemically quantify apoptosis, 
no intracellular marker has as yet been described for necroptosis. It is hence required to 
develop specific markers of cell death that can be readily and easily monitored.  
Necrosis has long been thought of as an accidental form of cell death occurring in an 
unregulated manner. However, early reports already demonstrated that necrosis can be 
induced by a variety of stimuli including TNF, TRAIL and CD95L (Holler et al, 2000; Laster 
et al, 1988). However recently, it was discovered that this form of death can, similar to 
apoptosis, also proceed in a controlled manner and it was hence named necroptosis (Degterev 
et al, 2005). So far, the kinase activities of RIP1 and RIP3 have been identified as required for 
necroptosis and RIP1 and RIP3 were shown to form a stimulation-dependent complex (the so-
called necrosome). However, down-stream mechanisms resulting in typical necroptotic 
hallmarks remain poorly understood. Generally, the formation of a stronger TNF-induced 
complex II is considered as a mechanism associated with enhanced TNF-induced cell death. It 
will hence be of great importance to analyse complex II formation in LUBAC-component-
deficient cells. So far, these analyses were only successfully conducted in human HeLa cells 
in which complex II precipitation is well established. Knockdown of any of the three LUBAC 
components led to increased complex II formation as assessed by increased interaction of 
caspase-8 with FADD, TRADD and RIP1 (Figure 35). Furthermore, caspase-8 activity was 
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increased in these cells compared with non-targeted control cells, and p18 formation and RIP1 
cleavage were significantly increased. However, HeLa cells do not express RIP3 and hence do 
not die necroptotically (Feoktistova et al, 2011; He et al, 2009). Re-expression of RIP3 in 
these and other RIP3-deficient cells rendered them susceptible to TNF-induced necroptotic 
death, indicating that RIP3 is the decisive factor required for necroptosis (He et al, 2009). 
Considering that cpdm-derived cells were prone to both TNF-induced necroptosis and 
apoptosis whilst Hoil-1-/- cells only became sensitive to apoptosis, it will be interesting to 
analyse the necrosome in SHARPIN-depleted as compared with HOIL-1-depleted RIP3-
expressing HeLa cells.  
The mechanism leading to increased susceptibility to TNF-, TRAIL- and CD95L-induced cell 
death in the absence of linear ubiquitin chains remains largely undefined. The identification of 
LUBAC as a component of TNF-induced complex II (Figure 36), combined with the finding 
that LUBAC-deficient cells are more prone to TNF-induced cell death (Figure 32), suggests 
that the presence of linear ubiquitin chains negatively regulates complex II formation and/or 
activity.  However, the LUBAC target responsible for thie effect remains to be determined. 
Oshima et al. described that Abin-1-/- cells were more susceptible to TNF-induced cell death 
due to increased FADD/caspase-8 interaction, which they attributed to enhanced complex II 
activity (Oshima et al, 2009). However, the precise mechanism as to how ABIN-1 inhibits 
complex II formation and activity, and thereby interferes with cell death induction, is only 
poorly described. Considering that the absence of particular linear ubiquitination events in 
SHARPIN- or HOIL-1-deficient cells inhibited ABIN-1 recruitment to the TNF-RSC (Figure 
20 and Figure 21), it might be possible that decreased levels of ABIN-1 in the TNF-RSC 
allow for efficient formation of complex II and hence the induction of cell death, thereby 
defining linear ubiquitin chains as negative regulators of complex II generation.  
Apart from ABIN-1, c-FLIP is known to inhibit death ligand-induced killing. TNF stimulation 
generally induces the transcriptional expression of c-FLIP, which is then recruited to 
complex II, in which it not only inhibits caspase-8-mediated apoptosis (Micheau et al, 2001), 
but also forms heterodimers with caspase-8 to block RIP1/RIP3-dependent necroptosis 
(Oberst et al, 2011). This process most likely involves processing of RIP1 (Lin et al, 1999) 
and RIP3 (Feng et al, 2007). SHARPIN-deficient cells exhibited lower basal levels of c-FLIPL 
(Figure 37). This down-regulation itself might be sufficient for the sensitisation effect 
observed in cpdm-derived cells. Given that TNF-induced gene transcription was severely 
inhibited in the absence of SHARPIN (Figure 27), c-FLIP levels are unlikely to increase 
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following TNFR1 engagement, further potentiating the failure to block complex II-mediated 
apoptosis, but also necroptosis. Overexpression of c-FLIPL and c-FLIPS (whose expression 
could not be detected by Western blotting) in cpdm-derived fibroblasts will offer insight into 
whether basal c-FLIP down-regulation is responsible for TNF sensitivity and, if so, whether 
this is isoform-specific. Accordingly, a constitutively active version of IKKβ allowing for 
constitutive NF-κB activation should be expressed in cpdm-derived fibroblasts to assess 
whether defects in NF-κB activation are responsible for TNF-induced death susceptibility. In 
contrast to the effects seen in cpdm-derived cells, c-FLIPL was not down-regulated but even 
slightly enhanced in Hoil-1-/- cells (Figure 37). Increased c-FLIPL levels might account for 
enforced activity of caspase-8/c-FLIPL heterodimers and hence inhibition of necroptosis in 
Hoil-1-/- cells, which did not die in a necroptotic manner (Figure 32). These results suggest 
that HOIL-1 drives the activity of HOIP to other targets as compared to SHARPIN and that 
these targets are rather involved in apoptosis inhibition, whereas SHARPIN-directed HOIP 
complexes ubiquitinate targets crucial for prevention of necroptosis. 
The mechanism of SHARPIN-deficiency-mediated c-FLIP regulation has not yet been 
investigated. However, only recently it was reported that SHARPIN inhibited the tumour 
suppressor protein PTEN (phosphatase and tensin homolog) (He et al, 2010). PI3K activation 
by a variety of stimuli including growth factors leads to the generation of phosphatidyl-
inositol-trisphosphate (PIP3), which subsequently recruits PDK1 (phosphoinositide-dependent 
kinase 1). PDK1 phosphorylates and thereby activates AKT, resulting in enhanced cell 
survival, proliferation and metabolism. Amongst others, AKT phosphorylates and thereby 
inactivates the transcription factor FOXO3a (Anderson et al, 1998; Brunet et al, 1999). By an 
uncompletely understood mechanism, AKT-mediated FOXO3a inhibition leads to an increase 
in the levels of c-FLIP which is associated with cell death resistance (Skurk et al, 2004). 
PTEN functions as the phosphatase that counteracts the activity of PI3K, thereby inhibiting 
AKT activation. Hence, the decreased c-FLIP levels in SHARPIN-deficient cpdm-derived 
cells might be due to increased PTEN activity resulting in decreased basal AKT activation. 
Despite showing an interaction between endogenous SHARPIN and PTEN, He et al. did not 
provide any mechanistic insight as to how SHARPIN inhibited PTEN activity. Considering its 
ability to form linear ubiquitin chains when complexed with HOIP, PTEN might be a novel 
LUBAC target whose activity is negatively regulated by linear ubiquitination. However, it 
remains to be tested whether HOIL-1 and HOIP are also capable of inhibiting PTEN and 
hence to be determined whether SHARPIN-mediated PTEN inhibition is dependent on linear 
ubiquitination or, more specifically, on SHARPIN/HOIP-mediated linear ubiquitination.  
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The E3 ligase Itch has also been implicated in the regulation of cFLIP levels (Chang et al, 
2006). Itch becomes activated by JNK1 and was shown to K48-ubiquitinate c-FLIP, thereby 
inducing its degradation. Therefore, the expression level and activation status of Itch in cpdm-
derived cells should be investigated. 
Taken together, the identification of TNF-induced linear ubiquitination of RIP1 and NEMO, 
associated with an inhibition of cell death, refines the model of TNFR1 signalling (Figure 48): 
Figure 48: The influence of SHARPIN-deficiency on TNF signalling. a) Binding of to TNFR1 initiated the 
formation of the TNF-RSC, which is stabilised by LUBAC-generated linear ubiquitin chains on NEMO, RIP1 
and possibly other TNF-RSC components. The IKK complex is recruited via NEMO to linear ubiquitin chains 
and becomes linearly ubiquitinated itself. This modification and additional phosphorlyation of IKKβ by TNF-
RSC-recruited TAK1 activates the IKK complex, which subsequently phophorylates IκBα, leading to its 
proteasomal degradation. Hence, NF-κB dimers are liberated and enter the nucleus. Together with AP1, which is 
activated by TAK1-mediated MAPK activation, NF-κB drives the transcription of a variety of target genes, 
including A20 and FLIP. A20 is subsequently recruited to the TNF-RSC, de-ubiquitinates a variety of target 
proteins including RIP1, thereby destabilising the complex and terminating NF-κB and MAPK activation. 
Simultaneously, RIP1 forms an intracellular complex with FADD, caspase-8 and RIP3. However, this complex 
does not get activated to induce cell death due to NF-κB/MAPK-enforced c-FLIP expression, which on the one 
hand inhibits caspase-8 homo-dimer maturation and on the other hand forms a hetero-dimer with caspase-8, 
which inhibits necroptosis induced by RIP1 and RIP3, most likely via cleaving these two proteins. b) In the 
absence of SHARPIN, the protein levels of HOIL-1 and HOIP are decreased and less of these proteins are hence 
recuited to the TNF-RSC. The TNF-RSC is therefore destabilised and unable to fully activate NF-κB and 
MAPKs. Gene activation is decreased in the absence of SHARPIN, therefore inhibiting the expression of A20 
and c-FLIP. This one the one hand leads to inefficient RIP1 de-ubiquitination and incorporation of ubiquitinated 
RIP1 into complex II. On the other hand, the absence of c-FLIP (due to decreased basal levels and inhibited 
TNF-induced expression) allows for caspase-8 activation and hence apoptosis induction and at the same time for 
RIP1/RIP3-dependent necroptosis. Taken together, the absence of SHARPIN results in a dysbalance of TNF-
induced signalling which favours cell death execution. 
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Following TNFR1 trimerisation, TRADD is recruited via its death domain to TNFR1 and 
subsequently recruits RIP1 and TRAF2, which in turn recruits cIAP1/2 that then induce 
ubiquitination of several TNF-RSC components, including RIP1 and cIAP1/2 themselves. 
Subsequently, the tripartite LUBAC is recruited via HOIP to cIAP-generated chains, activated 
at the TNF-RSC and, by yet to be determined mechanisms, linearly ubiquitinates RIP1 and 
possibly other substrates. NEMO, which preferentially binds to linear ubiquitin chains 
subsequently allows for the recruitment of the IKK complex and, once in the complex, also 
becomes linearly ubiquitinated. Apart from the UBAN domain of NEMO, cIAP1/2 were 
shown to efficiently bind to linear ubiquitin chains via their UBA domains (Gyrd-Hansen et 
al, 2008). Hence, linear ubiquitin chains generated by LUBAC stabilise the TNF-RSC and 
allow for tight, prolonged retention of TNF-RSC components. Concomitant to IKK 
recruitment, the TAK1/TAB complex is recruited and becomes activated by as yet 
incompletely understood mechanisms, which possibly also involve ubiquitination (Wang et al, 
2001). Taking into account that K63-linked ubiquitin chains were dispensable (Xu et al, 2009) 
but that TAK1 is required  for TNF-induced signal transduction (Sato et al, 2005), it is 
unlikely that the recruitment of the TAK1/TAB complex to the TNF-RSC is solely mediated 
via binding of the NZF of TAB2 or TAB3 to K63-linked ubiquitin chains. Once recruited, 
TAK1 phosphorylates and hence activates IKKβ, which then leads to activation of NF-κB. 
Furthermore, TAK1 activates the p38 and JNK1/2 pathways, which, together with NF-κB 
allows for the transcription of a variety of target genes implicated in cell survival and 
proliferation. Despite formation of complex II, caspase-8 does not get activated under 
physiological conditions. However, in the absence of SHARPIN and hence the formation of 
SHARPIN/HOIP-mediated linear ubiquitin chains, c-FLIP levels are decreased and 
transcription of pro-survival genes inhibited. This leads to enhanced complex II formation, 
possibly mediated by less ABIN-1 recruitment, and increased caspase-8 activation (in the 
absence of c-FLIP), associated with enhanced apoptotic and necroptotic cell death. 
 
4.3.2 LUBAC in TRAIL- and CD95L-induced cell death 
While the major function of TNF is associated with survival and proliferation, TRAIL and 
CD95L are rather implicated in cell death responses. Assessing the effect of LUBAC in these 
two pathways, it became apparent that loss of SHARPIN or HOIL-1 also sensitised cells to 
TRAIL- and CD95L-mediated death (Figure 41). As shown in Figure 47, LUBAC recruitment 
to the TRAIL and CD95 DISC inhibited caspase-8 ubiquitination and hence activation 
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through a yet to be identified mechanism (Jin et al, 2009). Although SHARPIN and HOIL-1 
deficiency were also associated with reduced activation of NF-κB, it remains to be determined 
whether diminished TRAIL- and CD95L-induced NF-κB activation are causative for the 
observed sensitisation towards these death ligands. Overexpression of a constitutively active 
IKKβ mutant will provide the answer to this question. The effect of LUBAC deficiency on 
TRAIL-induced JNK1/2 activation was less clear and varied between individual experiments, 
indicating that LUBAC is less likely to be involved in TRAIL-induced JNK1/2 activation. 
Similar to TNF signalling, TRAIL- and CD95L-induced ERK1/2 activation was slightly 
enhanced in cpdm-derived, but reduced in Hoil-1-/- fibroblasts, again indicating that HOIL-1 
and SHARPIN serve divergent, non-redundant functions.  
TRAIL-induced cell death in cpdm-derived fibroblasts was purely of apoptotic nature whereas 
TNF- and CD95L-induced death was partially apoptotic and partially necroptotic (Figure 38 
and Figure 39). In 2000, Holler et al. for the first time described a function of RIP1 in 
caspase-8-independent TRAIL- and CD95L-induced cell death in T cells (Holler et al, 2000). 
However, whereas CD95L-induced cell death in the presence of the caspase-inhibitor zvad-
fmk was readily detectable in a variety of cell lines and primary T cells, TRAIL only induced 
caspase-independent cell death when co-administered with the protein synthesis inhibitor 
CHX, indicating that the synthesis of yet to be identified proteins renders cells susceptible to a 
purely caspase-dependent form of death. Hence, despite employing the same adaptor and 
signalling molecules, at least as far as we know to date, the nature of cell death induced by 
TRAIL significantly differs from the one triggered by CD95L. It will be of great importance 
to dissect both signalling pathways to understand why TRAIL and CD95L, despite initially 
appearing similar, differ so profoundly in their cell death responses. Taking the result by 
Holler et al. into consideration, it is less surprising that TRAIL-induced cell death in 
SHARPIN-deficient cells was exclusively apoptotic, whereas CD95L-mediated death also 
involved necroptosis.  
CD95L- and TRAIL-induced necroptosis required the presence of FADD, whereas TNF-
induced cell death was even increased in Fadd-/- Jurkat T cells (Holler et al, 2000), indicating 
that different signalling platforms are formed following stimulation by TNF and TRAIL or 
CD95L. While TNF-induced complex II formation and the requirement of the kinase 
functions of RIP1/RIP3 for necroptosis induction are well established, little is known about 
TRAIL- and CD95L-induced necrosome formation. Although RIP1 has been described to be 
recruited to the TRAIL and CD95 DISCs, particularly in the absence of cIAPs which enable 
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induction of necroptotic death (Geserick et al, 2009), RIP3 has so far not been detected in the 
two DISCs. However, He et al. showed that RIP3 was required for TRAIL- and CD95L-
induced necroptosis by a yet to be determined mechanism (He et al, 2009). It will therefore be 
necessary to identify at which level RIP3 exerts its necroptotic function in these pathways, i.e. 
at the level of DISC formation or further down-stream in secondary cytosolic complexes. 
Although such a secondary, intracellular complex II has been described following TRAIL 
stimulation, its function has so far rather been associated with pro-survival NF-κB and MAPK 
activation (Varfolomeev et al, 2005).  Considering that CD95L- and TRAIL-induced 
necroptosis was FADD-dependent (Holler et al, 2000), it is highly likely that RIP3 would be 
recruited to a FADD-containing complex, whose formation and activity should be increased 
in the absence of SHARPIN. 
Depletion of cIAP1/2 by IAP antagonists rendered cells susceptible to TRAIL- and CD95L-
induced necroptosis, indicating that cIAP1/2 determine the kind of cell death a given cell 
succumbs to (Geserick et al, 2009). The recruitment of LUBAC to the respective DISCs is 
mediated by cIAPs and their ubiquitin-chain-forming capacity (Haas et al, 2009). Hence, 
depletion of cIAP1/2 results in the absence of LUBAC recruitment to the DISCs, which is 
associated with increased cell death. Contrary to this, the levels of RIP1 in the DISCs increase 
in the absence of cIAP1/2. Through yet to be identified mechanisms, increased levels of RIP1 
modulate the kind of cell death resulting in caspase-8-dependent apoptosis and RIP1-
dependent necroptosis. 
Taken together, LUBAC is recruited to the TRAIL and CD95 DISC and inhibits apoptosis, 
most likely by inhibiting efficient caspase-8 ubiquitination. However, the mechanism as to 
how LUBAC confers protection from CD95L-induced necroptosis remains elusive, but might 
be due to increased formation and activity of RIP1-RIP3 intracellular signalling platforms in 
the absence of SHARPIN/HOIP-generated ubiquitin chains. Although CD95L and TRAIL 
signalling share a variety of similarities, the quality of cell death observed in cpdm-derived 
cells significantly differs following stimulation with the two death ligands. It is therefore of 
great importance to functionally dissect the two pathways and identify proteins required for 
apoptosis versus necroptosis induction. 
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4.3.3 Function of LUBAC in other signalling pathways 
The identification of NEMO as an endogenous LUBAC target suggests that its function is not 
limited to TNF-induced signalling but rather involved in a variety of pathways utilising the 
IKK complex. We and others showed that LUBAC was also required for signalling by 
CD40L, IL-1 (Gerlach et al, 2011; Tokunaga et al, 2009; Tokunaga et al, 2009), LPS (Ikeda et 
al, 2011), other Toll-like receptor agonists (Zak et al, 2011) and for anti-viral responses (Inn 
et al, 2011). These results suggest that, similar to the situation in TNF, TRAIL, CD95 and 
CD40 activation, LUBAC will be recruited to a signalling platform generated following 
stimulation with the respective ligands. It will be interesting to analyse these platforms to 
identify possible other LUBAC targets, thereby getting a better understanding of signal 
transduction induced by the various stimuli. 
The above mentioned pathways are generally involved in immune responses associated with 
NF-κB and MAPK activation. In contrast to this, but similar to CD95L and TRAIL, genotoxic 
stress is capable of inducing cell death. As shown in Figure 42, the absence of SHARPIN and 
HOIL-1 also profoundly sensitised cells to etoposide-induced cell death. Although differences 
in the quantity of cell death following cisplatin treatment were not that pronounced, small 
doses of cisplatin also induced more cell death in cpdm-derived and Hoil-1-/- cells than in 
wild-type cells. This observation is in accordance with a recent publication by Niu et al. who 
showed that LUBAC promotes genotoxic stress-induced NEMO ubiquitination and hence 
NF-κB activation (Niu et al, 2011). Following DNA damage, LUBAC was reported to interact 
with NEMO in the cytosol thereby enabling activation of the IKK and TAK1/TAB complex. 
Absence of HOIL-1 or HOIP strongly diminished this interaction and activation of pro-
survival signalling, indicating that LUBAC is not only involved in cell death responses 
emanating from cytokine and other immune cell receptors, but also required for DNA-damage 
responses. 
Only recently, the two groups of Pascal Meier and Martin Leverkus described a novel 
intracellular signalling platform which is capable of inducing apoptotic and necroptotic cell 
death. Given that RIP1 constitutes the critical factor for this signalling platform, it has been 
dubbed as the “ripoptosome” (Feoktistova et al, 2011; Tenev et al, 2011). Following treatment 
with an IAP antagonist and poly(I:C) or etoposide, RIP1 formed an intracellular complex with 
RIP3, FADD, and caspase-8/10 which induced necroptosis as well as apoptosis. Formation of 
the ripoptosome and subsequent cell death execution was independent of endogenous 
production of TNF, TRAIL or CD95L in a variety of cell lines, suggesting that the 
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ripoptosome constitutes a previously unknown signalling platform distinct from death ligand-
induced secondary complex II. However, ripoptosome formation was decreased in the 
presence of TNF-blocking agents in some cell lines, suggesting that it is cell-type specific and 
depends on the ability of a given cell type to produce endogenous TNF. Consistently, Biton 
and Ashkenazi recently showed the formation of an intracellular complex following DNA 
damage in HeLa cells whose formation was induced by endogenous TNF (Biton & 
Ashkenazi, 2011). Ripoptosome activity was negatively regulated by c-FLIP, cIAP1, cIAP2 
and XIAP and cells expressing high levels of these molecules were resistant to ripoptosome 
formation and cell death. Considering up-regulation of these inhibitors in a variety of 
tumours, targeting the ripoptosome might constitute a novel strategy in cancer therapy. 
Although the role of LUBAC in ripoptosome formation has so far not been analysed, due to 
similarities in composition to TNF-induced signalling platforms, it is highly likely that 
LUBAC also interferes with ripotosome activity. 
Taken together, its panoply of functions in a variety of signalling pathways defines LUBAC 
and hence linear ubiquitination as a new regulator of innate immunity and inflammation.  
 
4.4 Deregulated LUBAC signalling 
4.4.1 SHARPIN-deficient cpdm mice 
The NF-κB pathway regulates cellular responses in physiology and disease. It constitutes a 
quick detection system capable of recognising potential threats within the microenvironment, 
which it then rapidly translates into distinct gene expression programs. Expression of pro-
inflammatory proteins including cytokines, chemokines, adhesion molecules and enzymes 
possessing microbicidal activity elicit appropriate immune responses protecting the organism 
from infection and injury. At the same time, NF-κB signalling leads to cell survival by 
induction of anti-apoptotic genes and proteins with anti-oxidative function to protect cells 
from ROS-mediated necrosis (Pham et al, 2004; Sakon et al, 2003). Deregulated NF-κB 
signalling has been associated with the development of various inflammation-related diseases 
and cancer. Studies in knockout mice lacking particular components required for NF-κB 
activation (e.g. IKK components) or termination (e.g. A20 and CYLD) showed that 
ubiquitous NF-κB inhibition was embryonically lethal (Beg et al, 1995b; Li et al, 1999a; Li et 
al, 1999b; Makris et al, 2000; Rudolph et al, 2000; Schmidt-Supprian et al, 2000). 
Conversely, ubiquitous removal of NF-κB inhibitors is associated with the development of 
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severe inflammation and early postnatal death (Beg et al, 1995a; Klement et al, 1996; Lee et 
al, 2000). Surprisingly, targeted NF-κB inhibition in non-immune, epithelial or parenchymal 
cells triggered the development of severe inflammatory conditions, indicating that NF-κB 
inhibition in certain tissues results in pro-inflammatory outputs by disrupting physiological 
immune homeostasis. Keratinocyte-specific ablation of IKKβ or NEMO led to the 
development of severe skin inflammation associated with postnatal death of the mice. The 
development of skin lesions was shown to depend on TNFR1 signalling given that 
concomitant deletion of TNFR1 in these epidermis-specific gene-deficient mice completely 
(IKKβ) or partially (NEMO) rescued the inflammatory phenotype (reviewed in Pasparakis, 
2009). Hence, NF-κB inhibition in epidermal keratinocytes disturbs skin immune 
homeostasis, which is generally maintained by extensive cross-talk between epidermal 
keratinocytes and stromal and immune cells in the dermis. However, the molecular 
mechanisms by which NF-κB signalling controls skin homeostasis are poorly defined.  
The results obtained in this study show that LUBAC is another complex required for full 
NF-κB activation. Similar to epidermis-specific IKKβ and NEMO knockout animals 
(IKKβEKO and NEMOEKO), depletion of SHARPIN in cpdm mice induced the development of 
overt skin lesions, which first appear three to four weeks after birth (HogenEsch et al, 1993). 
In contrast, IKKβEKO and NEMOEKO mice already developed severe skin inflammation three 
to four days following birth resulting in postnatal death (Nenci et al, 2006; Pasparakis et al, 
2002), consistent with the absolute requirement of both components for NF-κB activation. 
Although SHARPIN was required for full NF-κB signalling (Figure 23), cpdm-derived cells 
did not completely lack IκB phosphorylation, indicating the existence of SHARPIN-
independent mechanisms of NF-κB activation. Hence, the severity and occurrence of 
pathology depends on the requirement of a particular molecule on NF-κB signalling. 
Macrophages rather than neutrophils and T cells have been demonstrated to be the cells 
mediating skin inflammation in IKKβEKO and NEMOEKO mice (Pasparakis et al, 2002; Stratis 
et al, 2006). It remains to be determined whether these cells are also responsible for the 
pathology observed in cpdm mice.  
Concomitant heterozygous deletion of TNF in SHARPIN-mutant mice was sufficient to 
inhibit the development of inflammation in a variety of organs including skin, liver and 
oesophagus (Gerlach et al, 2011), indicating that loss of the SHARPIN-driven inflammatory 
phenotype was TNF-dependent. However, heterozygosity was only capable of delaying the 
onset of disease progression as skin lesions became apparent several months after birth (J. 
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Silke, personal communication). Furthermore, we were unable to inhibit or even delay the 
inflammatory phenotype by injection of the TNF-blocker Enbrel (data not shown; N.B: this 
experiment was conducted together with Eva Rieser), indicating that levels of TNF are 
decisive for inflammation and disease inevitably progresses once a certain threshold has been 
exceeded. As yet, it was assumed that TNF-based auto-immune diseases were mediated by 
elevated levels of TNF-induced pro-inflammatory gene transcription. However, this is 
unlikely to be the case for the cpdm phenotype: although it constitutes a TNF-driven disease, 
loss of SHARPIN resulted in decreased TNF-induced gene transcription (Figure 27), 
suggesting that TNF-induced pro-inflammatory cytokines are less likely to be the cause of 
inflammation. Accordingly, it remains to be determined whether TNF protein levels were 
increased in cpdm mice and might therefore account for increased levels of keratinocyte cell 
death (Liang et al, 2011). Alternatively, the quantity of TNF present in the skin is unaltered 
and increased sensitivity of keratinocytes is the sole reason for elevated cell death. So far, 
mRNA levels of TNF were described to be unaltered in cpdm skin samples as compared with 
skin from wild-type animals (HogenEsch et al, 2001). Furthermore, I was unable to detect 
significant differences in TNF protein levels between various skin homogenates obtained 
from wild-type and cpdm mice by ELISA (data not shown), indicating that increased TNF 
levels are unlikely responsible for elevated cell death quantities. Immuno-histochemical 
analyses of skin sections may further clarify this issue. Additionally, the source of TNF 
responsible for inducing cell death has not yet been identified. I did not detect any measurable 
levels of TNF or IL-1 in keratinocyte cultures (data not shown), suggesting that either the 
ELISA method was not sensitive enough or that TNF was produced by other cells, for 
instance epidermis-infiltrating macrophages or mast cells. 
TNF-inhibiting drugs are generally applied in the treatment of inflammatory diseases 
including rheumatoid arthritis and Crohn’s disease (Feldmann et al, 2004) and was thought to 
inhibit pro-inflammatory TNF-driven gene transcription associated with manifestation of 
inflammatory conditions. However, TNF not only activates gene transcription, but can, under 
certain conditions also induce cell death. It is therefore possible that the inflammatory 
phenotypes observed in IKKβEKO, NEMOEKO or SHARPIN-mutant mice, but also in humans 
suffering from rheumatoid arthritis or Crohn’s disease are driven by increased rates of cell 
death. SHARPIN-deficient cpdm-derived fibroblasts and keratinocytes exhibited signs of 
TNF-mediated apoptosis as well as necroptosis (Figure 30 and Figure 31), a pro-inflammatory 
form of cell death. Hence, endogenous TNF present in the epidermis of the skin might induce 
keratinocyte death, which would subsequently release pro-inflammatory molecules, resulting 
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in the attraction and activation of immune cells from the dermis and the evocation of 
inflammation. Deficiency in TNF in cpdm mice inhibited keratinocyte death and hence the 
manifestation of an inflammatory milieu. Consequently, and in contrast to previous 
assumptions, TNF-blockers used in the treatment of rheumatoid arthritis or Crohn’s disease 
might not be effective due to inhibition of TNF-mediated gene activation of pro-inflammatory 
cytokines but rather by preventing TNF-induced pro-inflammatory cell death. If this were the 
case and inflammation a consequence of cell death, new treatment options for these diseases 
could be established by the identification of necroptosis inhibitors.  The proof-of-principle 
that necroptosis inhibition can indeed prevent inflammatory conditions was recently provided 
by numerous reports showing that concomitant RIP3 (or RIP1) knockout in mice deficient for 
caspase-8 or FADD rescued lethality associated with FADD and caspase-8 depletion (Kaiser 
et al, 2011; Oberst et al, 2011; Zhang et al, 2011) and prevented colitis induced by intestinal 
epithelial cell- or keratinocyte-specific FADD deletion (Bonnet et al, 2011; Gunther et al, 
2011; Welz et al, 2011). Caspase-8 was shown to form heterodimeric complexes with c-FLIPL 
which inhibit RIP1/RIP3-dependent necroptosis. In the absence of caspase-8, RIP1/RIP3 
complexes are no longer inhibited and transmit necroptotic signals leading to inflammatory 
cell death and hence liver failure. Accordingly, absence of FADD inhibits the formation of a 
secondary, necroptosis-inhibiting complex consisting of caspase-8 and c-FLIPL. Thus, apart 
from their pro-apoptotic activities, caspase-8 and FADD also exhibit non-apoptotic functions 
during embryogenesis by inhibiting necroptosis. This mechanism most likely involves 
cleavage and hence inactivation of RIP1 and RIP3, but might also be regulated by a yet 
unidentified target of the caspase-8/c-FLIPL heterodimers. Considering the increased 
occurrence of cell death in the skin of cpdm mice (Liang & Sundberg, 2011) and the increased 
susceptibility of cpdm-derived cells to TNF-induced necroptosis, it will be interesting to 
determine whether the inflammatory phenotype observed in cpdm mice can be reverted by 
concomitant RIP3 deficiency. If TNF (or CD95L)-induced necroptosis was the cause for the 
development of inflammatory skin lesions, cpdm;Rip3-/- mice should be protected as 
keratinocytes would only succumb to apoptotic, non-immunogenic cell death. This finding 
would further support the notion that patients, in whom necroptotic cell death rather than pro-
inflammatory gene induction was the cause for inflammation, could be treated with 
necroptosis inhibitors. Accordingly, the RIP1 inhibitor necrostatin-1 should be tested for its 
ability to prevent skin lesion formation. However, treatment of lesion-free cpdm mice with 
Enbrel starting at fifteen days of age could not prevent the occurrence of skin pathology, 
indicating that once the threshold has been reached and various cells succumbed to 
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necroptotic cell death, the vicious circle is initiated and blockage of TNF-induced cell death 
alone is no longer sufficient to exert a therapeutic effect. Nevertheless, patients might still 
benefit from a necroptosis-targeting therapy once the inflammation resulting from necroptotic 
death of keratinocytes has been cleared, for instance by corticosteroid treatment, and the 
development of new lesions subsequently blocked by inhibition of necroptosis. 
Besides Tnf gene deletion, Liang et al. reported that concomitant deletion of the IL-1 
Receptor accessory protein (IL-1RAcP) in cpdm mice was also capable of inhibiting the 
formation of inflammatory skin lesions (Liang et al, 2010). In contrast to the results obtained 
in this thesis, Liang et al. suggest that SHARPIN plays a negative regulatory role in NF-κB 
activation as they showed increased constitutive NF-κB activation in the skin of cpdm mice. 
However, no functional activity assays with isolated cells were performed in that study, which 
only monitored overall NF-κΒ activity. Considering that the skin is highly inflamed and 
populated with activated immune cells, it is not surprising to detect increased overall NF-κB 
activation. It will be interesting to test whether Il-1Racp-/-;cpdm mice still exhibit elevated 
levels of keratinocyte death but do not develop skin lesions due to inhibited signal 
transduction of released pro-inflammatory cytokines including IL-1 and IL-33 utilising the 
IL-1RAcP. This result would further support the notion of TNF-induced inflammatory cell 
death being the elicitor of inflammation and IL-1 or related cytokines being the mediators. It 
should hence also be tested whether blockade of IL-1 by the IL-1R antagonist Anakinra 
(Kineret) is capable of inhibiting the development of skin lesions if injected into mice 
shortly after birth (where TNF-blockade was unable to prevent pathology).  
As shown by concomitant deletion of the Tnf gene in cpdm mice, TNF doubtlessly plays a 
role in skin pathology observed in these mice. Consistent with the necroptotic kind of cell 
death, it is highly likely that inflammatory cell death is the cause for inflammation. However, 
it remains to be determined whether, and to which extent, TRAIL and CD95L contribute to 
the observed phenotype. Considering that CD95L induced apoptotic as well as necroptotic 
cell death, a role of the CD95 pathway for disease initiation is well possible. It will therefore 
be interesting to test whether genetic deletion of CD95L or CD95 in cpdm mice is also 
capable of inhibiting or attenuating the inflammatory phenotype. In contrast, TRAIL-induced 
cell death in cpdm-derived cells was purely apoptotic in nature. It is therefore less likely that 
TRAIL contributes to the manifestation of skin pathology. Contrarily, TRAIL application has 
been shown to alleviate auto-immunity in several models (Cretney et al, 2006; Ikeda et al, 
2010; Stratis et al, 2006). Although the mechanism explaining the beneficial role of TRAIL in 
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these models remains poorly defined, it might be possible that TRAIL shifts the balance from 
TNF-induced pro-inflammatory necroptosis towards non-immunogenic apoptosis, thereby 
preventing the manifestation of an inflammatory milieu. Hence, it should be analysed whether 
TRAIL injection into cpdm mice prevents skin inflammation by altering the kind of cell death 
keratinocytes succumb to. However, considering that SHARPIN was depleted from all 
organs, TRAIL application on the other hand might be toxic to cpdm mice if for example 
hepatocytes deficient in SHARPIN were rendered sensitive to TRAIL-induced apoptosis. 
Studies on primary hepatocytes isolated from cpdm mice, or indeed the systemic treatment of 
cpdm mice with TRAIL, will provide the answer to this question.  
ABIN-1 has been described as a protein that specifically binds to linear ubiquitin chains 
(Rahighi et al, 2009) and whose function is associated with the termination of TNF-induced 
signalling through recruitment of the DUB A20. Reduced levels of ABIN-1 were recruited to 
the TNF-RSC in the absence of linear ubiquitination (Figure 20 and Figure 21). Hence, 
although initial TNF-induced NF-κB and MAPK activation were decreased in cpdm and 
Hoil-1-/- cells (Figure 23, Figure 24 and Figure 27), it is possible that, due to reduced ABIN-1 
recruitment, and hence decreased A20 activity, the TNF-induced activatory signal cannot be 
completely shut off in cpdm-derived cells, including in immune cells. As a consequence there 
would be a constant signalling of low TNF-induced gene activation creating an inflammatory 
microenvironment that could be causative for auto-inflammation in cpdm mice.  It is a 
challenging task to dissect the separate contributions of cell death and constant, albeit reduced 
NF-κB and MAPK activation to the formation of the inflammatory phenotype. Generation of 
skin- and macrophage-specific SHARPIN-deficient mice and crosses with mice deficient in 
key necroptosis, NF-κB and MAPK pathway components will be very instructive in this 
regard. 
 
4.4.2 HOIL-1 and HOIP deficiency 
Hoil-1-/- mice do not develop any obvious skin lesion during maturation (Tokunaga et al, 
2011; Tokunaga et al, 2009) and HOIP deficiency is embryonically lethal (unpublished data 
by the group of K. Iwai). These in-vivo results are in accordance with the biochemical data 
presented here showing that HOIP is the central component of LUBAC, mediating formation 
of a tripartite complex, allowing for its recruitment to the TNF-RSC (and possibly other 
signalling complexes) and endowing the complex with its catalytic, linear ubiquitin chain-
forming activity. It will be interesting to test whether TNF-induced NF-κB and MAPK 
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activation is completely blocked in the absence of HOIP or whether linear ubiquitin-
independent mechanisms of activation exist. As mentioned earlier, despite presenting reduced 
CD40L-induced NF-κB and JNK activation in B cells in which the expression of HOIP was 
genetically depleted by somatic gene targeting, other pathways were not completely inhibited, 
arguing for LUBAC-independent mechanisms (Hostager et al, 2011). Considering LUBAC’s 
pleiotropic effects in various signalling pathways and its ability to confer resistance to death 
ligands, it is not surprising that the complete absence of linear chain formation in Hoip-/- mice 
results in embryonic lethality. Furthermore, these phenotypes argue for the existence of 
remaining linear ubiquitin chains in the absence of SHARPIN or HOIL-1 which were 
sufficient for embryos to be born but, as in the case of cpdm mice, induced auto-inflammation 
and immunological abnormalities with age. Moreover, the observation that HOIL-1 and 
SHARPIN deficiency did not induce identical phenotypes suggests that the HOIL-1-directed 
HOIP activity has functions that are distinct from the ones of SHARPIN-HOIP complexes. 
However, possible targets of the respective dimers remain to be identified. Moreover, it has to 
be tested whether the sensitivity of primary keratinocytes from Hoil-1-/- mice to TNF- and 
possibly other death ligands is comparable to the quantity and quality observed in cpdm mice. 
In this respect, Hoil-1-/- animals should be monitored for the presence of active caspase-3 
(indicative of apoptosis) and necroptotic cells in the skin. If my hypothesis regarding HOIL-1 
as an inhibitor of apoptosis and SHARPIN as an inhibitor of necroptosis is correct, 
keratinocytes from Hoil-1-/- mice should still die apoptotically but this should not result in 
inflammation due to the non-immunogenic nature of apoptosis. 
Alternatively, phenotypic differences between cpdm and Hoil-1-/- mice could be due to a 
LUBAC-independent function of SHARPIN. SHARPIN was initially identified as a SHANK-
interacting protein whose activity was associated with neuronal signalling (Lim et al, 2001). 
Only recently, Liang proposed that SHARPIN, independently of its function as LUBAC 
component, negatively regulates NF-κB signalling by interacting with TRAF2 (Liang, 2011). 
Despite the unconvincing nature of the data presented in the mentioned study, it is entirely 
possible that SHARPIN possesses activities unrelated to linear ubiquitination. In line with this 
notion, Rantala et al. recently reported on an inhibitory function of SHARPIN in β1-integrin 
activation, which they claimed to be independent of HOIL-1 and HOIP (Rantala et al, 2011). 
However, it remains a challenging task to differentiate between functions of SHARPIN 
associated with LUBAC and those that are possibly independent thereof. 
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4.4.3 LUBAC inhibition  
Since persistent NF-κB activation is associated with a variety of diseases including cancer and 
auto-immunity, the development of NF-κB inhibitors has been a focus of research for several 
years. However, NF-κB inhibitors lack specificity and hence interfere with the pleiotropic 
functions of NF-κB in immunity, inflammation and cellular homeostasis, resulting in non-
tolerable side effects. In order to develop cell-type specific inhibitors less prone to the 
development of adverse effects, a better understanding of the NF-κB pathway is required.  
Ubiquitination is a prominent event in NF-κB activation and its deregulation implicated in 
disease initiation and progression. Thus, similar to kinase inhibitors, inhibition of particular 
E3 ligases might be therapeutically beneficial if diseases were driven by enhanced ubiquitin-
mediated signalling. Enhanced expression of SHARPIN and HOIL-1 were commonly found 
in a diversity of human tumours (Gustafsson et al, 2010; Jung et al, 2010). Up-regulation of 
LUBAC components might result in more rapid and progressive tumour growth due to its pro-
survival activity, the expression of anti-apoptotic genes and inhibition of cell death. There are 
several opportunities to interfere with ubiquitin-mediated signalling. Ubiquitin chain 
formation itself can be blocked by inhibitors binding to the active site of particular ligases, 
thereby inhibiting their activity. Furthermore, enhancing the expression or activity of DUBs 
could be a valuable tool to terminate signalling. Alternatively, small-molecules interfering 
with the binding of UBDs to ubiquitin chains of certain linkage can inhibit the recruitment of 
downstream signalling adaptors and hence signal transduction. Proof-of-principle has been 
provided by ubistatins, small-molecule inhibitors capable of binding to K48-linked ubiquitin 
chains, thereby preventing their recognition and subsequent degradation by the ubiquitin 
receptors RPN10 and RPN13 of the proteasome (Verma et al, 2004). Although ubistatins were 
proven inadequate for therapeutic use due to their inability to penetrate cell membranes, this 
example nevertheless strengthens the notion that ubiquitin-mediated protein-protein 
interactions can be disrupted by small-molecules. New-generation inhibitors with improved 
pharmacological qualities might overcome this limitation, however they require high 
specificity. Tumour cells overexpressing LUBAC components should exhibit enhanced linear 
ubiquitin chain formation as compared with normal cells. Thus, the application of small 
molecules preventing binding of UBDs to linear ubiquitin chains, or indeed inhibitors of the 
enzymatic activity of HOIP, could potentially inhibit tumour growth, without major side 
effects. Furthermore, the utility of such ligase inhibitors is not restricted to NF-κB, but also 
targets MAPKs, which are also up-regulated in cancer and auto-inflammatory diseases. 
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4.5 Outlook 
In this study, SHARPIN was identified as a new component of the linear ubiquitin chain 
assembly complex (LUBAC) interacting with HOIP and HOIL-1. Following TNF, TRAIL, 
and CD95L stimulation, the tripartite LUBAC complex was recruited to the respective 
receptor signalling complexes. SHARPIN, HOIL-1 and HOIP were all required for efficient 
NF-κB and MAPK activation associated with gene transcription of anti-apoptotic as well as 
pro-inflammatory target genes allowing cells to survive and elicit an immune response at the 
same time. However, in the absence of SHARPIN and therefore linear ubiquitination pro-
survival signalling was disturbed and the balance shifted towards cell death execution. This 
cell death was partially of necroptotic nature and therefore associated with inflammation. 
Hence, contrary to the previously assumed notion that TNF generates an inflammatory 
microenvironment solely due to expression of pro-inflammatory mediators, these data suggest 
that deregulated TNF-mediated necroptosis might also contribute to pathology. Considering 
the high incidence of patients suffering from auto-immune or auto-inflammatory conditions 
and the tremendous cost of current treatment options, the development of necroptosis 
inhibitors preventing inflammatory cell death or agents shifting inflammatory death towards 
non-immunogenic, apoptotic death is highly recommended. However, patients have to be 
categorised according to whether pro-inflammatory cytokines or increased inflammatory cell 
death are the main drivers of inflammation. Moreover, primary or secondary TNF-non-
responders might benefit from such a therapy which is not restricted to TNF-induced 
necroptotic cell death, but also inhibits necroptosis induced by other death stimuli, including 
CD95L. Hence, the blockade of death ligand-induced necroptosis opens new opportunities for 
the treatment of auto-immunity. Given that patients treated with anti-TNF therapies are 
generally more susceptible to infection, inhibition of necroptosis instead of TNF, a major 
cytokine involved in innate immunity, illustrates a further therapeutic advantage. 
It will furthermore be interesting to screen auto-immune and cancer patients for genetic or 
epigenetic alterations in the expression or activity of LUBAC and to determine whether 
disturbed or enhanced linear ubiquitination contributes to disease initiation and progression. If 
this were the case, development of inhibitors of LUBAC or of the pathological consequences 
of its functional perturbation may define novel opputunities for the treatment of auto-
inflammatory diseases and cancer. However, further studies will be required to understand the 
physiological roles of linear ubiquitination in more detail and to determine how the 
knowledge about these processes can be employed to the treatment of patients. 
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5. Appendix 
5.1 Abbreviations 
ABIN   A20 binding inhibitor of NF-kappaB 
AICD   Activation induced cell death  
AMP   Adenosin-monophosphate 
AMPK  AMP-activated protein kinase 
AP-1   Activator protein 1 
APF-1   ATP-dependent proteolysis factor-1 
Apaf-1  Apoptotic protease-activating factor-1  
APC/C  Anaphase-Promoting Complex 
APF-1   ATP-dependent proteolysis factor  
AQUA  Absolute quantification 
ASK1   Apoptosis signal-regulating kinase-1  
ATP   Adenosin-triphosphate 
Bad   Bcl-2 antagonist of cell death  
BAFF   B cell-activating factor 
Bak   Bcl2-antagonist/killer 
BARD   BRCA1-associated RING domain protein 
Βax   Bcl2-associated X protein 
Bcl-2   B cell lymphoma 2 
Bcl-XL  B-cell lymphoma extra large 
BCMA  B cell maturation antigen 
BH3   Bcl-2 homology 3  
Bid   BH3-interacting domain death agonist  
Bim   Bcl-2-interacting mediator of cell death  
BIR   Baculoviral IAP repeat 
bp   base pair 
BRCA   Breast cancer 
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C   Cysteine 
CAD   Caspase Activated DNase  
Caspase  Cysteinyl-aspartate specific proteases 
CD   Cluster of differentiation 
CD40L  CD40 ligand 
Cezanne  Cellular Zn finger anti-NF-κB 
c-FLIP  Cellular FLICE-inhibitory protein 
CHX   Cycloheximide 
cIAP   Cellular inhibitor of apoptosis protein 
CIM   cIAP1/2 interacting motif 
ConA   Concanavalin A 
cpdm   Chronic proliferative dermatitis 
CRD   Cysteine rich domain 
CREB   cAMP response element-binding 
CYLD   Familial Cylindromatosis Protein 
CXCL   Chemokine (C-X-C motif) ligand 
Da   Dalton 
DAMP  Danger-associated molecular pattern 
Dc   Decoy-Receptor 
DC   Dendritic cell 
DD   Death domain 
DED   Death-effector domains  
DIABLO  Direct IAP binding protein with low PI 
DISC   Death inducing signalling complex 
DMEM  Dulbecco’s modified Eagle’s medium 
dsRNA  Double stranded ribonuclease acid 
DUB   Deubiquitinases 
EBNA   EBV-specific nuclear antigen 
EBV   Epstein-Barr virus 
ELISA  Enzyme-linked immunosorbent assay 
ER   Endoplasmic reticulum 
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ERK   Extracellular signal related kinase 
FADD   Fas-associated death domain  
FACS   Fluorescence activated cell sorting 
FCS   Fetal calf serum 
G   Glycine 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GC   Germinal centre 
GCK   Germinal centre kinase  
GCKR  Germinal centre kinase related 
GITR   Glucocorticoid-induced TNF-R family receptor 
gld   Generalised lymphoproliferative disease 
GLUD1  Glutamate dehydrogenase 1 
GLUL   Glutamata ammonia ligase 
GM-CSF  Granulocyte macrophage colony-stimulating factor  
GTP   Guanosine-triphosphate  
HBS   Hepes buffered saline 
HECT   Homologous with E6-associated protein C-terminus 
HEK   Human embryonic kidney 
HOIL-1  Haeme-oxidized IRP2 ubiquitin ligase 1 
HOIP   HOIL-1-interacting protein 
HPRT   Hypoxanthine-guanine phosphoribosyltransferase gene 
HRP   Horseradish-peroxidase 
HUVEC  Human umbilical vein endothelial cell  
HVEM  Herpes virus entry mediator  
IBR   In Between RING 
ICAM   Intercellular adhesion molecule 
IFN   Interferon 
Ig   Immunoglobuline 
IκB   Inhibitor of kappaB 
IKK   Inhibitor of kappaB kinase 
IL   Interleukin 
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iNOS   Inducible nitric oxide synthetase 
IP   Immunoprecipitation 
IRAK   IL-1R-associated kinase 
JAMM  JAB1/MPN/MOV34 metalloprotease 
JNK   c-Jun N-terminal kinase 
K   Lysine 
KD   Dissociation constant 
LB   Lysogeny Broth 
lpr   Lymphoproliferative disease 
LPS   Lipopolysaccharide 
Lt   Lymphotoxin  
LUBAC  Linear ubiquitin chain assembly complex 
M   Methionine 
MAPK  Mitogen-activated protein kinase 
Mcl-1   Myeloid leukaemia cell differentiation 1  
MEF   Mouse embryonic fibroblasts  
MEKK  MAP/ERK kinase kinase  
MHC   Major histocompatibility complex 
MKP   MAPK phosphatase 
MMP   Mitochondrial membrane permeabilisation  
moTAP  Modified tandem affinity purification 
MS   Mass spectrometry 
MW   Molecular weight 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NEMO  NF-κB essential modulator 
NF-κB  Nuclear factor kappaB 
NIK   NF-κB inducing kinase 
NK   Natural Killer 
NLK   Nemo-like kinase 
NLS   Nuclear localisation sequence 
NZF   Npl4-type zinc finger 
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OPD   o-Phenylene-diaminedihydrochloride 
OPG   Osteoprotegerin 
OTU   Ovarian tumour proteases  
P   Proline 
PAGE   Polyacrylamid gel electrophoresis 
PAMP  Pathogen-associated molecular pattern 
PARP-1  Poly(ADP)-Ribose-Polymerase-1 
PLAD   pre-ligand assembly domain 
PBMC  Peripheral blood mononuclear cells 
PBS   Phosphate buffered saline 
PDB   Pull-down buffer 
PE   Phycoerythrin 
PH   Pleckstrin homology  
PI   Propidium iodide 
PI3K   Phosphatidylinositol-3-kinase 
PKC   Protein kinase C 
PLAD   Pre-ligand-binding assembly domain  
Pru   Plextrin receptor for ubiquitin 
PRR   Pattern recognition receptor 
PS   Protease cleavage site 
PS   Phosphatidyl-serine 
PTP   Protein tyrosine phosphatase 
PUMA  p53 up-regulated modulator of apoptosis 
PYGL   Glycogen phosphorylase 
RANK  Receptor activator of NF-κB 
RBCK1  RBCC protein interacting with PKC 1 
RBR   RING-IBR-RING 
RHD   Rel homology domain 
RHIM   RIP homotypic interaction motif 
RING   Really Interesting New Gene 
RIP1   Receptor interacting protein 1 
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RNAi   RNA interference 
RNF   RING finger protein  
ROS   Reactive oxygen species 
RPMI   Roswell Park Memorial Institute medium 
RSC   Receptor signalling complex 
RTK   Receptor tyrosine kinase 
S   Serine 
SAPK   Stress-activated protein kinases 
SCF   Stem-cell factor 
SCFβ-TrCP  Skp1, Cul1, Roc1 and the F-box protein β-TrCP 
SEM   Standard error of the mean 
SHARPIN  SHANK-associated RH-domain-interacting protein 
SLE   Systemic lupus erythematosus  
SM   Smac mimetic 
Smac   Second mitochondria-derived activator of caspases 
SOS   Son of sevenless  
T   Threonine 
TAB   TAK1 binding protein 
TACE   TNFα converting enzyme  
TACI   Transmembrane activator and CAML interactor 
TAD   Transactivation domain  
TAK1   TGF-β-activated kinase 1 
TAP   Tandem-affinity purification 
TAX1BP1  Tax 1 binding protein 1  
TCR   T cell receptor 
TH   T helper cells 
THD   TNF homology domain 
TIM   TRAF-interacting motif 
Tpl2   Tumour progression locus 2 
TLR   Toll-like receptor 
TMD   Transmembrane domain 
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TNF   Tumour necrosis factor 
TNFR   Tumour necrosis factor receptor 
TRADD  TNF-R1-associated death domain 
TRAF   TNF-receptor associated factor 
TRAIL  TNF-related apoptosis-inducing ligand 
TrCp   Transducin repeat-containing protein 
Trx   Thioredoxin  
TWEAK  TNF-like weak inducer of apoptosis 
UBA   Ubiquitin-associated 
UBAN   Ubiquitin-binding domains found in ABINs and NEMO 
UBD   Ubiquitin-binding domain 
UBL   Ubiquitin-like 
UCH   Ubiquitin C-terminal hydrolase 
UEV   Ubiquitin-conjugating enzyme variant 
UIM   Ubiquitin-interacting motif 
USP   Ubiquitin-specific proteases  
UTR   Untranslated region 
v/v   Volume/volume 
wt   wild-type 
w/v   Weight/volume 
XEDAR  X-linked EDA-A2 receptor  
XIAP   X-chromosome linked inhibitor of apoptosis 
ZF   Zinc finger 
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